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ABSTRACT 
Both acute (AP) and chronic (CP) pancreatitis are complex diseases, with a number of 
aetiologies and complex pathogeneses. A number of contributing factors are assessed here. 
Genetic studies were performed looking at a high activity polymorphism of the alcohol 
metabolising enzyme cytochrome P450 2E l. Assessing a role in alcohol abuse and end 
organ disease; alcohol abusers (n= 239) and controls (n= 208) were studied. A significantly 
lower number of alcohol consumers (2.1 %) had the polymorphism than controls (5.8%); 
p= 0.049, Fisher's exact test. Any association with end organ disease could not be further 
elucidated due to the rarity of the polymorphism in this population. In another genetic 
study, looking at a polymorphism in interleukin-la, no associations were found with CP; of 
note no associations were found with genotypes implicated in AP. 
A double-blind, placebo controlled crossover trial of a leukotriene receptor antagonist in 
chronic pancreatitis revealed no benefit. 
Studies of production of arachidonic acid metabolites leukotriene E4 (LTE4), prostaglandin 
E2 (PGE2) and (a known marker of mast cell activation) prostaglandin D2 ( 11 P-PGF2a) 
were performed. Analysis looked at both acute (n= 19) and chronic pancreatitis (n= 19), 
employing age and sex matched controls. The L TE4 studies did not reveal any significant 
difference in levels. PGE2 levels were not different between CP patients and controls while 
they were significantly higher in AP than controls; p= 0.006, independent samples t-test. 
The variation appeared most marked for mild disease; one way ANOV A p= 0.024 and 
direct comparison of patients with mild disease and their matched controls; p= 0.0 11. The 
llP-PGFza study conversely showed no difference in AP but significantly higher levels in 
CP in comparison to their matched controls; p= 0.00 I, Mann Whitney U test. 
Based on a previous pilot study in CP and a difference in variance of L TE4 in AP in the 
above study, a genetic study of the known functional polymorphism in the gene of 
leukotriene c4 synthase (the first dedicated enzyme in the formation of the cysteinyl 
leukotrienes) was performed. Controls totalled 108 subjects; AP 238 (mild= 169 patients; 
severe= 69) and CP 57 subjects; no difference in the genotype or allele frequencies were 
found. 
In summary: A possible role for a functional polymorphism in cytochrome P450 2EI (not 
previously examined in patient groups) in protection against alcoholism has been 
identified. Perhaps analogous to the protection associated with high activity forms of 
alcohol dehydrogenase and low activity forms of aldehyde dehydrogenase. 
PGE2 is elevated in acute pancreatitis in humans consistent with the majority of the data in 
animals. Again consistent with the bulk of animal data this appears to be most marked in 
mild disease, possibly indicating a protective, and therefore potentially therapeutic, role. 
11 P-PGF2a, a metabolite of PGD2 and marker of mast cell activation, is elevated in chronic 
but not acute pancreatitis. This implicates mast cells in chronic pancreatitis and would be 
consistent with their known role in fibrosis and tissue remodelling and suggests a possible 
therapeutic target. 
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CHAPTER I: INTRODUCTION 
INTRODUCTION 
Pancreatitis can be broadly divided into two groups, they are Chronic Pancreatitis (CP) and 
Acute Pancreatitis (AP). Classification both within and between these forms has been 
debated for many years, the most recent meetings being in Cambridge 1983 (Samer, M. & 
Cotton, P. B., 1984) and Marseille 1984 (Singer, M. V. et al., 1985); with its more recent 
Rome update 1988 (Sarles, H. et al., 1989). 
CP is generally viewed with respect to its aetiology, which is addressed, in part, within 
these systems. AP may be subdivided by aetiology but also with respect to its' severity 
(Bradley, E. L., Ill, 1993). 
This Thesis will address both Acute and Chronic Pancreatitis, although Chronic 
Pancreatitis predominates and features in all areas studied. 
CHAPTER I: INTRODUCTION 
1.1 Pancreatic Anatomy: 
The pancreas, one of the butchers 'sweet breads', is a macroscopically lobulated gland 
with a fine capsule which lies retroperitoneally in the abdomen, roughly at the level of the 
first lumbar vertebra. lt is often described as the shape of a broad walking stick (figure 
1.1 ). It is separated for ease of description into a head, neck, body and tail passing from 
right to left and sloping gently upwards. The handle of the walking stick is as the head 
gives off, inferiorly, the uncinate process which passes infero-posteriorly then towards the 
left and behind the superior mesenteric vessels which were, in turn, behind the head (figure 
1.2). 
Some clinically relevant anatomical features of the pancreas are (figure 1.2): Its anterior 
surface is crossed in its lower part by the transverse mesocolon and thus it lies 
predominantly in the supracolic compartment and behind the lesser peritoneal sac (omental 
bursa). Thus the predominant site of a pancreatic pseudo-cyst (a fluid collection with a 
defined wall) complicating pancreatitis is the lesser sac and is often amenable to drainage 
into the stomach or duodenum. The head of the pancreas is 'held' in the concavity of the 
'C' shaped duodenal curve and can therefore be involved in duodenal ulceration. 
The pancreas is directly related to the superior mesenteric vessels (as above), the splenic 
artery, which courses posterior to it's upper border, and the pancreatico-duodenal arteries, 
which run in the grooves between the pancreatic head and duodenum. Thus, with gross 
pancreatic necrosis these vessels can be involved and eroded thus leading to pseudo-
aneurysm formation and haemorrhage. 
Pancreatic juice is drained to the duodenum via the main pancreatic duct (MPD), of 
Wirsung, and the accessory pancreatic duct (APD), of Santorini (figure 1.1 ). Their 
anatomy is best understood in light of pancreatic embryology. The pancreas is formed by 
2 
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the fusion of dorsal and ventral buds from the duodenum (figure 1.3). The smaller ventral 
bud migrating posterior to the duodenum to join the dorsal bud at is lower margin. The 
duct systems anastomose then separate leaving the proximal part of the lower, ventral duct 
to drain the main bulk of the pancreas (MPD) whilst the proximal part of the superior, 
dorsal duct drains part of the head and the uncinate process (APD). The relevance of this is 
that failed migration can lead to annular pancreas (whereby the pancreas encircles, and 
may obstruct, the duodenum) or the ducts (and pancreas) may fail to fuse normally, in the 
condition called pancreas divisium. There has been debate as to whether this condition 
predisposes to pancreatitis, since the technique of ERCP allowed us to identify it in living 
patients (Rosch, W. et al., 1976), until the present (Quest, L. & Lombard, M., 2000). It is 
probably true to say that it does so in some circumstances, for example, when associated 
with insufficiency of the minor papillae (Varshney, S. & Johnson, C. D., 1999) and 
perhaps should not be taken as being the cause without further, e.g. anatomical (Burtin, P. 
et al., 1991) or functional (Varshney, S. & Johnson, C. D., 1999) evidence. 
The MPD enters the duodenum in common with the common bile duct (CBD) at the 
hepato-pancreatic ampulla of Vater (figure 1.1 ); the common bile duct having arisen in 
common with the ventral pancreatic bud (figure 1.3). Also, secondary to the embryological 
rotation discussed the CBD lies (in its lower part) posterior to, indenting (sometimes 
embedded within) the pancreatic head. Thus it can be seen how passage of a gallstone can 
be associated with pancreatitis, although the exact mechanism is still an area of debate, see 
below. In addition, pancreatic enlargement or fibrosis can lead to obstruction of the CBD. 
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Diagrammatic Representation of Pancreatic Anatomy. 
MPD = main pancreatic duct 
APD = accessory pancreatic duct 
CBD = common bile duct 
Courtesy of Andrew Whitaker, www.instantanatomy.net 
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Figure 1.2 Detailed Pancreatic Anatomy. 
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Courtesy of Andrew Whitaker, www. instantanatomy.net 
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Figure 1.3. 
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iFigure 1 .3a. 
Figure 1.3b. 
Pancreatic Embryology. Courtesy of www.vesalius.com. 
Green represents the ventral duct arising in common with the common bile 
duct and purple the dorsal duct. 
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1.2 Pancreatic Function: 
The pancreas is a composite gland having both exocrine and endocrine functions. 
The exocrine function of the pancreas is secretion of digestive enzymes in a bicarbonate 
rich alkaline fluid via the pancreatic ducts into the duodenum. Water follows the osmotic 
gradient created by electrolyte transport. This constitutes a volume of some 2.5 litres per 
day and 6-20 grams of protein (Case R. M., 1998). 
1.2.1 Control of Secretion: 
Most evidence on the mechanisms involved in control of pancreatic secretion comes from 
rats and, at least in terms of control, they are not a good model for humans. However, the 
cellular mechanism involved for rats is probably one of two mechanisms which act 
together in humans (Case R. M., 1998). 
Basal levels of electrolyte and water secretion are low in humans (as they are in the dog 
and cat, but not certain other species, especially the rabbit) which can lead to an 
accumulation of enzymes in the ductal tree, subsequent to increased flow 'washing' them 
out (Case R. M., 1998). This may partially explain some species resistance to naturally 
occurring pancreatitis. 
Pancreatic duct cells are the major source of this bicarbonate rich fluid in which the 
pancreatic enzymes are secreted, these cells are primarily stimulated by the hormone 
secretin which stimulates increased volume and bicarbonate concentration at the expense 
of chloride. This cellular mechanism has an integral, rate limiting role for the Cystic 
Fibrosis Transmembrane Conductance Regulator (CFTR). Thus the existence of pancreatic 
fibrosis and insufficiency seen in Cystic Fibrosis and the apparent increased frequency of 
CFTR mutations found in CP (Cohn, J. A. et al., 1998; Sharer, N. et al., 1998) can be 
7 
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explained. Secretin is produced by the S cells of duodenum and jejunem in response to acid 
(pH 4.5-5) in the duodenum and to a lesser extent protein and fat digestion products 
(Ganong, W. F., 1995; Guyton, A. C. & Hall, 1. E., 2000). 
Digestive enzymes are secreted by the pancreatic acinar cells, this being largely dependent 
on the hormone(s) CCK (cholecystokinin), which only has a weak effect on fluid volume 
except to potentiate the effect of secretin. The independent role in fluid volume control 
may also be enacted via the acinar cells (Case R. M., 1998). CCK is secreted by the l cells 
of duodenum and jejunum in response to long chain fatty acids, peptides and amino acids 
(Ganong, W. F., 1995; Guyton, A. C. & Hall, 1. E., 2000). 
Somatostatin is secreted by the delta (or D) cells of the pancreatic islets and the intestinal 
mucosa. It has an inhibitory effect on a number of gastro-intestinal hormones, most notably 
in this context secretin. It is secreted in response to a number of factors associated with 
intake of food, e.g. acid in the duodenal lumen and fatty acids, amino acids and glucose in 
the blood (Ganong, W. F., 1995; Guyton, A. C. & Hall, J. E., 2000). 
Further controls of secretion include extrinsic nervous control: Sham feeding has been 
shown to increase enzyme secretion, but have little effect on volume (Anagnostides, A. et 
al., 1984). Gastric distension has been shown to have a similar effect (Cargill, 1. M. & 
Wormsley, K. G., 1979). 
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The enzymes produced by the pancreas are: 
PROTEOLYTIC 
• Trypsin(ogen)s 
Chymotrypsin( ogen) endopeptidases 
Elastases 
(Pro )Carboxypeptidases 
UPOLYTIC 
• Lipase(+ colipase) 
Phospholipase A2 
Cholesterol esterase 
CARBOHYDROL YTIC 
• Amylase 
They are secreted in excess to absolute requirements (presumably to enable maximal 
digestion) and show some adaptation to dietary intake (Metzger, A & DiMagno, E. P., 
1998). 
The controls of pancreatic secretion and especially its increase in response to food is the 
basis of pancreatic rest as a central part of the management of AP. It is well known for 
recurrence of pain to occur on refeeding in patients recovering from AP. However, the 
relevance of pancreatic rest has been questioned (Ballinger, A , 1998), especially in light 
of evidence suggesting that during a bout of AP in mice and rats pancreatic secretion is 
maximally suppressed (Niederau, C. et al., 1990). Also studies suggest that naso-jejunal 
feeding (distal to the site of maximal CCK stimulation) is safe and superior (on balance of 
benefits and disbenefits) to parenteral feeding (Kalfarentzos, F. et al. , 1997; McClave, S. 
A et al. , 1997; McGregor, C. S. & Marshall, J. C. , 2001 ; Pupelis, G. et al. , 2002). 
Nasogastric feeding is even thought by some now to be safe, this in a very small study 
(Eatock, F. C. et al. , 2000). 
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Also influencing the control of secretion forms the basis of various treatments which have 
been tested or employed in AP and CP. Somatostatin analogues are of benefit in the 
treatment of pancreatic fistulae and are used to prevent the same in pancreatic surgery, 
'though the extent of their benefit, if any, is not fully elucidated (Li-Ling, J. & lrving, M., 
2001). They have been looked at in AP but not shown to be of proven benefit (Uhl, W. et 
al., 1999a), although a benefit was suggested by meta-analysis (Andriulli, A. et al., 1998) 
prior to the largest trial (Uhl, W. et al., 1999b ). 
1.2.2 Control of digestive enzymes within the pancreas: 
Digestive enzymes need to be active in the gut but controlled within the pancreas (to avoid 
auto-digestion) both when intra-cellular and intra-ductal. 
Secretion by exocytosis, from zymogen granules within the acinar cells, is as pro-enzymes. 
A series of control mechanisms maintain a basal, low level equilibrium of activation and 
inactivation. In zymogen granules and thence the duct system the pancreatic secretory 
trypsin inhibitor (PSTUSPINK I, serine protease inhibitor Kazal type I) fulfils this role 
with an ability to 'control', by direct I to 1 binding, up to I 0 -20% activation of 
trypsinogen (Braganza, J. M., 1998; Naruse, S. et al., 1999) at physiological ratios. 
Further control involves enzyme Y and mesotrypsin which when activated degrade 
trypsinogen and other zymogens (Gates, L. K. et al., 1999). Cytoplasmic control also 
includes glutathione in it's reduced form and a degree of activation can be reversed by 
antioxidants (Braganza, J. M., 1998). Interstitial control is by alphal-protease inhibitor 
(Gates, L. K. et al., 1999). 
The possibility of therapy to control pancreatic 'autodigestion' in acute pancreatitis has led 
to trials of Gabexate, a protease inhibitor, however there does not appear to be a mortality 
benefit and evidence for a decrease in complications is weak (Dervenis, C. et al., 1999). 
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1.3 Acute Pancreatitis: 
Acute pancreatitis {AP) is a common disease, seen in both surgical and non-surgical 
practice, accounting for around 3% of admissions with acute abdominal pain (de Dombal, 
F., 1991). It carries a relatively high mortality of around 10% (Wilson, C. & Imrie C.W., 
1990) and, at present, we have no specific non-operative therapy. Mortality seems to have 
plateaued in the last one to two decades (Glazer, G. & Mann, D. V., 1998). In the previous 
two decades a decrease in mortality had been seen due to a number of factors: increased 
diagnosis of mild cases; improved diagnosis, understanding of natural history, imaging and 
selective operative intervention. 
The mortality of 5 to 10% can be sub-divided (approximately) into; mild cases 0%, severe 
-20% (infected necrosis -25%, sterile necrosis -10% )(Dervenis, C. et al., 1999). 
There is marked variability in progression and outcome from a brief bout of pain; through 
a long complicated course with recovery; to a rapid deterioration and death. This is one of 
the conundrums of pancreatitis. 
Severe acute pancreatitis is generally regarded as acute pancreatitis associated with 
complications. These may be systemic complications, i.e. dysfunction of single or multiple 
organ systems, and/or local complications. The forms are most commonly discussed in 
terms of the 1993 Atlanta Consensus (Bradley, E. L., Ill, 1993), Table I. I. 
As an aid to comparing studies in AP various attempts to categorise the disease had been 
made. From Marseilles (Sarles, H., 1963; Singer, M. V. et al., 1985) and Cambridge 
(Sarner, M. & Cotton, P. B., 1984) to Atlanta these have given a basis from which to 
compare outcome of different management techniques and enabled discussions to be 
carried out using agreed and standardised terminology. 
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Associated with: Evidenced by: 
Mild Acute Pancreatitis Minimal organ dysfunction 
Uneventful Recovery 
No features of Severe AP 
Severe Acute Pancreatitis Systemic/Organ Shock 
failure or dysfunction (systolic BP <90mmHg) 
Pulmonary Insufficiency 
(Pa02 ~ 60mmHg) 
Renal Failure 
(serum creatinine > 177J..U11ol/l, 
after rehydration) 
Gastro-intestinal bleeding 
(>500m 1/24 hours) 
Disseminated Intravascular 
Coagulation 
( platelets ~ 105/mm3; 
fibrinogen < lg/1; fibrin split 
products> 80~tg/ml) 
Severe metabolic disturbance 
(serum Calcium ~ 1.87mmolll) 
Local Complications Necrosis 
(> 3crn/30% nonenhancement 
CT; can be infected or sterile) 
Abscess 
(infected collection containing 
little or no necrotic tissue) 
Pseudocyst 
(collection enclosed by a wall 
of fibrous/granulation tissue) 
Table 1.1. Summary of the Atlanta Classification System for Acute Pancreatitis, 
after (Bradley, E. L., III, 1993). 
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Local effects consist, in the mildest form, of oedema of the pancreas and/or surrounding 
fat. Acute fluid collections can occur, these will then often resolve or can go on to form 
walled off collections, termed pancreatic pseudocysts. Infected collections are termed 
pancreatic abscesses and carry an increased mortality. While pancreatic necrosis can occur 
in varying degrees, including total pancreatic necrosis (Figure I. 4 ). This also carries an 
increased mortality, however, the greatest mortality is associated with infected pancreatic 
necrosis. 
Systemic complications, as outlined in Table 1.1, can occur in any of the bodys' organ 
systems. Classically ARDS, the adult respiratory distress, occurs but all degrees of 
respiratory dysfunction can occur as it can with all systems, defined levels being used for 
classification. How distant organ dysfunction occurs is a matter of debate. It is increasingly 
thought that those with local and systemic complications may represent two prognostic 
subgroups, however, with a large degree of overlap. 
Death tends to occur in the first week from multiple organ failure or thereafter from sepsis, 
either local to the pancreas or systemically (Mann, D. V. et al., 1994). However, those 
patients who survive, even severe episodes (Fenton-Lee, D. & Imrie C.W., 1993), 
generally have low long-term morbidity and good quality of life (Broome, A. H. et al., 
1996). 
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Figure 1.4. Total Pancreatic Necrosis. 
Courtesy University of Illinois (www.med.uiuc.edu) 
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1.3.1 Aetiology: 
The two common causes of AP remain gallstones, accounting for 30-50% of cases in 
Britain, and ethanol, accounting for around 8-38% of cases (Corfield, A. P. et al., 1985; 
Thomson, S. R. et al., 1987; Mann, D. V. et al., 1994; De Beaux, A. C. et al., 1995); the 
most extreme figures (low for alcohol and high for gall stones) from a study looking 
specifically at first episodes (Corfield, A. P. et al., 1985). The mechanisms by which the 
various causes lead to AP are, again, not fully understood. 
If these causes are not identified other potential causes should be sought which include; 
hyperlipidaemia, tumours (especially periampullary tumours) and infective causes; 
including viral, e.g .. mumps and coxsackie, and parasitic, e.g. ascaria and clonorchis. 
'Idiopathic' (or unidentified aetiology) remains a common diagnosis in reported series and 
appears to diminish with repeated investigation, the recent UK Guidelines suggest that this 
group should constitute no more than 20-25% of diagnoses of AP (Glazer, G. & Mann, D. 
V., 1998). 
1.3.2 Diagnosis: 
Abdominal pain, especially epigastric,+/- radiation to the back, associated with vomiting, 
are the common presenting features. Signs include abdominal tenderness (ranging from 
mild through rebound to rigidity) and, less commonly, Cullen's and Grey-Turners signs, 
which contribute to a more specific diagnosis. However, presentation can be varied and 
missed diagnosis remains a factor in the high mortality (Kingsnorth A. N., 1998). 
A clinical diagnosis is supported by the finding of raised serum (or urinary) pancreatic 
enzymes; most commonly amylase. They are typically elevated (amylase >3-Sx, lipase >2x 
normal) during an attack of AP. However, they must be sought to give a result and may not 
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be elevated even in a severe attack (lack of sensitivity) and can be non-specifically 
elevated in clinically similar conditions (lack of specificity). In addition, amylase is short 
lived in the blood (leading some commentators to recommend urine levels to be tested). 
Amylase also has other isoenzymes, which may, rarely, be the source of an abnormally 
high result. Lipase is marginally superior to amylase (Table 1.2). Combination of the two 
investigations improves sensitivity and specificity. 
Further assays, which show promise, include: Trypsin2-alphalantitrypsin complex, which 
also correlates with severity and AJpha2-macroglobulin-trypsin complex. Trypsinogen 2 is 
probably closest to a practical, accurate form and for which a simple urine test is available 
(Kylanpaa-Back, M. et al., 2000) Table 1.2. In addition, serum levels correlate with 
severity. 
As many as 12-42% of cases of fatal AP go undiagnosed prior to death. In one analysis, of 
patients diagnosed post-mortem, Wilson and Imrie (Wilson, C. & Imrie, C. W., 1988) 
suggest that a timely diagnosis may have altered management, potentially allowing 
survival, in 45% of cases. In addition to a variable clinical presentation, the lack of a 
highly specific diagnostic test leads to difficulties. 
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Sensitivity Specificity 
Amylase 52-95% 86-98% 
Lipase 74-100% 34-100% 
Trypsinogen-2 91-98% 89-95% 
(serum or urine) 
Table 1.2. Sensitivites of Diagnostic Tests in Acute Pancreatitis. 
Data from (K.emppainen, E. et al. , 1998). 
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1.3.3 Prognostication: 
As AP has such a range of clinical courses it is useful to be able to predict which patients 
are likely to have a severe (complicated) course. This enables most intensive observation 
ofthose at greatest risk, implementation of investigation and of management appropriately 
and opportunely. It also provides for standardised comparisons in and with studies. 
Attempts at predicting severity in AP have been made for over two decades, initially 
consisting of multi-factor scoring systems, such as the Ranson's (Ranson, J. H. et al., 
1974) and the Glasgow (Blarney, S. L. et al., 1984) Criteria. Other indicators are now also 
known and a large number of potential serum markers are being evaluated. The details of 
all the potential predictors are extensive and a number of reviews exist (Dervenis, C. et al., 
1999; Glazer, G. & Mann, D. V., 1998). In summary a combination of recognised 
predictors of severe outcome is, at present, the best approach: 
• Simple Tests: 
Clinical Assessment- not regularly reliable, still a vital component. 
Obesity- Body Mass Index ~30 (Lankisch, P. G. & Schirren, C. A., 1990; Funnell, I. 
C. et al., 1993; Martinez,J. et al., 1999). 
Chest X-Ray- pleural effusions (especially left sided and bilateral) (Lankisch, P. G. et 
al., 1994; Maringhini, A et al., 1996). 
C-Reactive Protein (CRP) - > l50mg!l (values from 100-210mg/l evaluated by various 
authors)(Leese, T. et al., 1988; Wilson, C. et al., 1989). 
• Multi-factor scoring systems: 
e.g. The Acute Physiology and Chronic Health Evaluation (APACHE)-11 ~8 
(values between ~6- ~9 recommended by various authors) (Larvin, M. & McMahon, M. 
J., 1989; Wilson, C. et al., 1990). Table 1.3. 
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A - A t Ph . I cue tySIO ogy s core 
PHYSIOLOGICAL VARIABLE HIGH ABNORMAL RANGE LOW ABNORMAL RANGE 
Temperature - Rectal ("C) 
Mean arterial pressure 
(mmHg) 
Heart Rate 
(ventricular response) 
Respiratory Rate 
(non-ventilated or ventilated) 
Oxygenation: 
A-aD02 or Pa02 (mmHg) 
a: Fi02 2: 0.5 record A-aD02 
b: Fi02 < 0.5 record only Pa02 
Arterial pH 
Serum Sodium 
(mmol/L) 
Serum Potassium 
(mmolfL) 
Serum Creatinine (mg/1 OO ml)-
double poins for Acute Failure 
Haematocrit 
(%) 
White blood count 
(x 103/mm3) 
Glasgow Coma Score 
( 15 minus actual score) 
A = Total of 12 above variables 
(the Acute Physiology Score) 
Serum HC02 (venous mmolfL) 
- NOT ereferred use if no ABGs 
8 - Age Points 
Age (years) Points 
:::: 44 
45-54 
55-64 
65-74 
2:75 
0 
2 
3 
5 
6 
C- Chronic Health Points 
+4 
2:41 
> 160 
2:180 
>50 
2:500 
2:7.7 
> 180 
2:7 
>3.5 
>60 
2:40 
2:52 
+3 +2 +1 
39- 38.5-
40.9 38.9 
130- 110-
159 129 
140- 110-
179 139 
35- 25-
49 34 _ 
350- 200-
499 349 
7.6- 7.5-
7.69 7.59 
160- 155- 150-
179 159 154 
6- 5.5-
6.9 5.9 
2- 1.5-
3.4 1.9 
50- 46-
59.9 49.9 
20- 15-
39.9 19.9 
41- 32-
51.9 40.9 
0 + I +2 +3 +4 
36- 34- 32- 30-
38.4 35.9 33.9 31.9 <29.9 
70- 50-
109 69 <49 
70- 55- 40-
109 69 54 ::::39 
12- 10- 6-
24 11 9 <5 
<200 
>70 61-70 55-60 <55 
7.33- 7.25- 7.15-
7.49 7.32 7.24 <7.15 
130- 120- Il l-
149 129 119 ::::110 
3.5- 3- 2.5-
5.4 3.4 2.9 <2.5 
0.6-
1.4 <0.6 
30- 20-
45.9 29.9 <20 
3- 1-
14.9 2.9 < 1 
22- 18- 15-
31.9 21.9 17.9 <15 
If the patient has a history of severe organ system insufficiency or is immunocompromised assign points as 
fo llows: for non-operative or emergency post-operative patients - 5 points; elective post-operative- 2 points. 
Organ insufficiency or immunocompromised must have been evident prior to this hospital admission and 
conforms to the following criteria: 
Liver: Biopsy proven cirrhosis and documented portal hypertension; or prior episodes of hepatic failure. 
Cardiovascular: NY Heart Association Class VI 
Respiratory: Chronic restrictive, obstructive or vascular disease resulting in severe exercise restriction, e.g . 
unable to climb stairs or perform household duties. Or documented chronic hypoxia, hypercapnia, secondary 
polycythaemia, severe pulmonary hypertension (>40mmHg) or respirator dependency. 
Renal : Recurring chronic dialysis. 
Immunocompromised: The patient has received therapy that suppresses resistance to infection (e.g. immuno-
suppression, chemotherapy, radiation, long-term or recent high-dose steroids) or has disease that is 
sufficiently advanced to suppress resistance to infection (e.g. leukaemia, lymphoma, AIDS). 
Table 1.3: The APACHE IT (Acute Physiology and Chronic Health Evaluation) Score. 
Total of Sections A + 8 + C. (from Knaus, W. A. et al. , 1985) 
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1.3.4 Management: 
In AP the management focuses on symptom control, supportive treatment and prevention 
of complications. In mild acute pancreatitis intravenous fluid administration, analgesics 
and avoidance of oml fluid or food intake is sufficient in most cases. The treatment of 
severe pancreatitis involves adequate volume replacement, nutritional support and careful 
monitoring of vital functions with early treatment of organ failure. Identification of 
pancreatic and peripancreatic necrosis is best demonstrated and evaluated by contrast-
enhanced computerized tomography (CT). Infection of such necrosis is associated with 
poor outcome and surgical intervention in certain specific situations, most notably that of 
infected pancreatic necrosis (McFadden, D. W. & Reber, H. A., 1994; Warshaw, A. L., 
2000), is one of the few specific interventions available in AP. 
Many additional aspects of management have developed and are developing. Although 
many of these are still contentious a number of consensus documents have been produced 
giving guidelines on the management of AP (Banks, P.A., I997a; Glazer, G. & Mann, D. 
V., 1998; Dervenis, C. et al., 1999). 
Areas of contention in its management include: 
•Antibiotic Prophylaxis. 
As infected pancreatic necrosis is associated with a much higher mortality than sterile 
necrosis the prevention of its development is an appealing avenue. A debate regarding 
antibiotic prophylaxis has been ongoing for many years, with the weight of evidence most 
often said, in the past, to fall against prophylaxis. However, much of the data was 
concerning ampicillin (Cameron et al., 1975; Finch et al., 1976) which we now know has 
limited pancreatic penetration (Trudel et al., 1994; Spicak et al., 1999), also studies 
included mild cases which may have masked a significant effect in severe cases. 
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A number of more recent trials have been performed, in addition to increasing evidence on 
which antibiotics attain appropriate tissue levels this debate continues (Barie, 1996). On 
balance it can now be argued that antibiotic prophylaxis is justified in patients with 
predicted severe disease or proven necrosis (Golub et al., 1998; Powell et al., 1998). This 
corresponds to present practice commonly found in the UK (Powell et al., 1999). However, 
much debate continues (Slavin & Neoptolemos, 2001) and certainly further studies are 
required to delineate the role, if any, of routine prophylaxis. 
Even the recent studies have not consistently shown a survival benefit or reduced 
pancreatic infections. Cefuroxime has been shown to decrease total infectious 
complications, need for operative intervention and death, but not pancreatic infection, in a 
trial of 60 patients (Sainio et al., 1995). Ceftazidime (with amikacin, which is poorly 
penetrant, and metronidazole) reduced all infections but not mortality in a small trial 
(Delcenserie et al., 1996). Otloxacin (with metronidazole) in a small trial was shown to 
decrease physiological disturbance and has good penetration and spectrum characteristics 
(Schwarz et al., 1997). lmipenem has been shown to decrease pancreatic and 
extrapancreatic infection, need for operation and systemic complications and be superior to 
pertloxacin without metronidazole, but has not to shown a survival benefit ( Pederzoli et 
al., 1993; Bassi et al., 1998; Nordback et al., 2001). 
In addition to which antibiotic, if any, is best other issues in antibiotic prophylaxis awaiting 
resolution include: Duration of administration and whether to commence antibiotics on 
purely prognostic grounds or only after necrosis is seen (as in most of the trials). 
The role of gut decontamination, in an attempt to prevent bacterial translocation, either 
alone or in addition to systemic prophylaxis is a further issue. Evidence at present is 
limited, although animal studies suggest a possible benefit. A single trial in humans 
showed only a non-significant decrease in mortality (although significance was obtained 
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with mulitvariate analysis) though it did show decreased pancreatic infections (Luiten EJ 
and Bruining, 1999). This trial involved oral, rectal and intravenous antibiotics. 
•Nutrition. 
The role of the gut in the development of infected necroses is becoming increasingly 
apparent and this brings us to another area of contention in the management of AP: 
Nutrition. As part of the, afore mentioned, pancreatic rest it had been traditional to 'feed' 
patients (who were expected to not be able to take orally or who did not settle) 
parenterally. The advantages of enteral feeding, especially in a context where translocation 
of gut organisms may be an important factor, led people to explore the possibility of 
feeding enterally in AP. This done especially beyond the ligament of Treitz which should 
thereby cause less stimulus to pancreatic secretion. A number of trials have shown 
advantages or a least no greater complications (Kalfarentzos et al., 1997; McClave et al., 
1997; Hamvas and Pap, 1998; Nakad et al., 1998; Berger and Papapietro, 1999; Powell et 
al., 2000). Although enteral feeding didn't have the hoped beneficial effect on 
inflammatory markers (Powell et al., 2000). 
•Endoscopic Sphincterotomy. 
Early (first one to three days of an attack) ERCP and endoscopic sphincterotomy (ES) in 
AP has a logical basis. CBD stones causing acute pancreatitis can be identified and 
removing a stone obstructing the CBD and/or pancreatic duct and decompressing the 
obstructed system should improve outcome. 
Some retrospective studies and four controlled trials have been performed. The trials have 
not all had the same conclusion and the largest is only available in abstract form (i.e. not 
peer reviewed) even some 8 years hence. Early ERCP has been shown to have a decreased 
overall complication rate in 'all' gallstone AP patients, but especially those with severe 
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disease ( Neoptolemos et al., 1988; Fan et al., 1993). Another study which did not show 
this in fact showed a (non-significantly) worse outcome in the treatment group (Folsch et 
al., 1997). This later study did not delineate mild and severe disease and excluded those 
with cholangitis or an elevated bilirubin, taking those to 'require' ERCP. The Hong Kong 
study (Fan et al., 1993) showed a significant reduction in biliary sepsis (presumably a 
number of these patients would have fallen into the automatic ERCP group in the Folsch 
study (1997)). Of interest the largest study, only ever published in abstract form, did show 
significantly lower complication and mortality rates in the treatment group (Nowak et al., 
1995). This 'despite' excluding those with an impacted stone at the papilla, who routinely 
had ES. A meta-analysis which included all four studies, severely limited by the varied 
inclusion criteria and lack of details on the largest'trial, showed a significant reduction in 
both mortality and complications (Sharma & Howden, 1999). 
Thus, evidence exists but the full role has not been delineated. It would seem reasonable to 
state that in AP with gallstones and evidence of biliary obstruction (obstructive liver 
function tests or biliary dilatation) early ERCP and ES is appropriate. As it is in a predicted 
severe bout (slightly more contentiously). There is likely to be less benefit of early ERCP, 
if any, in predicted mild disease without obstruction. 
1.3.5 Patbogenesis: 
Each aetiological cause of AP may initiate a bout by different (though overlapping) 
mechanisms. However, all theories of the pathogenesis suppose common pathways, 
although the exact point of the start of commonality is not fully understood. 
Why gallstones cause AP is not fully understood. Obstruction of the pancreatic duct at/near 
its confluence with the CBD is the most obvious and some evidence exists for obstruction 
(Steer, M. L. & Meldolesi, J., 1987) and reflux of bile (Opie, E. L., 1970). These theories 
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are not fully accepted, and certainly events such as acinar cell damage can lead to enzyme 
activation by a number of methods. 
In gallstone and other 'obstructive' causes of AP it is suggested that the back pressure 
resulting leads to increased ductal pressure, stassis of the pancreatic juice and/or reflux of 
bile thence abnormal activation of the pancreatic digestive enzymes. This activation could 
occur either intraductally, intracellularly (Scheele, G. A. et al., 1984; Saluja, A. et al., 
1989) or in the interstitium (Kioppel, G. et al., 1986) leading to autodigestion. The cause 
of this activation could be intracellular activation by eo-localization which has been shown 
to occur in models of duct obstruction (Saluja, A. et al., 1989). Autodigestion is also 
thought of as a central factor (and ar!,'Uably the factor) in all forms (Kioppel, G. & Maillet, 
B., 1993). 
This autodigestion leads pancreatic parenchyma! and/or fat damage then to the activation 
and recruitment of inflammatory cells and inflammatory mediators (Brady, M. et al., 
1999). 
Alcohol induced AP is an area of contention. It is accepted by many that a truly acute form 
of alcohol induced pancreatitis exists (Samer, M. & Cotton, P. B., 1984; Singh, M. & 
Simsek, H., 1990; Pelli, H. et al., 2000) although it appears the majority of cases of AP 
due to alcohol are in fact exacerbations ofCP, if undiagnosed (Meier P.B., 1995; Robles-
Diaz, G. & Gorelick, F.S., 1997). Thus the mechanism has much overlap with that 
discussed below for Alcohol Induced Chronic Pancreatitis, AICP. A summary of the 
effects implicated as having a role in acute pancreatitis includes: Alcohol has been shown 
to lead to increased fragility of zymogen granules (Haber, P.S. et al., 1994) which is 
associated with activation of digestive enzymes intracellularly. This can thus lead to 
cellular death, auto-digestion and instigation of inflammatory cascades. The induction of 
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enzymes involved in alcohol and other xenobiotic metabolism may lead to creation of 
reactive oxygen species (ROS) and the cellular dysfunction, thence inflammation+/-
autodigestion and inflammatory cascades this may induce (Braganza, J. M., 200la). Indeed 
acute ethanol has been shown to lead to oxidative changes (Altomare, E. et al., 1996). 
Similarly, direct toxic effects of alcohol, its metabolites and metabolites of other 
xenobiotics (reactive xenobiotic species, RXS) produced by these enzymes (Schenker, S. 
& Montalvo, R., 1998). 
Thus a central feature and possibly the central pathogenic factor in the common forms of 
AP may be auto-digestion, this occurring in the acinar cells themselves, interstitium or 
ducts/acini. The autodigestion then leads to necrosis, initially of the interstitial then 
peripancreatic fat probably due to lipase (the one pancreatic enzyme not requiring 
activation) (Kloppel, G. & Maillet, 8., 1993). The progression onto pancreatic 
parenchyma I necrosis can then be ascribed to a spiralling of enzymatic activation and/or 
alternatively the induction of inflammatory cascades, possibly associated with 
microvascular changes. 
However, auto-digestion as a central or initiating feature is not fully accepted (Braganza, J. 
M., 200 la). The argument here is dependent on oxidative stress as the initiating and 
central event, there is certainly evidence that oxidative stress is involved and as alluded to 
this is probably!! central factor in alcohol induced pancreatic damage. Also the 
inflammatory pathways can lead to a build up ofROS further involving this pathway. 
Microcirculatory changes also occur in AP and may be involved in progression (Menger, 
M. D. et al., 200 I). 
We do know that various components of the inflammatory cascades appear to be activated 
in AP (Brady, M. et al., 1999; Osman, M. 0. & Jensen, S. L., 1999), however, whether 
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they are primary or secondary factors is, again, unknown, as is the stage they become 
relevant. It is postulated that they could be the central factor in all AP and they certainly 
have a major part to play in the systemic effect of AP such as the systemic inflammatory 
response syndrome (SIRS) and multiple system organ dysfunction (MSOD) (Brady, M. et 
al., 1999). Although, prior evidence implicating proteases even in some systemic effects 
does exist (Ohlsson, K., 1 990). Those cytokines known to be involved are predominantly 
those derived from activated macrophages, e.g. TNFa, IL-l J3 and also fL-6, and also 
various chemokines (Viedma, J. A. et al., 1992; McKay, C. J. et al., 1996; Norman, J., 
1998) and are discussed at greater depth in section I. 5 .I. 
It is argued that an inflammatory pathway fundamental in possibly both local necrosis (fat 
and pancreatic) and also the development of systemic complications (often in advance of 
pancreatic necrosis) is activation of mast cells and releases of its mediators; histamine, 
PGD2 and L TE4 (Braganza, J. M., 2000). The argument is based on a number of points. 
They are consistent with pathological findings (which also support auto-digestion as a 
primary event). Wherein local fat necrosis is first seen, this is the site of a number of mast 
cells and these are seen to de granulate very early in the course of experimental AP, even 
prior to findings suggestive of activation of pancreatic enzymes. 
Indeed, as early as 1969 the mast cell, with its combination of secretory mediators was 
proposed as a cell pivotal in forming a common pathway between 'biliary', lipolytic and 
proteolytic forms of experimental acute pancreatitis (Wanke, M., 1969). With mast cells 
plentiful in the normal pancreas (Goldowski, M. et al., 1959) and increased in some 
experimental forms of AP (Frick, G., 1969). Whilst, very recently, mast cell stabiliser pre-
treatment has been shown to decrease local and systemic exudation and systemic 
neutrophil activity in a sodium taurodeoxycholate model in the rat (Dib, M. et al., 2002). 
28 
CHAPTER I: INTRODUCTION 
Evidence for mast cell derived mediators, especially the arachidonic acid metabolites is 
discussed in that section. 
1.3.6 Predisposition to Severe Disease: 
Thus it is seen that a number of postulated but no fully proven mechanisms of both the 
initiation and progression of AP exist. 
The severity of an attck may be down to the severity of the insult, however, other factors 
implicated are genetic which could pertain to all the proposed (Braganza, J. M., 200 I b). It 
is probably the fact that multiple factors are involved and a number of these may be 
genetic. 
An improved understanding of factors involved in acute pancreatic inflammation and 
genetic components to severity stand to aid our overall understanding and therefore ability 
to treat/minimise the problems associated with this condition. Especially because therapies 
for these multi-factorial conditions probably requires a multi-therapy approach especially 
in systems where 'redundancy' exists, such as inflammatory cascades. 
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1.4 Chronic Pancreatitis: 
Chronic Pancreatitis, as mentioned, has various aetiologies which may or may not cause 
disease through related pathological mechanisms. There is much overlap in clinical 
findings and natural history. At least in part, common mechanisms again appear to exist, 
especially in terms of some final common pathways and involvement ofthe inflammatory 
pathways. 
It's incidence and prevalence are difficult to ascertain and vary dependent on the 
techniques by which the figures are obtained. In Western practice figures for incidence are 
around 2-10 new cases per 100,000 population per year and prevalence 15 per I 00,000 
population (Worning, H., 1998). The figures available (from an in depth study by Balaji et 
at, ( 1994)) for Southern India, where the Tropical sub-form of CP is common, gave a 
prevalence of 126-168 cases per I 00 000 population. 
The most recent consensus classification of pancreatitis from Marseille/Rome (Sarles, H. et 
al., 1989) divided CP thus: 
•Chronic calcifying pancreatitis, which includes most of what is generally considered CP; 
that is Alcohol Induced CP (AICP), Idiopathic CP (ICP), Tropical CP (TCP) and 
Hereditary Pancreatitis (HP). Which generally present with recurrent bouts of, and/or 
continuous, pain and progresses to exocrine and/or endocrine insufficiency, see below. 
•Chronic obstructive pancreatitis, where the changes occur proximal to an obstruction 
such as tumour or stricture. 
•Chronic inflammatory pancreatitis, a separate entity where parenchyma is replaced by 
fibrosis infiltrated by mononuclear cells. 
The clinical features of CP are fairly consistent throughout the subdivisions of chronic 
calcifying pancreatitis with variation in degree, rather than form. 
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Pain is typically the first feature, especially in Western forms, although it may only be 
elicited in the history when a 'later' feature presents. Pain may be continuous or 
intermittent; which may be in acute exacerbation's with or without a background of pain 
(Warshaw, A. L. et al., 1998). Indeed a bout of AP, or an acute exacerbation ofCP, is 
commonly the initial presentation. The pain is classically upper abdominal with radiation 
to the back and may be found to diminish as the disease progresses, probably due to the 
decreasing amount of functional pancreatic tissue (Ammann, R. W. et al., 1984 ). Nausea 
+/- vomiting are also often features, especially associated with bouts of pain, as is 
anorexia. 
As discussed the common forms of CP are classified as forms of chronic calcifying 
pancreatitis. As such pancreatic calcification is a finding in these forms ofCP, however, it 
is not found invariably but is regarded as an inevitable consequence if the disease is of long 
enough duration. There is some debate as to whether non-calcifying forms of these 
diseases constitute different disease entities (Sarles, H. et al., 1992). 
Pancreatic Carcinoma may complicate, and is probably predisposed to by, CP (Ekbom, A 
et al., 1994). In TCP, studies have shown rotes of8.3% at 8 year follow up (Augustine, P. 
& Ramesh, H., 1992) and 3.25% at 4.5 years (Chari, S. T. et al., 1994), both studies 
showing pancreatic carcinoma to occur at a younger age than 'sporadic' cases with average 
ages found to be in the mid-forties. Hereditary Pancreatitis, HP, also has a higher than 
expected frequency of pancreatic cancer, an international study showing eight cases in 246 
patients with HP, average age at diagnosis was 57 years and an estimated cumulative risk 
at 70 years of 40% (Lowenfels, A. B. et al., 1997). In CP (AICP and ICP, primarily) 
another international study showed 56 cancers in 2015 patients over an avemge 7.4 year 
follow up (Lowenfels, A B. et al., 1993). 
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Other major clinical features are linked to the effect of CP on the function of the pancreas: 
Loss of exocrine function: Malabsorption, evidenced by steatorrhoea and/or weight loss, is 
due to loss of functional exocrine pancreatic tissue, although as much as 90% functional 
loss can be sub-clinical (DiMagno, E. P. et al., 1973). Typically exocrine function is lost 
in advance of endocrine function. A study performed during these MD studies but not 
included in this thesis suggests that a commercially available measure of Pancreatic 
Elastase in the faeces may be an indicator of decreasing pancreatic function prior to it 
becoming clinically evident (Cartmell, M.T. et al., 2003). Tn agreement with a study in 
cystic fibrosis over 5 years (Walkowiak, J. & Nousia-Arvanitakis, S., 2001 ). 
Loss of Endocrine Function: Diabetes mellitus is the result of endocrine insufficiency and 
generally occurs late in CP (Ammann, R. W. et al., 1987; Nauck, M. A, 1998). 
The classification of 'calcifying' CP is not simple as its overlap with AP or, more 
specifically, recurrent bouts of AP is difficult to define. From the Cambridge Conference 
onward CP was considered as a continuing disease characterised by irreversible 
morphological change (Samer and Cotton, 1984). However, tissue is rarely available for 
histological diagnosis. Thus surrogate markers must be employed, such as functional and 
structural tests. The latest concensus document is the Zurich International Workshop 
(Ammann, R.W., 1997). It defines Alcohol Induced Chronic Pancreatitis as a typical 
history and 'excessive alcohol intake' (2:80g/day for males, 2:60g/day for females). For 
definite CP one of the following is also required: 
Pancreatic calcification. 
Moderate to marked duct lesions (Cambridge Criteria (Axon, A.T.R. et al., 1984)). 
Marked exocrine insufficiency (steatorrhoea markedly reduced by enzyme 
supplementation). 
Typical Histology. 
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For probable CP one of: 
Mild ductal changes. 
Recurrent or persistent pseudocysts. 
Pathological secretin test. 
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Endocrine insufficiency (e.g. abnormal glucose tolemnce test). 
For clinical classification late stage CP was defined as probable or definite CP (as above) 
and end-stage CP as exocrine insufficient. Though others may have typical history and 
recurrent problems their diagnosis is reserved until more objective evidence, as above, is 
found. 
1.4. I Management 
Much management of CP is based around symptom control as it is chamcterised by 
irreversible changes. Thus pain management and treatment of exocrine and endocrine 
insufficiency are the major issues. 
However, removal of aetiological factors may help, especially in obstructive CP. This is an 
area of debate for AICP as the disease may progress with abstinence whilst pain will 
eventually abate with disease progress± continued alcohol consumption. Some evidence 
suggest abstinence improves progression of pain (Hayakawa, T. et al., 1989) whilst other 
evidence is against (Lankisch, P. G. et al., 1993). However, it would seem sensible to 
advise abstinence on the basis that it may decrease pain and/or progression (Gullo, L. et al., 
1988) and that abstinence generally improves survival (Bullock, K.D. et al., 1992). 
The evidence on treatments of pain in CP is variable, complicated by the varied disease 
progression. The subject is well reviewed by the American Gastroenterological 
Association {AGA) (Warshaw, AL. et al., 1998) and an approach suggested (A.G.A., 
1998) as laid out in figure 1.5. 
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Patient with chronic pancreatitis :lnd pain 
CT ± FRCP = F. S ± tipper endoscopy or upper CiT 
Pseudocyst. biliary 
~tri ·tun:. duodenal 
stenosis, peptic ulcer 
disease. pancreatic cancer 
.. 
I 
Meclicnl (PUr>), surgic:1l 
{PS. BS. DS) or endoscopic 
TX (PS) 
Lo'>v-fat diet. non-narcotic analgesics. no alcohol~ have patient keep log of pain and 
f ill out quality-of-life questionnaire 
I '\Jn rc~ponsc 
• 
8-W~ck trial of h igh·dl)sc pancreatic enzymes(in tablet form) - acid suppression 
No response 
Consider trial of endoscopic thcrnp) 
Endosropic lhcrupy nut pt>rfom1cJ or no rcspun!lc 
• 
L> i ~t·u::.~ wilh patient watchful waiting \S. narcotic ana lg~sics and 
risk of addictJon \ 'S. benefits and nsks or surg,cry 
.---------., ~ l ...... _s_u_rg_e_r_y_u_e_ci_u_eu_ .... 
[Small ducts . Large ducts 
• • Consider nerve ablation in cunlrullcd !letting St1rgical d rninage 
• 
Pancreatic Tt!'lt!ction 
Figure 1.5 Algorithm for the management of chronic pancreatitis. 
From the ' American Gastroenterological Associations medjcal position 
statement: Treatment of pajn in chronic pancreatitis.' ( 1998) 
Courtesy of Eisevier Health Sciences. 
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Management of exocrine insufficiency is with pancreatic enzyme supplements, normally 
porcine in origin, this is separate from the supplementation used as a strategy for pain 
relief. Endocrine insufficiency is managed as with other forms of diabetes mellitus. 
I. 4. 2 Aetiologica I sub-divisions: 
Tn western practice Alcohol Induced Chronic Pancreatitis (ATCP) is the commonest form 
accounting for some 60- 90% in the majority of studies (Worning, H., 1998). Its 
definitive diagnosis is as described above. The level of intake necessary to cause CP is not 
at a distinct level, indeed studies have shown a linear relationship between intake and the 
logarithm of the relative risk, without a lower 'safe' cut off(Durbec, J. P. & Sarles, H., 
1978). Risk for a given alcohol intake undoubtedly varies between individuals, as 
evidenced by only a small proportion of even heavy consumers of alcohol suffering from 
this disease (Singh, M. & Simsek, H., 1990). Studies of asymptomatic alcoholics have 
shown changes consistent with CP, on differing investigations, in 0-30% of patients 
(Worning, H., 1998). AICP is more common in males than females (as with alcohol 
consumption and this ratio is decreasing in most studies, probably as women consume 
more alcohol) and appears to be increasing in frequency alongside increased alcohol intake 
(Pitchumoni, C. S., 1998); and mortality was also seen to decrease with decreased alcohol 
sales in Sweden (Romelsjo, A & Agren, G., 1985). The explanation for the lack of 
consistency of development of AlCP and other alcohol induced end organ diseases is 
probably multi-factorial, see below. 
Idiopathic Chronic Pancreatitis (ICP), the second most common form in western practice 
has, as its name suggests, no known aetiology. Given the evidence regarding alcohol 
exposure above, making a definite of diagnosis in a social drinker can be difficult. Unlike 
AICP the sex distribution is approximately equal in the majority of studies (Chari, S. T. & 
Singer, M. V., 1998). Some commentators regard ICP has having two sub-divisions based 
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on age of onset; early onset/juvenile and late onset ICP (Layer, P. et al., 1994). A bimodal 
distribution of age of onset appears to exist, giving a peak in adolescence to early 
adulthood and another around the ages of 55-65 (Ammann, R. W., 1992). Why some 
people suffer ICP is again unknown and probably multi-factorial in nature. Some potential 
aetiological factors have been proposed whilst recent evidence has shown a probable role 
for candidate genes investigated in association studies, most notably CFTR (Cohn, J. A. et 
al., 1998; Sharer, N. et al., 1998) and SPINK I (Witt, H. et al., 2000; Truninger, K. et al., 
2002). 
Hereditary Pancreatitis (HP) is an inherited condition of autosomal dominant inheritance 
with a penetrance, from epidemiology studies , of around 80% (Sibert, J. R., 1978). 
Recently a number of mutations of the Cationic Trypsinogen (CaT) gene, accounting for 
over half of cases, have been described ( Chen, J. M. et al., 1999; Ferec, C. et al., 1999; 
Whitcomb, D. C. et al., 1996a). HP has an early age of onset (normally childhood) 
however this does vary on the mutation responsible (Gorry, M. C. et al., 1997). 
Tropical Chronic Pancreatitis (TCP) is the most common form ofCP in some regions of 
the tropics, including some African and Asian countries, most notably Southern India. lt 
was first described as a tropical form of pancreatitis in Indonesia by Zuidema in 1955 
(Zuidema, P. J., 1955). However, as early as 1937, Kini in India described operating on a 
man with pancreatic calculi complicating CP (Kini, M. G., 1937). 
TCP was many years ago described clinically thus, 'recurrent abdominal pain in childhood, 
diabetes around the age of puberty and death at the prime oflife'(Geevarghese, P. J., 
1968). The sex ratio is around 1: I ( as with HP and ICP), hospital studies showing a slight 
male preponderance and field studies a similar female preponderance (Ramesh, H., 1997). 
Age of onset is normally childhood to early adulthood (along with HP and juvenille ICP) 
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but the age at presentation does appear to be increasing (Ramesh, H., 1997). Pain is less of 
a feature than in AICP and this is more closely mirrored in ICP, in western practice 
(Pitchumoni, C. S., 1998). Further clinical features compared with other forms include a 
high frequency of calcification at around 90%. Also the nature of the calcification differs, 
with larger intraductal stones (Chari, S. T. et al., 1992; Mohan, V. & Pitchumoni, C. S., 
1998). Steatorrhoea is seen less frequently and is probably because of the low fat diet 
consumed in the areas where TCP is prevalent. Diabetes mellitus is common in TCP (it is 
even said to be inevitable (Mohan, V. & Pitchumoni, C. S., 1998)) and in its form known 
as FCPD ( fibrocalculus pancreatic diabetes) accounts for around 12-16% of diabetes in 
Kerala, South India (Thomas, P. G. et al., 1990). 
1.4.3 Pathology and Cellular Involvement in CP: 
The pathology of CP shows much consistency across types but also some variation. 
Generally the changes, in the forms we are discussing, are initially patchy with adjacent 
lobules affected to differing degrees (Kioppel, G. & Maillet, B., 1998). Typified by 
fibrotic changes, with infiltration ofleukocytes (Kloppel, G. & Maillet, B., 1998). There is 
irreversible degeneration of acinar cells which are replaced by fibrous tissue. The 
pancreatic duct can be variously narrow, of normal calibre or dilated. Dilatation with areas 
of stenosis associated with scarring is the most common finding, but is not necessary for 
'upstream' pathology to exist. Ductal lithiasis is a nearly universal finding with so-called 
protein plugs in the smaller ductules (found less commonly in TCP (Sarles, H. et al., 
1994)). Calcification of the stones is not invariable and some commentators describe two 
forms ofCP (Sarles, H. et al., 1992). 
Macrophage and T-cell infiltrates predominate and at increased levels in CP (Emmrich, J. 
et al., 1998; Gansauge, F. et al., 200 I; Ockenga, J. et al., 2000). Lymphocytes are found 
at the margins of parenchyma and fibrosis and increase in greater numbers than do 
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macrophages (Emmrich, J. et al., 199S), with a lesser proportion of memory cells than 
nonnal tissue or tissue adjacent to tumour. 
Systemic increases in T-cells (both Cn4+ and ens+ subtypes) have been found in CP, 
apparently returning to nonnal after resection of an inflammatory mass in the pancreatic 
head (Gansauge, F. et al., 200 I). In a study of peripheralleukocytes in CP although no 
increase in total number of leukocytes or lymphocytes was found an increased ratio of 
Cn4+:cns+ cells were found (Ockenga, J. et al., 2000). This is in contrast to, but not 
incompatible with the above study of pancreatic tissue (Emmrich., J. et al., 199S), where 
CDS+ cells just predominated. However, further studies of pancreatic tissue in CP did find 
a predominance ofCn4+ over ens+ cells in the pancreas in CP (Hunger, R. E. et al., 
1997; Ebert, M. P. et al., 199S). 
According to the necrosis-fibrosis theory of chronic pancreatitis circulating leukocytes 
responding to cytokine chemotaxis infiltrate the pancreas and become resident cytotoxic T-
cells (this is also compatible with other theories of pathogenesis). Recurrent acinar cell 
injury is caused by cytokine release from activated cytotoxic T -cells and macrophages, 
which also release TGF beta. TGF beta (a group of five cytokines) increases infiltration, 
differentiation and proliferation of pancreatic stellate cells. The perpetuation of the 
antigenic stimulus and cytokine production results in destruction of pancreatic parenchyma 
and fibrosis. 
Mast cells have again been implicated in CP, in addition to AP, in that they have been 
found in increased numbers in CP (Okolo CN et al., 2000). Another study confinned this 
(Esposito, I. et al., 2001), also showing that numbers correlated with fibrosis and 
inflammation; in addition, this study showed that lgE-activation of mast cells increased in 
CP. 
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Eosinophils, stimulated by mast cells mediators and producers of cysteinylleukotrienes, 
have been found in the perineural inflammation (Keith, R. G. et al., 1985). The interaction 
between mast cells and eosinophils is seen in that mast cell mediators have been shown to 
activate eosinophils (Raible, D. G. et al., 1992). Whilst the cysL Ts (produced by both) are 
chemotactic for mast cells. 
1.4.4 Aetio-pathogenesis: 
The underlying 'primary' pathology in CP is a matter of much debate. Many in-depth 
reviews, often reaching different conclusions, exist. The debate is often said to come down 
to either the 'protein plug' hypothesis which proposes that protein plugs obstruct the duct 
and damage the ductal epithelium leading to atrophy and fibrosis (Scheele, G. A. et al., 
1996) while the 'necrosis fibrosis' hypothesis suggests recurrent bouts of acute 
inflammation cause necrosis thence fibrosis (Kloppel, G. & Maillet, B., 1992). They can, 
in part, be brought together in the 'two hit hypothesis', however, the debate as to which 
'hit' comes first persists (Ammann, R. W. et al., 1999). This debate can be said in part to 
be a matter of semantics (Longnecker, D. S., 1996). Both mechanisms can be associated 
with increased oxidative stress but this most directly can be associated with the hypothesis 
of acinar cells as the site of primary dysfunction (Braganza, J. M., 1998). Indeed reviews 
concluding a number of features as primary exist: Oxidative stress (Braganza, J. M., 
1998); recurrent AP, probably autodigestive, leading to necrosis then fibrosis (Kloppel, G. 
& Maillet, B., 1991 ); protein plug, then stone obstruction of ducts leading to fibrosis 
(Sarles, H. et al., 1989). 
It should be borne in mind that the various sites and mechanisms are not mutually 
exclusive (Longnecker, D. S., 1996). It could be considered that the pathogenesis is a 
variable 'hit' disease dependent on the significance of each insult; the sequence, if not 
unimportant, certainly unknowable for most aetiologies at present. 
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If abnonnal activation of the digestive enzymes is seen as a fundamental 'fault', this would 
be closest to the necrosis-fibrosis view but with minor duct/acinar events as possible 
primary events in some fonns. This is favoured because HP in which we know the detect 
(at least in some cases) (Whitcomb, D. C. et al., 1996b) is pathologically indistinguishable 
from other fonns, in any given case. HP is due to abnonnal activation, or more strictly 
speaking abnonnal inactivation of the enzyme Cationic Trypsinogen, here only one 
'knock-out' hit is required. Further associations implicate abnonnal enzyme activation as 
having a role (Witt, H. et al., 1999). It should be noted that the necrosis-fibrosis theory 
was delineated based primarily on pathological observations (Kloppel, G. & Maillet, 8., 
1991) long before the defect in HP was understood. 
Acinar cell damage secondary to a number of insults can lead to abnonnal cellular 
transport and enzyme activation, alternatively direct damage could lead to inflammation 
and/or fibrosis without autodigestion. Considering the acinar cell as a site of primary insult 
(Freedman, S. D., 1998) can thus in part bring together the necrosis fibrosis and oxidative 
stress theories; whilst denying necrosis fibrosis (certainly due to autodigestion) as the sole 
primary event. 
Increased oxidative stress leads to tissue damage by a number of mechanisms, most 
notably lipid peroxidation (Slater, T. F., 1984). Evidence for which exists in CP 
(Schoenberg, M. H. & Birk, D., 1998). These compounded by diminished micronutrients 
(Rose, P. et al., 1986) which function as antioxidants and sustain GSH (the active fonn of 
glutathione) stores for the cytochrome P450 pathway of detoxification. 
Ductal obstruction (consistent with the 'protein plug' hypothesis) certainly is implicated in 
the association ofCP with mutations ofCFTR (Sharer, N. et al., 1998; Cohn, J. A. et al., 
1998) and pancreatic fibrosis and insufficiency in Cystic Fibrosis (CF). Here a defective 
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CFTR decreases bicarbonate and fluid secretion increasing concentration/decreasing 
solubility of protein. This could then promote protein plug and thence stone formation. 
Stones/strictures which can also obstruct larger ducts (indisputably the cause of obstructive 
CP (Gyr, K. et al., 1984)) are unable to explain the patchy pattern found in common forms 
of CP. Also, obstruction has been shown to lead to eo-localisation of acinar zymogens and 
Iysosomes (Saluja, A et al., 1989, Hirano, T. et al., 1991) which is a cause of premature 
enzyme activation; again revealing the lack of a true distinction between theories in such a 
complex multi-factorial disease. 
In CP of other aetiologies, and indeed HP due to mutations which have a lower penetrance, 
a variable number of hits at various site( s) is required. Whereas in high penetrance 
mutations only the one 'knock-out punch' is required. 
Looking specifically at AICP the mechanism is again unknown. However, evidence exists 
for mechanisms implicating all of the pathways discussed, again implicating a multi-
factorial aetio-pathogenesis. It may be through direct toxic, or indirect, effects. In addition, 
induction of enzymes by ethanol may lead to injurous bioactivation of oxygen free 
radicals, limited evidence exists for a number of the mechanisms (Braganza, J. M., 1996; 
Schenker, S. & Montalvo, R., 1998). Further, this effect may be due to alcohol or its 
metabolites, in all cases functional or productive variations in metabolising enzymes may 
be relevant. 
In Wistar rats ethanol administration has been shown to increase pancreatic lysosomal and 
zymogen fragility (Apte, M. V. et al., 1994). Chronic ethanol administration has also been 
shown to increase the protein and trypsinogen concentration of pancreatic juice in rats and, 
with longer duration, also to effect acinar cell ultrastructure (Gronroos, J. M. et al., 1988). 
These factors are of particular relevance when taken along side the ability of lysosomal 
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enzymes to activate the digestive enzymes contained in the zymogen granules and thus 
premature activation of pancreatic enzymes, leading to pancreatic autodigestion. 
Similarly, in TCP evidence for a contribution of a number of factors exists. From dietary 
toxins, oxidative stress (as evidenced by increased lipid peroxidation (Ganesh Pai, C. et al., 
1999)), possibly due to lack of anti-oxidant micronutrients (Braganza, J. M. et al., 1993). 
To recurrent gastro-enteritis leading to bouts of dehydration with the possible associated 
decrease in pancreatic secretary volume (which as discussed above is normally around 2.5 
litres). Thus both digestive enzyme concentration and potential for protein precipitation 
would increase. This coincides with the theory of pathogenesis (seemingly ignored in the 
majority of both western and 'tropical' reviews of the pathogenesis ofCP and TCP) 
proposed in 1980 by Nwokolo and Oli in Nigeria (1980). 
Inflammatory mediators and cells are no doubt involved in the pathogenesis but evidence 
as to whether they are primary or secondary factors is limited and an area of debate (Friess, 
H. et al., 1998). 
To account for these factors not leading to CP more widely genetic components (or hits) in 
one or more of the pathways could be present 
1.4.5 Evidence for a genetic component in Chronic Pancreatitis: 
One form of pancreatitis has a definite genetic basis and that is Hereditary Pancreatitis. As 
discussed above, before the genetic basis of HP was understood epidemiological studies 
showed it was due to dominant inheritance with a penetration of 80% (Sibert, 1978). Since 
that time a number of mutations in the gene for cationic trypsinogen have been found in 
families with HP. The relevant region of chromosome 7 was originally implicated in quick 
succession by Le Bodic, L. et al. (1996), Whitcomb, D.C. et al. (1996b) and Pandya, A, et 
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al. (1996). Then the first mutation discovered later that year (Whitcomb, D.C. et al., 
1996a). Mutations in this gene have been shown to be strongly associated with HP and are 
found in more than 50% of HP families (Ferec, C. et al., 1999). The various mutations 
have slightly differing phenotypic forms. 
In other forms the role genetic predisposition plays is less distinct, however, various 
factors in the diseases epidemiology implicate genetic factors, and indeed some genetic 
associations have been found: 
In AICP only a proportion of alcoholics get CP (around 5% (Dreiling, D.A., 1985)) (Singh, 
M. & Simsek, H., 1990; Haber, P. et al., 1995). A larger subgroup develop alcoholic liver 
disease, there is some overlap between these groups (Singh, M. & Simsek, H., 1990). 
Studies of asymptomatic alcoholics have shown changes consistent with CP, on differing 
investigations, in only 0- 30% of patients (Woming, H., 1998). A number also develop 
asymptomatic pancreatic fibrosis (Meier, P.B., 1995), however, even then, at post-mortem 
studies at least 32% of pancreata of alcoholics are found to have no or minimal fibrosis 
(Pitchumoni, C.S. et al., 1984). In addition, as discussed, the level of alcohol intake 
necessary to cause CP is not at a distinct level, without a lower 'safe' cut off (Durbec, J.P. 
and Sarles, H., 1978). 
Risk for a given alcohol intake undoubtedly varies between individuals. 
Diet has been implicated (Durbec, J.P. & Sarles, H., 1978) and smoking may have a role 
(Bourliere, M. et al., 1991; Haber, P. et al., 1995). However, perhaps the best controlled 
study on smoking failed to confirm this (Haber, P.S. et al., 1993a) and it remains a matter 
of debate (Haber, P. et al., 1995). 
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A genetic predisposition could explain these findings and indeed an increased frequency of 
CFTR (cystic fibrosis transmembrane conductance regulator) mutations have been found in 
AICP, although less commonly than in ICP (Cohn, J.A. et al., 1998; Sharer, N. et al., 
1998), see below. The same is true for SPINK I mutations (Witt, H. et al., 2001). Alcohol 
dehydrogenase polymorphisms have been analysed in two small studies, larger 
appropriately controlled studies are required (Haber, P. et al., 1995). A number of 
commentators (Adler, G. & Schmid, RM., 1997; Singh, M. & Simsek, H., 1990) have 
proposed a genetic component or at least believed it worthy of analysis (Meier, P.B., 
1995). 
With no identified aetiological factor, but no obvious family associations in most cases ICP 
may have a genetic component in parallel with unknown factors. CFTR mutations have 
been found in up to 11 times the expected number oflCP patients (Cohn, JA et al., 1998; 
Sharer, N. et al., 1998). There is also an association with SPINK I mutations (Witt, H. et 
al., 2000; Truninger, K. et al., 2002). 
TCP has long been known to have a family tendency. Indeed, one of Geevarghese and 
Pitchumoni's early essays (Pitchumoni, C.S. & Geevarghese, P.J., 1966), and an early 
study (Pitchumoni, 1970), were entitled Familial Pancreatitis. More recent studies (Mohan, 
V. et al., 1989; Thomas, P.G. et al., 1990) in southern India have again shown familial 
aggregation. Of the proposed aetiological factors in TCP all occur outside the regions 
where TCP is common and can be found where TCP does not occur (Mohan, V. & 
Pitchumoni, C.S., 1998). In addition, many of the proposed factors are associated with 
poverty and Kerala, where TCP is most common, has some of the best socio-economic 
markers in India. However, some of these factors are likely to have a role in its 
pathogenesis but it is believed that a genetic factor would be a reasonable, or even 
probable, explanation for the geographic variation, especially in relatively static 
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populations (Pitchumoni, C.S. & Geevarghese, P.J., 1966; Rarnesh, H., 1997; Mohan, V. & 
Pitchumoni, C.S., 1998). 
Genetic mapping using genetic variation can be used to investigate traits with Mendelian 
inheritance (as with HP). However, to identify possible genetic associations in 
multifactorial disease is more complex; a number of techniques can be employed. A known 
candidate gene can be studied. If that gene has genetic variability (as most do) these can 
then be studied to see if they are associated with the disease. The variation, known as 
polymorphism (or mutation, especially if is has a functional effect) can be of various 
forms. Single nucleotide polymorhisms (SNP, also known as point mutations), variable 
number tandem repeats (VNTR, which are polymorphic microsatellites) and 
insertion/deletion polymorphisms. 
A polymorphism can be studied in isolation and its association to a given disease studied 
by comparing the frequency of each allele (polymorphic variant) in patient groups 
compared to controls. Obviously it is important to have as few other differences between 
the patient groups and controls. Another weakness is that in multifactorial disease the 
'association' may be relevant but not numerically strong because of other factors. 
Association studies are best performed when the polymorphism (mutation) has a functional 
role. This can be true of all forms of polymorphism: SNPs which can affect transcription, 
even when outside the coding region, (e.g. that discussed later in leukotriene C4 synthase, 
where it creates a transcription factor binding site) or translation (e.g. by changing the 
amino acid for which a codon codes, as in the Rl22H mutation in HP). Insertion/deletion 
polymorphisms can equally affect transcription or translation (e.g. the CYP2E I insertion 
studied here which is associated with increased activity; though the mechanism here is not 
yet understood). 
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1.5 Cytokines: 
Cytokines are small peptides involved in cell-cell signalling in a predominantly paracrine 
but also autocrine and even endocrine manner. They are secreted by leukocytes and other 
cell types and act through specific receptors. They are integral to the inflammatory and 
post-inflammatory cascades. 
They are a disparate group and individual cytokines are often pleiotropic (having multiple 
actions). They signal a number of 'messages' ranging from chemotaxis (the 'chemokines') 
(Rossi, D. & Zlotnik, A., 2000), to cellular activation/proliferation (Dinarello, C. A., 1998) 
to fibrosis (Apte, M. V. et al., 1999). Not all are proinflammatory (e.g. interleukin(IL)-10), 
and a balance between, for example, a secreted receptor antagonist and agonist (e.g. IL 
(interleukin)-l a, IL-l band IL-l receptor antagonist) further enables regulation (Dinarello, 
C. A., 1998). They are sometimes regarded as being grouped by the cellular subtypes 
which secrete them, such as T helper I versus T helper 2 cells, there is, however, a great 
deal of overlap in their actions, some which remain to be fully elucidated (Dinarello, C. A. 
& Mier, A. W., 1987; Haddad, J. J., 2002). 
Tumour necrosis factor alpha (TNF-alpha) and IL-l are the archetypal Th I cytokines. The 
interleukin I family includes the proinflammatory cytokines (IL-l alpha and IL-l beta). 
They are integrally involved in inflammation, primarily through stimulation of 
macrophages, neutrophils, lyrnphocytes and endothelial cells for production of cytokines 
(Dinarello, C. A., 1998). 
1.5.1 Evidence on Cytokines in Acute Pancreatitis: 
•TNF-alpha is elevated in the pancreas in experimental AP (Norman, J.G. et al., 1995). In 
humans it is elevated, especially in severe disease (Pooran, N. et al., 2003). High levels 
have been found in serum and lymph in AP patients with ARDS (Montravers, P. et al., 
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1995), and in around two thirds of ICU patients with AP (Brivet, F.G. et al., 1999). TNF-
alpha is not easily measured as it is rapidly metabolised in the liver and some studies have 
shown elevated levels only in small percentages of patients (Dugemier, T.L. et al., 2003). 
TNF-alpha has been found to be produced at higher levels, in vitro, by monocytes from 
patients with systemic complications (McKay, C.J. et al., 1996) implicating it in 
progression to systemic disease. Though one study of 16 patients did not show elevation 
from mononuclear cells (De Beaux, A. C. et al., 1996). 
Soluble TNF receptors are found to be elevated when septic complications occur 
(Heresbach, D. et al., 1998) and more so in more severe disease (Kaufrnann, P. et al., 
1997). Where they may be predictive of severe disease (Hi rota, M. et al., 2000). 
•Interleukin-1 has been shown to be of importance in a number of animal studies, with 
elevated mRNA levels( also for IL-1 ra) and IL-1 itself in the pancreas and serum (Fink, 
G. W. & Norman, J.G., 1997; Mozo et al., 2002). While the lL-l receptor is not required 
for pancreatitis per se but is required for its 'full progression' (Norman, J.G. et al., 1996). 
However, evidence from humans is not so clear. Though high levels have been found in 
lymph and serum of AP patients with ARDS (Montravers, P. et al., 1995), in the study by 
McKay, C.J. et al. (1996) lL-1 beta did not appear elevated in complicated disease (whilst 
TNF-alpha, IL-6 and IL-8 did). Another study did not find IL-1 beta in a number of the 
patients with post ERCP pancreatitis, but did show elevated IL-l ra in comparison to 
patients who did not develop pancreatitis post procedure (Messmann, H. et al., 1998). Also 
IL-l levels and ratio to fL-1 ra were lower where septic complications occurred 
(Heresbach, D. et al., 1998). 
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Thus TNF-alpha has an important role as lL-1 probably does, though evidence in humans 
for the later is inconclusive. But neither IL-l beta nor TNF-alpha would appear to be 
causal, as perfusion of the human pancreas with either does not induce pancreatitis 
(Denham, W. et al., 1998). 
•Interleukin-6 is a cytokine produced early in the pathway of acute phase protein 
production and since being shown to be elevated early in the course of human AP 
(Viedma, J.A. et al., 1992) has been studied of interest not just from the point of view of 
aetiopathogenesis but as an early marker and predictor of disease (Heath et al., 1993;Leser 
et al., 1991 ). 
•Interleukin-10 is an anti-inflammatory cytokine, has been shown to be elevated in AP in 
humans (Brivet, F.G. et al., 1999) and provides a possible therapeutic avenue. Pre-
treatment with IL-l 0 has been shown to decrease post-ERCP pancreatitis (Deviere, J. et al., 
200 I), but this not universally (Dumot, J .A. et al., 2001 ). 
•The chemokines are cytokines involved in chemotaxis. lnterleukin 8 is the 'prototypical' 
CXC chemokine (these are chemotactic for neutrophils), whilst monocyte chemotactic 
protein 1 (MCP-1) is the prototypical CC chemokine (which predominantly affect 
monocytes). Both are produced in response to IL-l beta and TNF-alpha (Andoh, A. et al., 
2000). 
IL-8 has been seen to be higher in complicated than LDlcomplicated AP (Gross, V. et al., 
1992) and in severe AP than controls and mild AP (Pooran, N. et al., 2003) and to rise over 
the first days of an attack, more rapidly so in severe disease (Bemey, T. et al., 1999) and 
decrease with clinical improvement (Gross, V. et al., 1992). Higher levels in severe AP 
have also been found for other CXC chemokines (Shokuhi, S. et al., 2002). This would be 
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in agreement with the findings of neutrophil involvement in the pancreas in AP (Folch, E. 
et al., 1998) and systemic complications (Mora, A. et al., 1997). MCP-1 (along with other, 
but not all, CC chemokines) increases in AP patients who develop complications (Rau, B. 
et al., 2003). 
•Worthy of discussion, though data is limited (especially in humans), is the nuclear factor 
kappaB (NF-KB) which is a transcription factor for many cytokines. NF-KB increases with 
morphological damage and cytokine mRNA in experimental AP (Vaquero, E. et al., 2001). 
Transfection of pancreas with a viral vector containing NF-KB cause pancreatic and lung 
infiltration by neutrophils (Chen, X. et al., 2002). Indeed NF-KB seems to have a central 
role being involved in the production of chemokines in response to TNFalpha and IL-l beta 
and of cytokines in response to neutrophils (Kim, H. et al., 2000), also being early in the 
cascade it offers a potential therapeutic avenue. However, its role is not simple as it has a 
number of actions ( Grisham, M. B., 1999) and further details await elucidation. 
Thus the cytokine response in AP is both anti- and pro-inflammatory and is certainly 
involved with the progression, if not initiation, of AP, with imbalance of response having a 
role in outcome. Especially involved is 'Th 1 type' response and neutrophils in the systemic 
complications. 
1.5.2 Evidence on Cytokines in Chronic Pancreatitis: 
Cytokines involved in the T-cell and macrophage responses, such as TNF-alpha, 
interferon-gamma and IL-l alpha and beta and IL-6 warrant consideration in CP as T-cells 
and macrophages are major cell types involved, as discussed above. 
In a study by Bamba et al ( 1994) serum levels of both IL-l beta and IL-6 were found to be 
elevated in patients with CP. 11-1 b was confirmed as elevated in serum in CP (Szuster-
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Ciesielska, A et al., 2000). Also TNF-alpha was found at increased serum levels in the 
study by Szuster-Ciesielska et al (2000). Interestingly, this study did not show increased 
levels of either lL-10 or TGF-beta (see below). In addition, mRNA (in peripheral blood 
mononuclear cells) ofTNF-alpha and both soluble TNF-Receptors (p55 and p75) are 
significantly elevated in CP compared to healthy controls (Hanck, C. et al., 1999a). From 
these observations it is clear that the T-cell response in the CP includes a Th-1 type with 
secretion ofTNF and related mediators. Pancreatic cell lines have been shown to produce 
IL-6 and the chemokine IL-8 in response to TNF-alpha and to endotoxin (Blanchard, J. A 
et al., 2000), implicating the Th-1 pathway further. That said, evidence on Th-2 mediators 
is lacking. 
Chemokines IL-8 and MCP-l are also secreted by human periacinar myofibroblasts in 
response to IL-l beta and TNF-alpha and RANTES to TNF-alpha, although a further 
chemokine {MTP-lalpha) was not elevated in this study (Andoh, A et al., 2000). 
Chemokines are also found in the pancreata of patients with CP, which are not found in 
normal pancreata, including MCP-1 (Saurer, L. et al., 2000). 
A study, arguably, showing conflicting results with the above findings, but looking at the 
pancreatic juice of patients with CP did not detect IL-6, IL-l 0 or TNF alpha, although 
TGF-beta was found in a greater number of patients than controls (Kazbay, K. et al., 
2001). TGF-beta has, on account of its role in the induction of fibrosis, been one of the 
most studied cytokines in chronic pancreatitis, although as stated above serum levels were 
not increased in one study (Szuster-Ciesielska, A. et al., 2000). 
TGF-betal mRNA expression is increased in AICP, with transcripts found in several cell 
types including pancreatic stellate cells, acinar, and ductal cells (Casini, A et al., 2000). 
Immunohistochemical studies showed TGF-beta maximal in ductal and acinar cells (Korc, 
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M. et al., 1994) and perifibrotic acinar cells and spindle cells (Haber, P. S. et al., 1999), 
with similar findings in human CP and a mt model. In a further study TGF-beta1 was 
found in CP throughout the ducts, rather than isolated acinar and distal ductular cells in 
normal controls (Slater, S. D. et al., 1995). Analogous findings were shown with enhanced 
mRNA expression ofTGF-beta1, TGF beta Receptor-Il, connective tissue growth factor 
(which is regulated by TGF-beta), and collagen type I in CP compared with normal 
controls (di Mola, F. F. et al., 1999). 
Functional animal studies investigating TGF-beta also suggest a role in CP. A rat model 
indicated a peak ofTGF-betal activity occurring before the peak of fibrosis (Su, S. B. et 
al., 2000). The pancreatic morphology oftransgenic mice that overexpress TGF-betal in 
the pancreas partially resembles morphological features of chronic pancreatitis, (such as 
progressive accumulation of extracellular matrix). Also increased mRNA levels ofTGF-
beta I occur early, coincidentally with collagen types I and m, and later with increasing 
numbers of pancreatic stellate cells (Vogelmann, R. et al., 2001). Another study of a 
transgenic mouse overexpressing TGF-betal in pancreatic beta cells revealed massive 
fibrosis of the pancreas; in adult mice, most of the acini were replaced by fibrotic and 
adipose tissues (Sanvito, F. et al., 1995). In a series of studies by van Laetham et al. TGF-
beta was not only being secreted in ductal cells and mononuclear cells (Van Laethem, J. L. 
et al., 1995) in humans, but was shown to promote fibrosis following repeated bouts of 
experimental acute pancreatitis (Van Laethem, J. L. et al., 1996). 
1.5.3 Evidence for a genetic component to cytokine responses in CP: 
In any condition with an inflammatory or fibrotic basis, or even a component, this process 
will be subject to genetic variation. The variation in response may predispose the 
individual to a more proinflammatory/fibrotic response, or an imbalanced response to a 
given (relevant) stimulus. As such, the influence of genetic variability of either the 
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inflammatory response or fibrosis may affect predisposition to disease or progression of 
disease and therefore its clinical presentation. Cytokines are key mediators in both 
pathways. 
With the study of cytokines in chronic pancreatitis in it's infancy, the evidence regarding a 
genetic component in the responses of different cytokines is also early in its development. 
The 'Thl cytokines' involved with recruitment and activation ofT cells and macrophages 
are implicated by the evidence above and are the first to have been studied with regard to 
genetic predisposition. 
In a study, available in abstract form only, an association between CP and genetic variation 
in the interferon gamma gene (a microsatellite in intron I) was found in a study of 54 
patients with CP and 104 controls. Increased frequencies of the 12 (high production) and 
14 alleles were associated with CP (O'Reilly, D. A. et al., 2000a). This is in keeping with 
a Th-1 response in the pancreas. 
Studies from two groups, again available only in abstract form, have looked at a possible 
role for genetic predisposition in relation to TNF-alpha. It must be born in mind that a 
difficulty, as with any genetic study, is with the surrounding area of the chromosome, and 
the TNF-alpha gene lies within the MHC (class HI) region. This is proposed as the reason 
for an apparent functional association ofTNF levels associated with the TNF-alpha -238 
polymorphism in anti-phospholipid syndrome (Bertolaccini, M. L. et al., 2001 ). 
There are polymorphisms at the -238 and -308 positions in the promoter region of the 
TNF-alpha gene; the frequency of the variant allele at -308 is associated with increased 
transcription (in a reporter gene study) (Wilson, A. G. et al., 1997) and increased 
production ofTNF-alpha (Louis, E. et al., 1998). In the first of the two studies the high 
53 
CHAPTER I: INTRODUCTION 
production variant allele was found at significantly higher frequency in patients with 
AICP; whilst for the -238 polymorphism, there was no difference in the frequency 
(Abdulrazeg, E-S. M. et al., 2000). 
The second study also indicated a possible genetic role in TNF-alpha studied with regard to 
microsatellite haplotypes. However, in this study those haplotypes associated with 
intermediate function, notably the TNFa6b5cld3e3 haplotype, were found significantly 
more frequently in CP than normal controls, with a suggestion of an association of the 
higher secreting haplotypes with alcoholic liver disease (O'Reilly, D. A. et al., 2000b). 
1.5.3 Genetics of IL-la in Acute Pancreatitis: 
The Interleukin-1 gene cluster, located on the long arm of chromosome 2 (Nick! in, M. J. et 
al., 1994), consists of: IL-Ia (encoding IL-Ia). IL-lb (encoding IL-tp). ILI-RN which 
encodes the ILI-receptor antagonist. The IL-l receptors IL-IRI and, the 'decoy' IL-1RI1. 
I L-1 a and IL-l p share a range of activities acting via both receptors; JL-1 a generally 
remaining cytosolic, acting in an autocrine manner, although some becomes membrane 
bound and is active after cell death (Dinarello, C. A., 1998). 
A number of polymorphisms exist within IL-Ia. Specifically the (AC)n repeat VNTR 
polymorphism within intron 5 (Todd, S. & Naylor, S. L., 1991; Epplen, C. et al., 1994). 
In a previous study of this polymorphism, in acute pancreatitis, the 2,4 genotype was 
associated with alcoholic acute pancreatitis and the I ,2 genotype with worse organ failure 
score (Smithies, A. M., 2001). This polymorphism has also been looked at in Rheumatoid 
(Gomolka, M. et al., 1995) and Juvenille Chronic (Donn, R.P. et al., 1999) Arthritis with 
no positive associations detected. Also no association was found with Tuberculosis in a 
study by Bell amy et al. ( 1998). Smithies also looked at a VNTR polymorphism in JL I a (no 
association), a SNP in lL-lb finding no associations and a VNTR in ILl-m showing weak 
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1.6 Alcohol Metabolism: 
As discussed above, alcohol is the primary aetiological factor for chronic pancreatitis in 
Western countries accounting for around 70% of cases (Woming, H., 1998). In addition, it 
is one of the two major causes of the acute fonn of the disease, along with gallstones. 
Whether these cases in fact represent acute exacerbations of either previously known or 
unknown chronic pancreatitis (CP) in all, or some, cases is a matter of debate (Singh, M. & 
Simsek, H., 1990). 
The genetic predisposition to both alcoholism and alcohol induced end-organ damage is an 
area of debate. Family and twin studies suggest a genetic component to alcoholism (Reed, 
T. et al., 1996; National Institute of Alcohol Abuse and Alcoholism, 2000). As discussed 
alcohol-induced pancreatitis occurs in approximately 5% of alcoholics (Dreiling DA, 
1985); alcoholic cirrhosis in around I 0% and hepatitis in I 0-35% (Grant, B. F. et al., 
1988). No, or minimal, fibrosis is found in 32% ofpancreata of alcoholics (Pitchumoni, C. 
S. et al., 1984). The heterogeneity of the response to alcohol implicates genetic factors. 
Some evidence suggests that the majority of genetic predisposition to psychosis and liver 
disease may be accounted for by disposition to alcoholism (Reed, T. et al., 1996). 
One area of possible relevance is the role of mutations and polymorphisms of the alcohol 
metabolising enzymes. In humans, three main pathways are involved. Two of these are 
oxidative pathways (Figure 1.6) and one is non-oxidative, metabolising to fatty acid ethyl 
esters. The primary mechanism, at low alcohol levels, is metabolism of ethanol to 
ethylaldehyde by ADH (alcohol dehydrogenase) and the metabolism ofethylaldehyde to 
acetic acid by ALDH (aldehyde dehydrogense) (Parkinson, A., 1996). The other oxidative 
pathway via cytochrome P450 2E I is a minor pathway at low alcohol levels, accounting 
for around I 0% at low alcohol levels. CYP2E1 is however inducible by alcohol and may 
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therefore account for a higher percentage of function in alcoholic patients (Lieber, C. S., 
1997a), Figure 1.6. 
The relevance of the enzymes is obvious though not simple. As discussed above the 
mechanism of alcohol induced end organ damage is incompletely understood. It may be 
through directly toxic, or indirect, effects. In addition, induction of enzymes by ethanol 
may lead to injurous bioactivation of oxygen free radicals, limited evidence exists for a 
number of the mechanisms (Braganza, J. M., 1996; Schenker, S. & Montalvo, R., 1998). 
Further, this effect may be due to alcohol or its metabolites. In all cases functional or 
productive variations in metabolising enzymes may be relevant. Thus variability in all or 
any of the three pathways could be implicated in genetic predisposition. 
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Ethanol 
Xenobiotics 
Acetaldehyde 
ToxicMetabolites 
Acetic Acid 
Figure 1.6. Oxidative Metabolism ofEthanol. 
CYP2E1 = Cytochrome P450 2El 
ADH Alcohol Dehydrogenase 
ALDH = Aldehyde Dehydrogenase 
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1.6.1 Alcohol and Aldehyde Dehydrogenase: 
ADH fonns the primary phase I metabolising enzyme of ethanol at low levels. The genes 
coding for the enzyme are ADH1 to ADH5 (ADH6 and 7 are more recently identified) 
each encoding a different subunit (a,~. y, 11:, x). In addition, there are three alleilic variants 
of the~ subunit and two of they subunit. The functional protein is a hetero- or homodimer 
oftwo subunits. The enzymes are divided into three major classes: Class I contains ADHI 
(aa, a~, ay), ADH2 (~~. ~y) and ADH3 (yy). Class n contains ADH4 (nn) and Class Ill 
ADH5 (XX)- Class I is primarily involved with the oxidation of small, aliphatic alcohols, 
including ethanol. Class 11 and Ill have little role in metabolism of ethanol. Class I 
isoenzymes containing a ~2 subunit (coded for by ADH2*2) are especially active in 
oxidising ethanol at physiological pH (tenned atypical ADH), these are present in 85% of 
the Japanese and Chinese population, but are present at very low frequencies in 
Caucasians. ADH3*1 also has more rapid metabolism of ethanol to acetaldehyde (Bosron, 
W. F. et al., 1988) and is the predominant fonn in the Japanese and Chinese, whilst the 
two alleles are approximately equal in Caucasians. The risk of alcoholism appears to be 
diminished by possesion of a rapidly metabolising allele (Chao, Y. C. et al., 1994) 
probably due to higher concentrations of aldehydes and the concomitant unwanted effects. 
In a small study looking at ADH3*1 when results for the higher activity allele were pooled 
for alcoholics with end organ disease (either liver disease (59 patients) or chronic 
pancreatitis (13 patients)) this allele was significantly more frequent in patients than 
controls (Day, C. P. et al., 1 991); possibly indicating that the higher aldehyde levels are 
related to end organ damage. ADH3 polymorphisms were not different between controls 
and AICP patients (n= 15) in France (Couzigou, P. et al., 1991). Chao et al (1995) looked 
at alcohol induced AP, AAP (n= 48), alcoholic cirrhosis (n= 75), 19 'well' alcoholics and 
235 healthy controls. They found ADH2*1 and ALDH2*1 increased in ALD compared 
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with normal controls; ALDH2*1 in alcohol induced AP compared to controls, while 
ADH2* I was lower in alcohol induced AP compared to ALD; this was in Chinese patients 
who have a high rate of ADH2*2 and ALDH2* 1, unlike Caucasians. In a Japanese 
population ADH2*2/2*2 genotype was increased in AICP v alcoholic controls (no 
significancant difference was found for, ALDH2, and CYP2E1) (Maruyama, K. et al., 
1999). 
Interestingly, although the class I ADH isoenzymes are said to be most closely associated 
with ethanol metabolism (Holmes, R. S., 1994) a recent study found significant levels of 
ADH ethanol metabolism in rat pancreas blocked by a class 1-JH inhibitor but not a class I-
ll inhibitor (nor interestingly a CYP450 inhibitor carbonmonoxide, 'though these rats had 
not been prefed with alcohol to induce p450 activity) (Haber, P. S. et al., 1998). 
The ALDH enzymes are again divided into three classes: ALDHl are cytosolic enzymes 
that oxidise a wide variety of xenobiotic aldehydes. ALDH2 are sited in the mitochondria 
and (with their low Km) are primarily responsible for oxidising simple aldehydes, 
including acetaldehyde. ALDH3 for which acetaldehyde is not a substrate. 
A polymorphism (ALDH2*2) of the gene coding ALDH2 (in fact a homotetramer of the 
gene product) again common in Japanese and Chinese populations, causes a significantly 
decreased rate of metabolism of acetaldehyde and in combination with atypical ADH leads 
to a flushing syndrome secondary to a build up of acetaldehyde (Mizoi, Y. et al., 1983) 
(similar to the mechanism of action of disulfiram (Antabuse) an ALDH inhibitor). The 
ALDH2*2 allele has not been described in Caucasian populations. A novel polymorphism 
in the ALDH2 gene occurring in Caucasians has been described recently (Chou, W-Y. et 
al., 1999; Harada, S. et al., 1999). Aldehydes can also be oxidised by aldehyde oxidase 
and xanthine oxidase. 
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1.6.2 Fatty Acid Ethyl Esters: 
Evidence is also now emerging that Fatty Acid Ethyl Esters (F AEEs) may be implicated in 
end organ damage, including in the pancreas. FAEEs are found at increased levels in 
ethanol fed rats (Hamamoto, T. et al., 1990), FAEEs can lead to uncoupling of 
mitochondrial phosphorylation (Lange, L. G. & Sobel, B. E., 1983) and increased 
lysosomal fragility in acinar cells (Haber, P. S. et al., 1993b ). F AEEs have also been 
shown to induce a pancreatitis-like injury in rats (Wemer, J. et al., 1997). ln addition, 
F AEE synthase activity is highest in the pancreas (Hamamoto, T. et al., 1990). The gene 
for one enzyme responsible for F AEE synthesis have been cloned and localised to 
chromosome 11 (Bora, P. S. et al., 1997). 
Study ofFAEE synthase molecules and genes are in their infancy, FAEE synthase Ill is a 
newly identified gene in which polymorphic variation has been described. This was not in 
a peer-reviewed article but is referred to as unpublished data in the peer reviewed article 
(Beckemeier, M. E. & Bora, P. S., 1998). 
1.6.3 Cytochrome P450 2El: 
Cytochrome P450 2EI (CYP2EI) is the major component of the microsomal enzyme 
oxidising system, which is one of the two major pathways of oxidative metabolism of 
ethanol (Lieber CS & DeCarli LM, 1970; Lieber, C. S., 1997b). It also metabolises a 
large number of xenobiotics (Parkinson. A., 1996). CYP2E I is induced to greater activity 
by its substrate ethanol, probably via a number of mechanisms, including transcriptional, 
post-transcriptional and postranslational (Ohnishi K & Lieber CS, 1977; Takahashi T et 
al., 1993; Lieber, C. S., 1997b). 
CYP2E 1 activity is expressed in the liver, at sites of maximal alcohol induced damage 
(Tsutsumi, M. et al., 1989), and the pancreas, where it is also induced by chronic alcohol 
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consumption (Kessova, T. G. et al., 1998; Norton, I. D. et al., 1998); two of the major sites 
of damage following chronic consumption of ethanol. In addition, it is found in the brain 
(Upadhya, S.C., et al., 2000), also a site of ethanol induced damage. 
Genetic variations in CYP2E 1 have been looked at in a number of studies. Their 
association with alcoholism has been studied, with no association found for the cllc2 
alleles (Iwahashi, K. et al., 1995; Maezawa, Y. et al., 1995) but a positive association for 
the D form of the CID polymorphism in Japanese subjects (Iwahashi, K. et al., 1998). 
Association with alcohol induced end-organ disease for these polymorphisms is also 
conflicting, showing association with the c I allele (Maezawa, Y. et al., 1994), c2 allele 
(Tsutsumi, M. et al., 1994; Tanaka Fetal., 1997; Grove, J. et al., 1998) or no association 
at all (Carr, L. G. et al., 1995; Pirmohamed, M. et al., 1995; Carr, L. G. et al., 1996; 
Matsumoto, M. et al., 1996; Frenzer A et al., 1997; I toga, S. et al., 1999; Y ang, B-M et 
al., 200 I). Many of the polymorphisms of CYP2E I occur at a low frequency in certain 
populations, especially Caucasoids, and thus an association may be difficult to identify. 
Recently, an insertion polymorphism in the promoter region of the gene coding for the 
enzyme CYP2E1 has been described; sequencing has shown a 96 base pair (bp) insertion 
as a series of eight repeats, as opposed to six in the wild type (Hu, Y. et al., 1999; Fritsche, 
E. et al., 2000). This corresponds to a restriction fragment length polymorphism, between 
positions -2270 and -1672. Presence of which is associated with higher CYP2E I 
metabolic activity (employing an in vivo chlorazoxazone 6-hydroxylation test) in the 
presence of recently consumed alcohol or obesity (McCarver, D. G. et al., 1998). The Hu 
et at ( 1999) study, a luciferase reporter study, did not show a difference in constitutive 
expression, this is consistent with McCarver's findings of increased activity only in the 
induced state. 
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The 96 bp insertion, previously described, is a 729 base pair fragment employing the PCR 
based analysis ofFritsche et al. (2000). The wild type allele is 633 bp in length. In 
addition, a GenBank record also exists for a 48 base pair deletion (Accession No. J02843), 
corresponding to 585 base pairs, which has net been identified in any other studies and is 
of no known functional significance. 
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1. 7 Arachidonic Acid Metabo1ites: 
Arachidonic Acid (AA) is a free fatty acid liberated from cell membrane phospholipids by 
the action of phospholipases A2 in response to certain hormonal, neuronal or 
immunological stimuli. The eicosanoids are fatty acid mediators derived, via various 
pathways, from the polyunsaturated (four double bonds) arachidonic acid (Serhan, C. N. et 
al., 1996). Their name derives from their chemical composition wherein they have twenty 
carbon atoms (Greek: eikosi, twenty). 
AA is metabolised down two primary pathways: By the enzyme 5-lipoxygenase (5-LO) to 
the leukotrienes (Samuelsson, B. & Funk, C. D., 1989) and the cyclo-oxygenases (COX-1 
and COX-2) to the prostaglandins and thromboxanes (Smith, W. L. et al., 1996) (Figure 
1. 7). A further product of the breakdown of membrane phospholipids in response to these 
stimuli is PAF (platelet activating factor) trials of an antagonist of which (lexipafant) 
initially showed great promise in management of severe AP (Kingsnorth, A. N. et al., 
1995) although a more recent, larger, trial suggests a benefit only in subgroup analysis 
(Johnson, C. D. et al., 200 l ). Formed directly from the phospholipids these lipid mediators 
are released on formation and not stored as, say, cytokines are. 
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1.7.1 Leukotrienes: 
Leukotrienes (L Ts) are inflammatory mediators formed from arachidonic Acid by 5-
lipoxygenase (5-LO) via 5-HPETE (hydroperoxyeicosatetraenoic acid), figure 1.8. 5-LO is 
found predominantly in leukocytes, where it requires calcium influx for activation 
(Samuelsson, B. & Funk, C. D., 1989). It requires FLAP (five lipoxygenase activating 
protein), probably for AA binding and presentation (Mancini, J. A. et al., 1993a). 
L Ts are grouped A-E based on their structure, with a suffix indicating the number of 
double bonds. The first in the pathway is the unstable LT At., which is hydrolysed to L TB4 
or converted to L TC4 by addition of a glutathione group by the enzyme L TC4 synthase (Fig 
1.8). LTC4 and its subsequent metabolites L TD4 and L TE4 are collectively known as the 
cysteinyl (or peptido-) L Ts (Samuelsson, B. et al., 1987). The cysteinyl L Ts ( cys L Ts) 
constitute the slow reacting substance of anaphylaxis (SRS-A) (Bremm, K. D. et al., 1983) 
and they are known to act though via the cysteinyi-L T1-Receptor (Figueroa, D. J. et al., 
200 I). 
Cysteinyl L Ts are formed by a number of cell types, most notably basophils (Schleimer, R. 
P. et al., 1985; Mita, H. et al., 1993), mast cells (MacGiashanJr, D. W. et al., 1982; 
Schleimer, R. P. et al., 1985; Colamorea, T. et al., 1999; Hsieh, F. H. et al., 2001) and 
eosinophils (Weller, P. F. et al., 1983) in response to a number of stimuli (Weller, P. F. et 
al., 1983; Verhagen, J. et al., 1984; Shaw, R. J. et al., 1984; Mahauthaman, R. et al., 
1988). Whilst neutrophils are more responsible for production ofL TB4 (Weller, P. F. et al., 
1983; Shaw, R. J. et al., 1984; Verhagen, J. et al., 1984). The chemotactic action both 
L T84 and cys-L Ts have for eosinophils have been suggested to indicate a possible role for 
neutrophils in initiation of eosinophil recruitment and thus cys-L T formation (Shaw, R. J. 
et al., 1984). The interaction with mast cell products must also be noted in that PGD2 and 
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histamine from mast cells are activators of eosinophils (Raible, D. G. et al., 1992). As well 
as the mast cells ability to produce LTB4 and cysteinyl L Ts (Schleimer, R. P. et al., 1985). 
Both L TB4 and L TD4 have a chemotactic function for neutrophils whilst for eosinophils 
L TD4 is far more potent than L TB4 (Spada, C. S. et al., 1994 ). In addition, the cysL Ts 
cause vasoconstriction and increase vascular permeability (Dahlen, S-E. et al., 1981; 
Mayatepek, E. & Hoffmann, G. F., 1995). 
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5-HPETE = 5-hydroperoxyeicosatetraenoic acid 
L TC4S = leukotriene C4 synthase 
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1.7.2 Leukotrieoe C4 Synthase: 
This is the first dedicated enzyme in the formation of the cysL Ts and functions as a 
specific glutathione-S-tranferase. L TC4 synthase is over-expressed in bronchial biopsies of 
patients with aspirin intolerant asthmatics (Sampson, A P. et al., 1997). 
A polymorphism exists in the promoter region of L TC4 synthase. The A to C base pair 
change creates a novel binding site for the transcription factor AP-2, figure I. 9. This single 
nucleotide polymorphism (SNP) has been shown to be linked to aspirin induced asthma 
(Sanak, M. et al., 1997). It was postulated that the SNP may alter expression of L TC4 
synthase and now has been associated with functional significance. The ( -444)C variant is 
associated with increased transcription in a reporter gene study (Sanak, M. et al., 2000) 
and increased production of L TC4 by stimulated eosinophils with the A/C and C/C 
genotypes (Sampson, A. P. et al., 2000). It also may predict those who would most benefit 
from leukotriene receptor antagonists (Sampson, A P. et al., 2000). 
This SNP creates a novel cutting site for the enzyme M.\p I, allowing identification by PCR 
and restriction endonuclease digestion (Sanak, M. et al., 1997). Figure I. 9. 
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Promoter region A to C polymorphism (blue) of L TC4 synthase 
Showing the transcription factor AP 2 binding site (CCCG, red) 
and the Msp I cutting site (c/c g g, t,rreen) created. 
70 
CHAPTER I: INTRODUCTION 
1.7.3 Leukotrienes in the Pancreas and Pancreatitis: 
Cysteinyl L Ts are implicated in a number of conditions. Most notably asthma (Mayatepek, 
E. & Hoffinann, G. F., 1995). In asthma LT production is most closely associated with, 
and increases with aspirin challenge in, AlA patients (Christie, P. E. et al., 1991). Cys-LTs 
are also elevated in other conditions associated such as: Active Crohn's disease, elevated 
urinary levels (Kim, J. H. et al., 1995). Interstitial cystitis, elevated urinary levels 
(Bouchelouche, K. et al., 200 I). Juvenile rheumatoid arthritis, elevated urinary levels 
(Fauler, J. et al., 1994). Chronic urticaria, successful treatment with cys-LTRJ antagonist 
(Pacor, M. L. et al., 200 I). Atopic dermatitis, elevated urinary levels (Hishinuma, T. et al., 
200 I; Sansom, J. E. et al., 1997). Kawasaki disease, increased urinary levels (Mayatepek, 
E. & Lehmann, W. D., 1995). Eosinophilic cellulitis, elevated in affected skin (Wong, E. 
et al., 1984). 
5-lipoxygenase activity has been shown in the human pancreas, along with FLAP (Natsui, 
K. et al., 1991; Mancini, J. A et al., 1993b). 
Cysteinyl L Ts have been shown to be elevated in pancreatic lymph and ascites in pigs with 
experimental AP (Vollmar, B. et al., 1989). Interestingly, in taurcholate induced, 
experimental AP in rats L T84 was seen to be elevated without elevation of PGs (Zhou, W. 
et al., 1994), the reverse true in CP. However, in another rat study L TB4 was again 
elevated but here not as early as the prostaglandins (Ciosa, D. et al., 1993), cysteinyl L Ts 
were not evaluated in these studies. In a study by Folch et al (l998b) both cysL Ts and 
L TB4 were elevated in the pancreas in a sodium taurcholate (necro-haemorrhagic) rat 
model concomitant with neutrophil infiltration. In the lung neutrophil infiltration was more 
delayed at the final measurement point, at this stage the L Ts were not elevated in the lung; 
indicating LT are not involved at the earliest stages in the lung in this model. Also L TC4 
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has been shown to increase rat acinar cell enzyme secretion (Jaworek, J. & Konturek, S. J., 
1993). 
Himno et al. showed that in a rat model pre-treatment with a cysL T receptor antagonist 
decreased pancreatic oedema and microvascular leakage (Hirano, T., 1997). 
A study by Coelle et al. ( 1983) looking at protective effects of PGE2 in a diet-induced 
model of AP found decreased mortality with PGE2 but increased with, the COX inhibitor, 
indomethacin. However, in a dog model of AP indomethacin lessened haemodynamic 
effects (Kiviniemi, H. et al., 1988). These indicate one or all of; the complexity in the 
pathogenesis of pancreatic inflammation, the limited benefits from animal models but also 
that possibly the indomethacin, by blocking PG production, lead to increased LT 
production in a mechanism analogous to aspirin induced asthma. It is interesting to 
postulate a link in ICP with the proposed role of analgesic use in its aetiology. 
1.7.4 Measurement of Leukotrienes: 
The cysteinyl L Ts, as discussed, are L TC4, D4 and E4. Levels of cysL Ts have been 
assessed in broncho-alveolar lavage fluid (Wenzel, S. E. et al., 1995), joint fluid 
(Koshihara, Y. et al., 1988), tears and blister fluid (Bisgaard, H. et al., 1985) representing 
local production. To represent whole body production in blood, plasma or serum 
measurements are limited by levels being too low to measure (Heavey, DJ. et al., 1987; 
Sampson, A.P. et al., 1995) and the risk of ex-vivo production. This is not a problem for 
urinary levels where L TE4 represents whole body cysL Ts as demonstrated that 
radio labelled L TC4 is excreted, as L TE4 representing around 5-7% of total cysL Ts 
(Kumlin, M., 1997) and proportionate to administration/production (Christie, P. E. et al., 
1994). Measurement of L TE4 in the urine correlates with response to aspirin challenge in 
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sensitive asthmatics (Christie, P. E. et al., 1991) and also is proportionate to infused dose 
ofLTC4 and LTE4 (Smith, C. M. et al., 1992). 
The technique of measurement has varied over time. Initially high performance liquid 
chromatography (HPLC was used), more recently techniques employing gas 
chromatography/ mass spectroscopy (GC/MS) (Kishi, N. et al., 2001) and liquid 
chromatography/ mass spectroscopy (LC/MS)(Mizugaki, M. et al., 1999) were used the 
latter two being highly accurate but laborious and requiring expensive equipment. More 
recently immuno-assays have become available. Notably radio-immunoassays (RIAs) 
(Granstrom, E. et al., 1987) and enzyme immunoassays (E!As). The monoclonal antibody 
based El A from Cayman chemicals has been validated (Kumlin, M. et al., 1995) and 
employed in a number of studies. The debate as to the need for purification is undecided, it 
is argued that contaminants mean results may be unreliable (Westcott, J. Y., 1999). 
However, at least in paired samples, direct measurement has been validated (Kumlin, M. et 
al., 1995). If purification is required the methods available include HPLC and the more 
recently available immuno-affinity resin (Cayman Chemicals) which has been validated 
(Westcott, J. Y. et al., 1998). 
L TB4 metabolism is less well understood and therefore at present although an EIA for 
L TB4 is available measurement in urine is not reliable, although local measurement would 
be reasonable. 
I. 7.5 Leukotriene Receptor Antagonists: 
Study of cysteinylleukotriene receptors are in their infancy. Two have been identified on 
smooth muscle cells. Their role in the inflammatory actions are just coming to light. They 
have been identified on lung macrophages cells, peripheral eosinophils and other 
inflammatory cells (Figueroa, D. J. et al., 200 I), including mast cells (Melior, E. A et al., 
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200 I). In addition, effects of the receptor antagonists on inflammatory cells, most notably 
eosinophils, implicates direct (though cannot exclude indirect (Moqbel, R., I999)) anti-
inflammatory effects. They suppress eosinophil numbers both in blood (Reiss, T. F. et al., 
1998) and airways (Calhoun, W. J. et al., 1998). 
The cysteinyl-L T 1-receptor antagonist group of drugs are of proven benefit and licensed in 
the treatment of asthma. Probably acting to block mast cell derived cysL Ts to diminish the 
early response and the late response possibly secondary to blockage of eosinophil derived 
cysL Ts (Sampson, A. P. & Holgate, S. T., 1998). Cys LT -Receptor antagonists have also 
proved of benefit in atopic dermatitis (Capella, G. L. et al., 200I ). 
In addition, as noted, pre-treatment with one cysteinyl LT 1-receptor antagonist, 
Pranulokast, has been shown to decrease some of the inflammatory changes associated 
with experimental AP (Hirano, T., I997). 
I.7.6 Prostaglandins: 
As discussed above, the prostaglandins (PGs), along with thromboxanes, are the products 
of the cyclo-oxygenase metabolism of arachidonic acid, figure 1.6. There are two cyclo-
oxgenases (isoforms) termed COX-I and COX-2 (Xie, W. L. et al., 199I). The two appear 
to have distinct roles one being constitutive in nearly all cells (COX-I) and the other 
induced (COX-2), being undetectable in cells at rest. This pattern has been confirmed in 
pancreatic acinar cells (Zabel-Langhennig, A et al., I999). The induction of COX-2 
being, most commonly, inflammatory stimuli. The COX enzymes in fact also possess (in a 
spatially distinct active site) peroxidase activity responsible for the conversion ofPGG2 to 
PGH2, see figure 1. 7. 
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The prostaglandins are divided into groups A-J based on the substituent groups on the 
cyclopentane ring, the ring distinguishing them from the other eicosanoids. A suffix is then 
generally applied (as with LTs) according to the number of double bonds in the side 
chains. Which metabolites are formed is somewhat dependent on the cell type concerned. 
Platelets form predominantly thromboxanes (TXs), vascular endothelium prostacyclin 
(PGh aka PC). These are both formed enzymatically whilst the major prostaglandins 
(D,E,F) are formed non-enzymatically with enzymatic conversion also occurring in the 
case of E2 and D2. 
The active TX (TXA2) stimulates platelet aggregation whilst this is inhibited by PC. 
Similarly TXA2 is a vasoconstrictor whilst PGs are vasodilators most notably PC and 
PGEs (Crofford, L.J., 2001) 
In pancreatic disease PGF2a increases in haemorrhagic but not oedematous AP whereas the 
opposite was found for PC (Berger, Z. et al., 1989)); whilst Closa et at (Closa, D. et al., 
1994a; Closa, D. et al., 1994b) found elevation of PGs D2, E2, 6-keto F la and F 2a but not 
E1 and TXB2 (the breakdown product ofTXA2). Here indomethacin has been seen to 
decrease a number of these effects whilst increasing morta1ity(Closa, D. et al., 1994c). In 
contrast one study examining arachidonic acid metabolites in AP and CP in rat models 
found that although a number ofPGs (E2, D2, 6-keto F1a), TXB2 and PAF increased in a 
duct ligation model ofCP, in their AP model PGE2, along with 6-keto PGF 1a and TXB2 
decreased significantly (Zhou, W. et al., 1994). 
It is interesting to note the study by Victorov & Hoek ( 1995) in which PGs E2, D2, F2a and 
6 keto- F la were produced by cultured rat Kupffer cells in response to lipo-polysaccharide 
(after a Jag) and ethanol (gradually), the former having a greater effect and PGE2 more 
markedly raised than the other PGs and TXB2. 
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I. 7. 7 Prostaglandin E2 in the Pancreas and Pancreatitis: 
PGE2 was initially found to be elevated in AP in a dog model in 1976 (Glazer, G. & 
Bennett, A., 1976) with, on bioassays, elevated prostaglandin like activity in blood and 
PGE2-like material in peritoneal exudate. Closa et al also found increased PGE2 early in a 
taurcholate model in rats (Closa, D. et al., 1993), and this earlier than the L Ts; the same 
group have repeated this finding a number of times in studies looking at a number of AA 
metabolites ( Closa, D. et al., 1994a; Closa, D. et al., 1994b; Closa, D. et al., 1994c ). 
PGE2 was again elevated (in a necrotising, 'though not oedematous model) of AP in rats 
(Gloor, B. et al., 2001) along with TXB2 and L TB4, reduced by steroids. A study by 
Jaworek and colleagues (2001) found increased PGE2 in experimental AP in a caerulein rat 
model, enhanced with pre treatment with LPS, which corresponded to decreased 
inflammation. 
In light of the 'protective' effects ofPGE2 on gut mucosa a possible protective role in AP 
was investigated. In a mouse model Manabe et al. (Manabe, T. & Steer, M. L., 1980) 
found prior and concurrent administration ofPGE2 decreased mortality and markers of the 
pancreatic damage. A study over a longer time period in rats did not show significant 
differences and questioned the longer term relevance of the previously seen short term 
effect (Martin, D. M. et al., 1981 ), 'though in a different animal and model. 
PGE2 again appeared to have a protective effect, in rats over 7 days, improving mortality 
and inflammation (Coelle, E. F. et al., 1983); interestingly in this study indomethacin (a 
non-selective COX inhibitor) significantly worsened outcome implying the protective 
effects ofPGE2 +/-other COX products outweighed other 'pro-inflammatory' COX 
products. This effect of indomethacin has been shown again (Closa, D. et al., 1994c), 
associated with decreased levels ofPGE2, as well as other prostaglandins. A study not 
showing a benefit for PGE2 (given intraductally, intraperitoneally or subcutaneously), in 
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1983, was performed on a rat model with the pancreatitis induced by retrograde pancreatic 
duct injection of sodium taurcholate (Lankisch, P. G. et al., 1983). The original group then 
looked again (Taylor, I. L. et al., 1985) and found the protective effect ofPGE2 (4 day 
mortality) still occurred with 'post' treatment, however, this did not persist to 7 day 
mortality or if the inducing diet was continued for longer. They, quite rightly, concluded 
that the effect can be inferred to depend on duration of inflammatory stimulus, time of 
treatment and type and dose of PG. 
Further positive evidence for a protective effect came in 1983 (Standfield, N. J. & Kakkar, 
V. V., 1983) again with a survival benefit, with both pre- and post-induction treatment. 
This same study showed a beneficial effect for membrane stabilisation effect for PGE2 in 
humans. Lysosomal stabilisation was also seen in rats (Manabe, T. et al., 1993). 
Lysosomal stabilisation in the liver (Diugosz, J. et al., 1982), kidney(Triebling, A. T. et 
al., 1984) and pancreas (Gabryelewicz, A. et al., 1983) has also been shown for 
prostacyclin. PGE2 treatment has also been shown to decrease the hyperamylasaemia and 
oedema in pancreata of opossums with common bile duct ligation (Ramirez, R. et al., 
1984 ). [n a caerulain model in rats again decreased findings of AP (e.g. oedema and 
necrosis) were seen with PGE2 (Robert, A. et al., 1989). Van Ooijen et al found a decrease 
in mortality with PGE2 although this only became significant when combined with 
thromboxane inhibition in a rat model (van Ooijen, B. et al., 1989). 
As discussed the majority, but not all, studies have shown a beneficial or 'protective' effect 
for PGE2. Further contradictory studies warranting mention are that Reber required PGE2 
to cause pancreatitis with enterokinse and glycodeoxycholate (Reber, H. A., 1985). The 
first study to show a significant negative effect ofPGE2 treatment was in 1986 (Oiazabal, 
A., 1986). Another 1986 study (Wedgwood, K. R. et al., 1986) found an increase in 
haemorrhagic, as opposed to oedematous, AP in cats with PGE2 in a high dose; the same 
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effect also with histamine, but not isoproterenol, implying increased permeability as the 
mechanism. 
The effect ofPGE2 on pancreatic function has also been investigated with contradictory 
effect seen: An inhibitory effect on volume and bicarbonate whilst stimulating enzyme 
secretion (Rosenberg, V. et al., 1976). PGE2, PC and PGFlalpha inhibited secretagogue 
induced enzyme secretion from isolated rat acini (Jaworek, J. & Konturek, S. J., 1993), 
although this was much less marked than that from a stable PGE2 analogue. 
In summary, PGE2 appears to be elevated in most models of AP, and in the one model of 
CP studied; although the time scale is variable. As before this is associated with the 
weakness of animal models as a whole. Whether the role ofPGE2 is generally 'pro' or 
'anti' inflammatory or 'protective' you could not definitively conclude; certainly to the 
point of suggesting therapy. However, the balance of the animal evidence would suggest 
that its effects are more beneficial than detrimental, perhaps in a complex balance with the 
other lipid, and non-lipid, mediators. 
1.7.8 Measurement ofPGE2: 
In vivo PGE2 is converted to 13, 14-dihydro, 15-keto PGE2 then some on to 13, 14-dihydro, 
15-keto PGA2 both of which can be converted to bicyclo PGE2 by reaction with Na2C03 
which is stable. Thus to measure urinary PGE2 an initial 'derivitisation' step is performed 
converting the metabolites to a single, stable, measurable form. 
1.7.9 Prostaglandin D2 in the Pancreas and Pancreatitis: 
As discussed above PGD2 has been shown to be elevated in pancreatitis in a small number 
of studies in AP (Closa, D. et al., 1994a) and CP (Zhou, W. et al., 1994 ). Mast cells 
produce PGD2 (Schleimer, R. P. et al., 1985), by both COX-I (early) and COX-2 
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(delayed) dependent mechansims (Reddy, S. T. et al., 1999). The value ofthe 
measurement of PGD2 and its metabolites is therefore not just of itself but because it is a 
marker of mast cell activation (O'Sullivan, S. et al., 1996; O'Sullivan, S. et al., 1997; 
O'Sullivan, S., 1999a). 
As discussed in section 1.3.5 there is evidence and a theoretical argument for a role for 
mast cells in both AP and CP. 
1.7.10 Measurement of PGD2: 
Measurement of PGD2 can be simplified by that of it's urinary, stable metabolite 9-alpha, 
11-beta PGFza (Liston, T. E. & Roberts, L. J., 1985; O'Sullivan, S., 1999b). Which 
corresponds to mast cell activation (O'Sullivan, S. et al., 1996; O'Sullivan, S. et al., 1997). 
An EIA, which recognises 9-alpha, 11-beta PGF2a (and 2 closely related PGD2 
metabolites) has been validated against the 'gold standard' of gas chromatography mass-
spectroscopy GC-MS (O'Sullivan, S. et al., 1999b). 
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AIMS 
To identifY factors which are associated with a person's predisposition to Acute and 
Chronic Pancreatitis and the role of Arachidonic Acid metabolites in these conditions. 
I) To look for association between the known, functional 96 base pair Insertion/Deletion 
Polymorphism in the Cytochrome P450 2EI gene and alcoholism and/or alcohol 
induced end organ disease (Alcohol Induced Chronic Pancreatitis and Alcoholic Liver 
Disease). 
2) To assess if the exon 5 dinucleotide repeat polymorphism of IL-Ia is associated with 
disposition to Chronic Pancreatitis, especially those genotypes implicated in Acute 
Pancreatitis 
3) To see if use of a cysteinyl LT receptor antagonist is beneficial to patients with painful 
Chronic Pancreatitis. 
4) To assess if elevated levels of the Arachidonic Acid metabolites PGE2, PGD2 and the 
cysteinyl L Ts are found in Acute and/or Chronic Pancreatitis and whether a functional 
single nucleotide polymorphism in the promoter region of the gene for the enzyme 
L TC4 synthase has a role in predisposition to either condition or severity in Acute 
Pancreatitis. 
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MATERIALS AND METHODS: 
GENERAL 
In this chapter the general reagents and methods used during this work are discussed. 
Specific reaction conditions, subjects and techniques are addressed in the relevant 
Materials and Methods chapters. 
3.1 General Materials: 
3.1.1 Water 
Double distilled water was used to make up all stock, general purpose and specialist 
solutions. Sterile water (Baxter Healthcare, Newberry, UK) was used to make primer 
solutions and used for PCR and in preparation ofEIA reagents. 
3.1.2 Reagents 
All reagents used were analytical grade or equivalent. 
Acetic Acid, Disodium ethylenediamine tetra-acetic acid, Glycerol, Hydrochloric acid, 
Magnesium chloride, Orthoboric acid, Sodium hydroxide, Sucrose and Tris 
(hydroxymethyl) aminomethane were purchased from (BDH Laboratory Supplies-Merck 
Limited, Leicester, UK). Ethanol and methanol purchased from (Rathbums 
Limited,Tweedale, UK). Ammonium persulphate, Ethidium Bromide, Tetra-methyl-
ethylene-diamine (TMED), Triton -X-100 and Xylene cyanol purchased from (Sigma 
Chemicals, Poole, UK). 
3.1.3 Specialised reagents, enzymes and materials 
Agarose, the DIG luminescent detection system and the restriction enzymes were 
purchased from (Boehringer Mannheim GmBH, Germany). Taq polymerase, PCR buffer 
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and deoxynucleotide 5'-triphosphates (dNTP's) were purchased from Gibco (Life 
Technologies, Paisley, UK). 
3.1.4 Stock solutions 
1. Trislborate electrophoresis buffer (TBE) 
lOx solution: 0.89mM Tris base, 0.89M Boric acid, 2mM EDTA (pHS) 
11. Ethidium bromide 
111. Tris-acetate (T AE) buffer 
50x solution: 242g Tris base, 57.1 ml Glacial acetic acid, 0.5M EDTA (pHS) 
1v. Phosphate Buffered Saline (PBS) 
I OOmM potassium phosphate buffer (pH 7.4) in 0.9%NaCI 
3.1.5 Autoclaving 
All solutions and all glassware and plastic ware used in the techniques of DNA analysis 
were autoclaved at a temperature of 121 °C and pressure of 15 p.s.i for 30 minutes in a 
steam autoclave (Rodwell Instruments, UK). 
3.2 Extraction of Genomic DNA 
5-l Oml of peripheral venous blood was taken from all subjects into 5% EDT A (Becton 
Dickenson,Oxford, UK) and used to extract that subjects genomic DNA. 
DNA extraction ofUK samples employed the commercially available Nucleon BACC2 kit 
(Tepnel Life Sciences plc, Manchester, UK). In summary, 5-l Oml sample of frozen blood 
was thawed at room temperature and transferred to a 50ml falcon tube (Philip Harris, 
Cardiff, UK). 40mls of Nucleon A (JOmM Tris-HCL, 320mM sucrose, 5mM MgCI2, 1% 
Triton X-1 00, pH 8.0 using 40% NaOH) (Tepnel Life Sciences plc, Manchester, UK) was 
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added and the sample shaken for 4 minutes at room temperature and then centrifuged at 
1300g for a further 4 minutes at room temperature in a MSE Mistral 1000 centrifuge 
(MSE, UK). The supematant containing the lysed red cells was discarded and 2ml of 
Nucleon B (400mM Tris-HCL pH 8.0 using 40% NaOH, 60mM EDT A, 150mM NaCI, l% 
SDS) was added to the pellet to disrupt nuclear membranes. The pellet was resuspended by 
vortexing (Vortex Genie 2, Scientific Instruments Inc., USA) and then incubated at 37°C 
for 30 minutes (Yl4 Waterbath, Cambridge, UK) to ensure that the nuclear membranes 
were disrupted and the protein denatured. The suspension was transferred to a 15ml falcon 
tube and 500f.ll of 5M sodium perchlorate was added, to deproteinise, and the mixture was 
inverted 7 times. 2ml of chloroform (Sigma, Poole, UK) at -20°C was then added and the 
tubes inverted a further 7 times. 300f.ll of resuspended Nucleon silica (Tepnel Life 
Sciences plc, Manchester, UK) was added without re-mixing the phases and then 
centrifuged at 1300g for 3 minutes at room temperature. The upper, aqueous, phase 
containing the DNA was decanted to a fresh tube. The DNA was precipitated by addition 
of ice-cold I 00% ethanol (Rathbums Ltd, Tweedale, UK) and gentle inversion. The DNA 
was extracted into an Eppendorftube (Fisher, Loughborough, UK) containing 70% ethanol 
using a hooking pasteur pipette, it was then air dried and finally resuspended in an 
Eppendorf tube containing 0.5ml of sterile water. 
The DNA sample was quantified visually and by measuring the optical density using a 
Cecil 5500 Spectrophotometer scanning 240nm to 280nm (Cecil, UK) and compared to a 
blank containing double distilled water at 260nm. DNA samples were then stored at -20°C. 
DNA from some peripheral blood samples employed in the CYP 2El study were extracted 
employing the commercially available QIAmp DNA Blood Minikits (Qiagen, Hilden, 
Germany). 
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3.3 DNA polymorphism analysis: 
All polymorphism analyses employed PCR (polymerase chain reaction) based techniques. 
The insertion/deletion polymorphism ofCYP 2EI employs PCR and is of sufficient size to 
be visualised with agarose gel electrophoresis, chapter?. 
The dinucleotide repeat polymorphism in intron 5 of IL-Ia was analysed with 
polyacrylamide gel electrophoresis (PAGE) following PCR, chapter 8. 
Restriction fragment length polymorphism (RFLP) analysis was used to investigate the 
L TC4 synthase polymorphism. This consists of a Single Nucleotide Polymorphism (SNP) 
which creates a novel cutting site for the enzyme MspJ (Roche, Lewes, UK) within the 
PCR product, chapter 9. 
3.3.1 Polymerase Chain Reaction: 
This technique employs a DNA polymerase enzyme to extend complimentary DNA to the 
relevant portion ofDNA. A primer is designed which is complimentary to a sequence of 
around 20 base pairs (bp) on the 'sense' strand 5' of the polymorphism of interest. The 
equivalent is done for the anti-sense strand. 
These primers (or amplimers) bind during the appropriate annealing temperature to the 
complimentary site on the native DNA. The polymerase then adds nucleotides to the 
primers complimentary to the next matching base of the native DNA. During recurrent 
rounds the strands amplified are thus the area between the two primers (Figure 3.1 ). 
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• 
D 
D 
DNA Replication in Polymerase Chain Reaction. 
The replication proceeds on consecutive cycles 'focusing' on and 
amplifying the portion of DNA sited between the primers. 
Primer 
Sequence ofDNA to which the primer is complimentary 
Native DNA 
DNA copy of the native DNA formed from the nucleotides contained 
in the reaction mixture; the polymerase catalysing the reaction. 
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The reaction thus requires native DNA, Primers (sense and anti-sense), nucleotides 
{NTPs), DNA polymerase (Taq), Magnesium (MgCh), PCR buffer and water. The Taq 
polymerase warrants further brief comment. This enzyme (derived from Thennus 
aquatic us) is heat (thermo-) stable and can thus remain intact whilst the PCR reaction is 
cycled through tempemtures of up to 94°c. The commercial prepamtion is from Eschericia 
coli cloned with the T. aquaticus DNA polymerase gene. 
PCR consists of cycles of denaturation (of the genomic and newly fonned double stranded 
DNA to single strands), annealing of the primers (to their complimentary sites) and 
extension (of the primers by the Taq). As each cycle builds on the previous cycle copies of 
the exact length multiply (the PCR 'product'). 
3.3.2 Oligonucleotide Primer design and production 
Oligonucleotide primers are used in both sense and antisense directions. Sense primers 
were complementary to the 5' - 3' strand of DNA and anti sense were complementary to the 
3'- 5' strand of DNA Primers were synthesised commercially by MWG-Biotech 
(Germany) at a scale of0.2Jlmol. 
Primers employed in these studies had been previously described, these were then checked 
against the GeneBank record to confirm their sequence and ordered. Primers are designed 
to be complimentary to sequences either side of the polymorphic area, however, this is 
within certain limits. Primers function best if approximately 20 bases in length and 
approximately 50% made up of guanosine and cytidine (G+C) bases. Sequences are 
checked on DNAstar software (Lasergene, USA) to avoid the possibility offonning 
'primer dimers' or 'hairpin-loops', when complimentary to other sequences, which may 
result in the fonnation of anomalies or artefacts. Thus primers must not identity an area of 
similar length elsewhere in the genomic DNA as this may confuse the analysis; this may be 
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a particular problem if analysing genes with considerable sequence homology. The target 
amplification lengths ranged from approximately 200-800 base pairs. The primer 
sequences for each analysis are detailed in the following chapters. 
3.3.3 Performance of the Polymerase Chain Reaction: 
All PCR reactions were prepared on ice in 0.2ml thin walled PCR tube strips (Anachem, 
Luton, UK). 
The reaction mixtures consisted of I00-200ng of genomic DNA, 10 pmoles of both sense 
and antisense primers, 2.5J..LI lOx PCR reaction buffer (50mM Tris-HCL, pH9, 250mM 
KC I, 1% Triton X-1 00, 0.1% [ w/v] gelatin), variable amounts of MgCh, 400mM of each 
NTP and 2 units ofTaq polymerase. The final volume was made up to 25J..LI with distilled 
water (in the case of the IL-l a (AC)n dinucleotide repeat polymorphism a total volume of 
30J..LI was used). 30 cycles of amplification were carried out in either a iCycler (Bio-Rad 
Laboratories Inc., Hemel Hempstead, UK) or a 48 well DNA engine (Genetic Research 
Instrumentation, USA). 
Details of exact proportions of reagents, especially MgCh concentration, were optimised 
by trial and error aiming to produce a prominent defined band representing the 'true' 
product with a minimum of accessory bands. Higher magnesium concentration favours 
more product but also (by promoting the reaction) more accessory bands, whilst higher 
annealing temperature favours less accessory bands at the expense of the amount of 
product. The initial annealing temperature, with a battery ofMg concentrations, was the 
mean of the melting temperatures (T m) of the two primers plus two degrees. 
The standard reaction settings for PCR were: A hot start of94°c for 4 minutes was 
employed to promote denaturing. Then 30 cycles of: Denaturation at 94°C for 30 seconds, 
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annealing for 2 minutes (at a temperature optimised for each reaction), and extension at 
72°c for 2 minute. A further extension of 10 minutes (at 72°c) was performed following the 
30 cycles. Samples were then held at 4°C until analysed. 
3.4 Separation of DNA fragments by agarose gel electrophoresis 
All PCR products were checked by electrophoresis on horizontal agarose gels, this was 
also the means of formal analysis for the L TC4 synthase and CYP 2E I genetic studies. The 
IL-l a study employed PAGE to analyses frequencies of the alleles. 
The percentage agarose employed dependent on the fragments size to be viewed, see 
individual chapters. To make a 1% gel: 1 gram of agarose (Boehringer Mannheim, 
Germany) was added to IOOml of0.5x TBE buffer in a 400ml glass bottle, and heated in a 
microwave for 2-3 minutes at 650 watts to dissolve. The agarose solution was cooled to 
60°C-65°C and 10!!1 ethidium bromide (IOmg/ml solution) was added and mixed by 
swirling. The agarose solution was poured into a lOcm ultraviolet light-transparent perspex 
tray (Fiowgen, Leicester, UK), which was sealed at both ends with masking tape and 
contained moulds to generate the sample wells (14 and 20 tooth combs). After the gel was 
set it was placed at room temperature to harden the agarose, after removing the tape the gel 
was submerged in 0.5-1% TBE buffer in an electrophoresis tank (Flowgen, Leicester, UK), 
and the comb moulds were removed. The gel was run for variable times and voltage 
dependent on fragment size. Also known standards were run on each gel and/or DNA 
ladders, of known base pair lengths (Roche, Lewes, UK). 
3.4.1 Result assessment: 
To minimise error all results were duplicated as follows. If a result considered probable or 
definite this was repeated to obtain at least one definite result confirmed with a probable or 
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second definite result. Unreadable results were considered no result or unreadable. Those 
'no results' were repeated once and if the result unreadable these were not further 
analysed. An unreadable but present result if on repeating was readable it was further 
repeated for confirmation. 
3.5 Statistical Analysis of data: 
All the data collected was entered into a computerised spreadsheet (Microsoft® Excel 7.0). 
This allowed statistical analysis to be performed within the SPSS for Windows 9.0 (SPSS 
Inc., USA) statistical package. 
Details in each study are contained in the relevant chapters. 
3.6 Ethical Approval: 
Ethical approval was gained from the Local Research Ethics Committee for collection of 
samples and all studies performed. 
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MATERIALS AND METHODS: 
CYTOCHROME P450 2El 
Based on the knowledge of the previously described (Fritsche, E. et al., 2000; Hu, Y. et 
al., 1999) functional (McCarver, D. G. et al., 1998) insertion polymorphism in the 
promoter region of CYP 2E I a possible relevance in alcohol consumption and alcohol 
induced end-organ disease was assessed. 
4.1 Subjects: 
Venous blood samples were drawn with patients giving informed consent and Local 
Research Ethics Committee Approval was obtained. 
Samples were collected on 239 Caucasoids who chronically consumed alcohol, ALC, with 
a history of 'excessive alcohol intake', based on the Zurich Criteria for Alcohol Induced 
Chronic Pancreatitis (Ammann, R. W., 1997), of consumption of greater than 80 grams of 
pure alcohol per day for males and 60g for females, for at least two years. They all fulfilled 
the criteria for ICD (the International Classification of Diseases) 10.1 and/or I 0.2; that is 
harmful use and/or alcohol dependence syndrome. As stated alcohol consumption was 
minimal of80/60 grams for all ALC, the actual ranges (available on United Kingdom 
patients only) were 56 to 400 units per week (median 106) for a duration of2 to 45 years 
(median 10). Ages 25 to 73 years (median 47). Males constituted 85% of the patient group. 
This study was in collaboration with the University of Magdeburg, specifically the 
Department of Surgery and Outpatient Clinic for Addiction Diseases, who kindly collected 
samples on patients with AICP and 'alcoholics' without evidence of end-organ disease. 
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These sub-divided as follows (also see Table 4.1 ): 
Sixty seven (36 local British and 31 Gennan) consumers of alcohol without known end-
organ disease, AC. 
One hundred and seventy two with alcohol related end-organ disease (AEOD), of which: 
One hundred and forty four (39 local British, Plymouth, and 105 Gennan, Magdeburg) 
patients had alcohol-induced chronic pancreatitis (AlCP); all fulfilled the criteria for late-
or end-stage (exocrine insufficient) AICP, as defined by the Zurich criteria (Ammann, R. 
W., 1997). That is they had a history consistent with CP, typically of pain and recurrent 
bouts of clinical AP. In addition, one or more of pancreatic calcification; moderate to 
marked pancreatic ductal changes (based on the Cambridge classification (Axon, A TR et 
al., 1984)); steatorrhoea corrected with pancreatic enzyme supplementation or histological 
for 'definite' CP (37 Plymouth AICP and 105 Magdeburg AICP). Or a history, for 'late 
stage' as above plus one or more of mild changes (Axon, A TR et al., 1984 ); recurrent/ 
persistent pseudocysts or diabetes mellitus (2 Plymouth and none of the Gennan patients). 
Twenty eight patients with alcoholic liver disease (ALD), having biopsy proven cirrhosis 
or a history, consistent with alcoholic hepatitis, including jaundice associated with excess 
alcohol consumption without other evident cause. Patients with evidence of both AICP and 
ALD were excluded to allow for sub-group analysis. 
Two hundred and eight samples of cord blood from Caucasoids with a nonnal, healthy 
delivery taken in Derriford Hospital, Plymouth, UK were employed as nonnal controls. 
Male constituted 47% (n= 98) and females 53% (n= 11 0). 
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4.2 Polymerase Chain Reaction: 
DNA amplification was perfonned for the promoter region ofCYP2El as previously 
described (Fritsche, E. et al., 2000), employing amplimers 5' -GTG ATG GAA GCC TGA 
AGA ACA- and 5' -CTT TGG TGG GGT GAG AAC AG-. A standard reaction mixture 
was used as described above in section 6.3.3. A temperature of 66°C was found to be 
optimal as the annealing temperature, with a MgCh concentration of3mM. 
Products were analysed on a 1.5% agarose gel stained with 0.0 I %v/v ethidium bromide, 
viewed under Ultraviolet light and compared to 50 and 100 bp molecular weight ladders 
(Roche Diagnostics, Lewes, UK). 
4.3 Statistics: 
Two sided Fishers' Exact tests were used throughout. A p value of <0.05 was taken as 
significant. Where appropriate multisided contingency tables were employed initially for 
comparisons with sub-group analysis only when a statistically significant result was seen in 
the initial comparison. Individual sub-group analyses for end-organ disease(s) involved 
comparison with alcoholic controls only. The ·l result, where expected cell numbers are 
greater than 5, are shown in brackets in table legends. 
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Patient Group 
Normal Controls (UK) 
ALC 
Of ALC: 
AC 
AEOD 
OfAEOD: 
AICP 
ALD 
Table 4.1. 
Total 
67 
172 
144 
28 
Total 
UK 
36 
67 
39 
28 
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Total 
208 
239 
Total 
German 
31 
105 
105 
0 
Subdivision of subject groups studied for polymorphism of CYP 2E 1. 
UK = Subjects from Plymouth. 
German = Subjects from Magdeburg. 
ALC = Fulfilling criteria for ICD 10.1 and/or I 0.2 
AC = Without evidence of ALD or AICP. 
AEOD = Alcohol induce end organ disease. 
ATCP = Alcohollnduced Chronic Pancreatitis. 
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MATERIALS AND METHODS: 
INTERLEUKIN 1 ALPHA STUDY 
5.1 Subjects: 
Venous blood samples were drawn with patients giving informed consent. Samples were 
collected from 54 patients with a diagnosis of 'end stage' CP, based on the Zurich Criteria 
for Alcohol Induced Chronic Pancreatitis (Ammann, R. W., 1997) and cord blood from 
150 Caucasoids with a normal, healthy delivery taken in Derriford Hospital, Plymouth, UK 
were employed as normal controls. The patients subdivided on aetiology of AICP 38 and 
ICP 16. ICP patients had no history of'excessive alcohol consumption' as defined above, 
additionally they had no history of borderline alcohol consumption but no or minimal to 
moderate 'social' drinking. There were 19 females (35%); age range 27 to 87 years 
(median 55 years). One hundred fifty cord blood samples from normal deliveries were 
employed as normal controls (NC), females constituting 53% (n= 80). These forming the 
same control group as in the AP study cited. 
5.2 Analysis: 
Products were analysed on a polyacrylamide gel, viewed by autoradiography and 
compared to known standards, after Smithies (2001). PAG electrophoresis (PAGE) is a gel 
electrophoresis technique enabling more precise separation of fragments than agarose gel 
electrophoresis. It enables separation of fragments di tiering in length by only one or two 
base pairs. Thus allowing analysis of the (AC)n dinucleotide repeat discussed in the 
introduction. The technique uses autoradiograhy to reveal the fragment separation on the 
gel. Wherein primers used in the PCR reaction are 'labelled' with a beta radiation source. 
The gel, after drying, is placed on an X-ray film which is thus marked at the sites of the 
fragments. The beta source employed is phosphorous (y32P) incorporated in the phosphate 
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of a nucleotide (in this case deoxyriboadenosine triphosphate) giving l 2P-A TP. This 
nucleotide is then incorporated onto the 5' end of a primer thus the PCR product is 
labelled. 
5.3 5' End Labelling of Oligonucleotide Primers: 
The 5' end of the sense primer was radio-labelled using "Ready-To-Go" T4 Polyucleotide 
Kinase (Pharmacia Biotech, Sweden). 
In the "Ready-To-Go" T4 Polynucleotide Kinase (PNK) reaction each individual reaction 
tube contained, reconstituted in a final volume of 50Jll, a solution containing 8-10 units of 
"FPLC pure" T4 PNK, 50mM Tris-HCL (pH7.6), I OmM MgC]z, 5mM DTT, 0.1 mM 
spermidine, 0.1 mM EDT A (pH8), 0.2JlM A TP and stabilisers. 25fll of distilled water was 
added to the tube that contained the "Ready-To-Go" T4 PNK, the tube was then incubated 
at room temperature for 2-5 minutes. The contents of the tube were then mixed by gently 
pi petting up and down. 5-l 0 pmoles of the desired oligonucleotide primer was added as 
well as a sufficient volume of distilled water to bring the total reaction volume to 48fll. 2111 
of y J2P dA TP (I OflCilf.ll) was added and mixed gently. The sample was centrifuged briefly 
at 13,000 rpm for 30 seconds in a benchtop Microfuge (Hereus Septech Germany) to 
collect the contents at the bottom of the tube, and then incubated for 30-45 minutes in a 
water bath at 3-fC. The reaction was terminated by placing on ice. The sample was then 
precipitated to remove unincorporated nucleotides using 2fll of Quick PrecipTM (Advanced 
Biotech Corps, USA) a biologically inert product that is used as a carrier for the rapid 
precipitation of DNA and oligomers > 16 bases. To the sample 0.1 volumes of 5M NaCl 
and 2-3 volumes of -20°C 100% ethanol was added. The sample was briefly vortexed and 
then centrifuged for 2-3 minutes at 13,000 rpm at room temperature. After centrifugation 
the sample was vortexed vigorously and centrifuged again for another 30 seconds. The 
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supematant was decanted and the tube was rinsed with 70% ethanol. The precipitated DNA 
was resuspended in 50J.ll of distilled water and the side of the tube was rinsed with the 
water to ensure complete recovery, the tube was then vortexed. 
5.4 Polymerase Chain Reaction: 
To assess the frequency of the (AC)n tandem repeat polymorphism previously discussed 
DNA amplification was performed for the relevant region of intron 5 IL la as previously 
described (Smithies, A. M., 2001 ), the amplimers used were 5' -GGT-A TT-TAC-ACC-
ATA-GGT-GGG-GAC- and 5'-GCA-CCC-ATG-TCA-AAT-TTC-ACT-GG- (MWG 
Biotechnology, Germany), these were initially derived from the published sequence 
Genbank. Accession number X03833. 
Standard reaction conditions were used. The optimum annealing temperatures were found 
to be 56°C. The optimum magnesium chloride concentration was found to be I mM. In 
addition to the normal PCR reagent mixture was included 1111 of diluted sense amplimer 
labelled with y32P-A TP. 
5.5 Preparation and Performance of the PAGE: 
All PCR reactions were checked by running a I OJ.ll aliquot of the sample and 1-1. 5J.ll of 
loading buffer on a 1% horizontal agarose gel for I hour at 150-200 volts, as described in 
Chapter 6. The gel was visualised under UV light to confirm an appropriately sized 
product band. If the PCR was successful the PCR products were electrophoresed on a 
vertical denaturing polyacrylamide gel. 
A Biorad Sequigen GT 30x50cm electrophoresis system (Bio-Rad Laboratories Inc., 
Hemel Hempstead, UK) was used with a 49 well vinyl sharkstooth comb with a 0.4mm 
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spacer set. Before use, all aspects of the rig were washed in warm soapy water (glass 
plates, spacers and comb and clamp binders). After a thorough rinse in water, plates were 
dried and washed in 70% IMS solution (Rathbums, Tweedale, UK). The inner surface of 
the back plate were siliconised with a thin layer ofRepelcote (a 2% solution of 
Dimethydichlorosilane in Octamethycyclotetra-siloxane) (BDH Lab. Supplies-Merck, 
Leicester, UK), this was to allow the gel to be removed from the plates after running. The 
plates were allowed to dry and then a small amount of petroleum jelly ran down each edge 
of the base plate to grip the vinyl spacers. The top plate was then placed on top and 
sandwiched together using two arm clamps. The assembled plate unit was then stood in a 
casting gel tray and laid in a horizontal position. The denaturing polyacrylamide gel was 
prepared using a series of solutions (National Diagnostics, U.S.A. ): Ultra Pure Sequagel. 
Sequencing ready made concentrate, diluent and buffer. 36 mls of concentrate (237.5g 
acrylamide, 12.5g methylene bisacrylamide and SOOg urea), ISmls ofbuffer (50% 8.3M 
urea in I M Tris-Borate, 20mM EDT A buffer pH 8.3), 99mls of diluent (SOOg 8.3M urea), 
and 12mls of 10% formamide (Sigma Chemicals, Poole, UK) were mixed in a 250ml 
conical flask. 70J.1l TEMED (Sigma chemicals, Poole, UK) and I.Sml of 10% Ammonium 
Persulphate (Sigma chemicals, Poole, UK) were used to polymerise the gel. 
The plate assembly was filled with the gel solution using a 200ml syringe connected to a 
delivery tube (part of the gel system). When the polyacrylamide reached the top, the vinyl 
sharkstooth comb was inserted between the plates in an inverted position to give a straight 
line. The gel was allowed to polymerise for at least one hour at room temperature. When 
the gel was set, the casting tray was removed and the gel unit placed in the base or lower 
buffer chamber of the gel system. This contained I x TBE buffer, the buffer chamber at the 
back of the base plate was also filled with lx TBE buffer to the top of the plate in the 
reservoir at the top of the system. 
97 
CHAPTER 5: MATERIALS AND METHODS- IL lA 
The system was connected to a Biorad PC3000 power pack (Bio-Rad Laboratories Inc., 
Hemel Hempstead, UK) and pre-warmed at 1 ,800V, for approximately 45 minutes, until 
the temperature indicator read 45-50°c. The gel was then disconnected from the power 
supply and the comb reinserted to generate the 40+ wells. 6J.1.l of the amplified DNA was 
mixed with 3J.1.l of 10x Stop solution (Gibco, Life Technologies, Paisley, UK). The stop 
solution contained formamide and was based on a standard sequencing gel-loading buffer 
(98% deionized formamide, IOmM EDTA [pH8], 0.025% xylene cyanol FF, 0.025% 
bromophenol blue). The samples were loaded into the wells using a lOJ.ll Drummond 
sequencing pipette (Drummond Laboratories, USA). Electrophoresis was carried out for 3-
4 hours at 1, 700-2000V ( unti I the marker dye had migrated to the desired distance) with 
the gel around the optimum temperature of 50°c. The gel was removed from the plate and 
transferred onto 3MM filter paper (Heto Laboratory Equipment, Camberry, UK) and dried 
on a vacuum/heated gel drying system (Heto Laboratory Equipment, Camberry, UK) at 
80°C for approximately 1-2 hours. 
5.6 Autoradiography: 
The gels were autoradiographed following drying the drying proceedure. The exposure was 
performed in a Cronex cassette between Cronex lightening plus intensifYing screens. The 
filters were covered with a sheet ofX-ray film, Kodak XLS5, whilst in a dark room and the 
cassette firmly closed. The film was exposed at -80°C for 12-72 hours. Usually after 16 
hours the film was developed using X-ray developer, indicator stop-bath solution and 
liquid fixer (Kodak Ltd, Exograph Image Systems, Jetbury, UK). This confirmed the 
specific activity of the labelled probe giving a readable result or predicting the length of 
total exposure to X-ray film required. If necessary a second sheet ofX-ray film was placed 
in the cassette and left for a further period. The polymorphic DNA bands were identified 
and sized according to the distance they travelled during electrophoresis. 
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Genotypes for each subject were assessed by comparison to known standards previously 
elucidated and allele frequencies for each group calculated. 
5. 7 Statistics: 
Fisher's exact tests were employed, other than in the multi-sided tables for genotypes in 
some analyses where the Chi squared (X.2) test was employed, see results chapter. As the 
2,4 genotype had previously been associated with AP of alcoholic aetiology a direct 
comparison for this genotype in AICP versus Controls was made. Similarly we performed 
a direct comparison ofCP versus controls (i.e. predisposition to disease) for allele 
frequency for 1,2 genotype as it was associated with severity (organ failure score >2) 
previously (Smithies, A. M., 2001 ). 
Multisided contingency tables were employed for other initial comparisons between groups 
for all alleles and genotypes, sub-group analysis only employed if a statistically significant 
result was seen in the initial comparison. A p value of <0.05 was taken as significant. 
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MATERIALS AND METHODS: 
CYSTEINYL LEUKOTRIENE RECEPTOR ANT AGONIST 
TRIAL IN CHRONIC PANCREATITIS 
Medical treatment of chronic pancreatitis is an area of contention. Some reasonable and 
widely used therapies lack evidence, e.g. acid suppression and enzyme supplementation 
(Warshaw, A. L. et al., 1998). Whilst other potentially useful therapies remain to be more 
fully evaluated (Warshaw, A. L. et al., 1998). 
This study was performed in collaboration with not only my supervisor Professor Andrew 
Kingsnorth but also my colleagues Derek O'Reilly and Christine Porter; in addition 
considerable statistical input was made by Dr David Wright of the Mathematics and 
Statistics Department of the University of Plymouth. 
6.1 Trial Design and Subjects: 
A placebo-controlled, double-blind, cross-over trial of 8 months duration. (Figure 6. I) was 
designed. This constituted a one month baseline, followed by three months in treatment 
arm A, a month of 'wash out' and three months in treatment arm B. Patients with CP, late 
or end stage by the Zurich criteria (Ammann, R. W., 1997), and suffering regular bouts of, 
or continuous, pancreatic pain, were recruited. 
Analysis suggested a sample of30 patients would give a power of90% in a placebo 
controlled, double blind cross-over study to detect a decrease in V AS of pain of 20%. After 
6-8 months of recruitment it became evident that at our single centre it would not be 
possible to recruit this number who would remain in trial, 30 of our patients attending our 
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clinic replied positively to recruitment letters, of these 23 attended and were recruited. We 
therefore recalculated the power based on the V AS variability found in those patients thus 
far recruited. This suggested a power of 80% for 16 patients, we thus persisted to analyse 
the data which would be available from our centre. Five dropped out of the trial within the 
first 1 to 2 months, failing to attend after repeated call for follow up, that is without 
completion of a month ofthempy. Of the remaining 18 three withdrew; one due to a new 
abdominal pain on placebo, one due to rash on active treatment and a further participant for 
personal reasons whilst on placebo. Fifteen remained in the study throughout. Of the 15 
who completed the trial 7 had definite alcohol induced chronic pancreatitis (on the Zurich 
Criteria), 6 idiopathic chronic pancreatitis (although one of these had had moderate alcohol 
consumption) and 2 hereditary pancreatitis. 
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4 8 12 16 20 24 28 
Baseline Treatment Period 1 Washout Treatment Period 2 
Treatment Arm: AB received active treatment in Period l. 
BA received placebo in Period 1. 
Figure 6.1. Study Design. 
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6.2 Outcome Measures: 
Primary outcome measure was pain as measured by visual analogue pain scores (V AS). 
These were recorded daily for one month after emolment and prior to medication; three 
months of treatment, the one month wash out period and a further three month treatment 
arm. V AS scores were from an unmarked linear scale of I 0 cm. Also, daily analgesics 
diaries (AD) were completed throughout the trial. 
In addition, Quality of Life Questionnaires (QLQs) were completed monthly. It has been 
suggested that all clinical trials in CP should include Quality of Life assessment (Warshaw, 
A. L. et al., 1998) and we employed the QLQ advocated by Glasbrenner and Adler 
(Glasbrenner, B. & Adler, G., 1997) based on the European Organisation for Research and 
Treatment of Cancer core questionnaire of30 questions with a disease specific supplement 
of20 questions (Figure 6.2), which was originally employed in cancer but has been 
employed and validated in CP (Bioechle, C. et al., 1995; Buchler, M. et al., 1995). 
Inflammatory markers employed were baseline C-reactive protein (CRP) and plasma 
secretory Tumour Necrosis Factor-Receptors (sTNF-R) were taken immediately prior to 
and following each arm of treatment, following unblinding of the study these were then 
measured for pre- and post- the active treatment arm. CRP was serum values processed 
routinely in Derriford Hospital, Department of Microbiology. CRP is a standard marker of 
inflammation and has been shown to elevated in AP and to be indicative of the severity of 
such an attack (Buchler, M. et al., 1986; Mayer, A D. et al., 1984). Soluble TNF-
Receptors (sTNF-R) have been shown to be elevated in AP (Kaufinann, P. et al., 1997) 
and also in CP (Hanck, C. et al., 1999a) where they have also found at increased levels in 
peripheral blood mononuclear cells (Hanck, C. et al., 1999b ). The sTNF-Rs are soluble 
forms of the two known TNF receptors (respectively 55 and 75 kilo Daltons in molecular 
weight, (Tartaglia, L. A & Goeddel, D. V., 1992)) detectable in the serum of healthy 
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individuals:and consistent over time (:Aderka, D: ettai., 1992). They ·may be independently 
' 
regulated (Spinas, @, A .et al;,, il992); HoWever; ith"y !)re:ofth~mselves anti-inflammatory. 
in .nat!Jre, circulating and 'mopping1up' IFNF (Porteu, •F. & Nathan, C, 1990). 
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No Yes 
I. Do you have any trouble doing strenuous acliVttics, like carrymg a heavy 1 2 
shopping bag or a SUitcase? 
2. Do you have any trouble taking a long_ walk? I 2 
3. Do you have any trouble taking a short walk outside the house? 1 2 
4 , Do you have to stay in bed or a chair for most of the day? l 2 
S. Do you need help with eattng. dressing, washing yourself, or using the toilet? I 2 
6 Are you lim1ted in any way in either doingyour work or doing household jobs? I 2 
7. Are you comple1ely unable to work at a job or to do household jobs? I 2 
During the last week: Not at A little Quite Very 
all a bit much 
8. Were you short of breath? 1 2 3 4 
9. Have you had pain? I 2 3 4 
10. Did you need to test? I 2 3 4 
11. Have you had trouble sleeping? I 2 3 4 
12. Have you felt weak? 1 2 3 4 
13. Have you lacked appetite? 1 2 3 4 
14. Have you felt nauseated? I 2 3 4 
15. Have you vomited? I 2 3 4 
16. Have _you been constipated? I 2 3 4 
17. Have you had diarrhca? I 2 3 4 
18. Were you tired? I 2 3 4 
19. Did pain interfere with your daily activities? I 2 3 4 
20 Have you had difficulties m concentrating on things, 1 2 3 4 
hke reading a newspaper or watching television? 
21. Did you feel tense? I 2 3 4 
22. Did you wo_rry? I 2 3 4 
23. Did you feel irritable? I 2 3 4 
24. Did you feel depressed? I 2 3 4 
25. Have you had difficulty remembering things? I 2 3 4 
26. Has your physical condition or medical treatment 1 2 3 4 
interfered with your family life? 
27. Has your physical condition or medical treatment I 2 3 4 
interfered with your social activities? 
28. Has your physical condition or medical treatment 1 2 3 4 
caused you financial difficulties? 
For the following questions please circle the number be1ween I and 1 that best applies to you. 
29. How would you rate your overall physical condition during the past week? 
I 2 3 4 s 6 1 
Very poor Excellent 
30. How would you rate your overall quality of life during the p_ast week? 
l 2 3 4 5 6 7 
Very poor Excellent 
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During the last week: Not at all A little Quite a Very much 
bit 
31. Was your physical power decreased? I 2 3 4 
32. Did you have to change your eating I 2 3 4 
habits? 
33. Did you lose weight? 1 2 3 4 
34. Did you have fever or shivering? I 2 3 4 
35. Did you notice yellow staining of your 1 2 3 4 
eyes or skin? 
36. Did you feel bloated? 1 2 3 4 
37. Did you feel thirsty more oflen than I 2 3 4 
usual? 
38. Did you feel sudden colicky pain? I 2 3 4 
39. Did you feel a lack of appetite? I 2 3 4 
40. Have you felt itching? I 2 3 4 
Did }'(JU feel pain 
41. before or after eating? I 2 3 4 
42. in straight body position? I 2 3 4 
43. in your belly, radiating to the back? I 2 J 4 
44. at other sites? I 2 3 4 
If yes, 
45. Did you take analgesics? I 2 3 4 
46. lf yes, did they help you? I 2 3 4 
47. How much has the medical treatment burdened you? 
1 2 3 4 5 6 7 
Not at all Very much 
48. In what way has the medical treatment burdened you? 
49. Besides the medical treatment, what has hcl£.ed _you the mosl so far? 
50. How confident are you regarding your health for the near future? 
1 2 3 4 5 6 7 
Hardly confident V~ confident 
Figure 6.2: Quality of Life Questionnaire. 
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6.3 Laboratory analysis ofsamples: 
Plasma samples were taken for sTNF-R values; whole blood was diluted one in 2, with 
phosphate buffered saline, prior to centrifugation for removal of lymphocytes (for an 
additional study) and plasma extraction. This dilution factor, dependent on packed cell 
volume, should be normalized as paired samples were used and paired statistical analysis. 
This is a slight weakness dependent on the initial collection of samples for additional 
studies with no plain serum stored. Analysis employed a commercially available Enzyme 
Linked lmmuno-Sorbent Assay (ELISA) (Quantikine, Rand D Syatems,Abingdon, UK), 
separate antibodies are employed for sTNF-Rs I and 2. 
6.3.1 Biochemistry of the Assay: 
This is a sandwich based ELISA with antibody to the antigen being measured (sTNF-RI or 
sTNF-RIT) coated on the wells. After fixing the sample sTNF-R to the well an enzyme 
linked polyclonal antibody for the antigen is added and then the unbound reagent washed 
off. The 'colour reagents' added contain the substrates (stabilised hydrogen peroxide and 
tetramethylbenzidine) for the enzyme and the catalysed reaction produces colour change 
proportional to the amount of enzyme present. 
50 111 of assay diluent RDIM is added to each well (coated with murine monoclonal 
antibody to sTNF-RI and -RU respectively) then 200 111 of standard or sample and 
incubated for 2 hours at room temperature. The standard is a serial dilution of sTNF-RI and 
-RIT respectively. The sample is a 10 fold dilution of the above plasma. All samples and 
standards are performed in duplicate. 
After incubation each well was aspirated and washed (for a total of three washes) with 
400J.ll of wash buffer. 200111 ofsTNF -Rl/ll conjugate was then added to each well and 
incubated for a further 2 hours at room temperature. The aspiration/wash step then 
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repeated. 200 fll of substrate solution was added to each well and incubated for 20 minutes 
at room temperature, protected from light. The reaction was then stopped with 50 fll of 
'stop solution' (sulphuric acid). 
The optical density was then determined (within 30 minutes) using a microplate reader 
(Dynatech Immunoassay System, Dynatech Laboratories) set to 450 run, with wavelength 
correction set to 550 run. 
6.4 Statistics: 
Mean V AS scores were taken as the primary outcome measure. Statistical comparison 
of V AS for analysis of cross-over employed t-tests, as did comparison of scores to 
baseline. Again crossover analysis for the QLQ employed t-test after analysis in the 
fashion validated for the QLQ. Paired t-tests were used to analyse the plasma sTNF-
Receptor results (differences being normally distributed). 
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MATERIALS AND METHODS: 
ARACHIDONIC ACID METABOLITES 
7.1 Urinary levels of Arachidonic Acid metabolites: 
For this work sample collection was at Derriford Hospital. Due to our laboratory not being 
licensed for tritiated eH) compounds the laboratory work was performed in the 
Department of Clinical Immunology, Royal Free Hospital, London under the guidance of 
Siobhan O'Sullivan. 
7.1.1 Subjects: 
Urine was collected from two groups of patients, each with age, sex and ethnically 
matched healthy controls. The matched controls age was within I year for those under 35; 
2 years for 35-50 years and 5 years over 50. 
Those with AP had a clinical diagnosis of AP and a serum amylase level >3x the upper 
limit of the normal range and totalled 19. Four had severe disease and 15 mild (Bradley, 
E.L.lll, 1993); APACHE II scores 0 to 12 and Acute Physiology Scores 0 to 7. Table 7.1. 
Urine was collected within 72 hours of onset of pain and 48 hours of admission to hospital. 
Those with CP totalled 19. Each having late or end stage disease by the Zurich criteria 
(Ammann, R. W., 1997a). The aetiology was alcoholic in 12 (all denied recent alcohol 
consumption) and idiopathic in 7. 
The urine was collected, stored temporarily at 4°c, then centrifuged at 2000rpm for 3 
minutes, to remove particulate matter, it was then stored at -80°c until thawed for the 
analysis. 
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Age 
(years) 
22 
27 
34 
35 
41 
50 
51 
52 
57 
59 
64 
70 
72 
72 
73 
75 
80 
80 
92 
Table 7.1. 
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Sex Aetiology Severity APS APACHEII 
F GS M 0 
M GS M 4 
F GS M 5 
M Ethanol M 3 
F GS M 1 
F GS M 1 
F GS M 0 
M GS M 3 
F GS M 2 
F GS M 1 
F I M .., _, 
M I s 4 
F I s 4 
F GS s 4 
F GS M 1 
M GS M 3 
M I s 7 
M I M 6 
F GS M l 
Subjects in urine studies with Acute Pancreatitis. 
Sex- F = fema le; M = male. 
Aetiology- GS = gallstones; I = idiopathic. 
APS- Acute Physiology Score 
0 
4 
5 
3 
1 
3 
2 
5 
5 
4 
6 
12 
9 
9 
6 
9 
12 
11 
7 
APACHE II- Acute Physiology and Chronic Health Evaluation 
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7.1.2 Sample Purification: 
Prior to analysis of the samples, using Enzyme Immuno-Assays (EIA), purification is 
performed to remove contaminants which might interfere with the assay. 
For the two PG studies to measure the percentage loss during purification the sample was 
first spiked with a tritiated PG (in this case PG h. was used). 5ml of urine was aliquoted 
into falcon tubes into each was added approximately 10,000 cpm of tritium-labelled PGF2a 
which is then mixed thoroughly by vortexing. A sample of this is then removed and spotted 
onto blotting paper and read for scintigraphy count. Further scintillation counting is then 
performed on the eluted sample and the fraction ofloss calculated. 
For the PGs a 6 ml C-18 SPE cartridge (Cayman Chemicals, USA) was used for the 
purification. It was first activated by rinsing with 5 ml methanol and then with 5 ml water. 
The tritiated urine sample was then passed through the SPE cartridge. Which was then 
rinsed with a further 5 ml of water and 5ml ofHPLC grade heptane. The eicosanoids are 
then eluted from the column with methanol. Each step was performed under a gentle 
vacuum. The methanol was then 'blown off' by evaporation under a stream of dry nitrogen 
and the PGs resuspended in 500 J.ll of EIA Buffer by vortexing. 
Whether L TE4 analysis involves significant crossover interaction with other molecules in 
the urine is an area of debate. It has been shown that although immunologically based 
techniques may detect a lesser proportion of urinary L TE4 this is consistent (Kumlin, M., 
1997). Therefore purification is arguably unnecessary for paired samples on the same 
patient, it can also be argued that purification is unnecessary if serial dilutions give 
consistent results. As samples were unpaired the urine here was purified and a single serial 
dilution performed on all samples to confirm lack of gross contamination. 
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This employed the commercially available cysteinyl-L T affinity sorbent resin (Cayman 
Chemicals, USA) (Westcott, J. Y. et al., 1998). Following the standard protocol: 25J.ll of 
resin was added to I ml of urine and mixed gently for 30-60 minutes. Briefly 
centrifuged at 500 x g to sediment the resin. The supematant was decanted and the pelleted 
resin washed once with 1 ml ofPBS. The resin was resuspended in 0.5 ml of cold 
methanol and vortex briefly for 5 minutes then centrifuged to sediment the resin and the 
methanol collected; this wash step is repeated. The methanol washes will displace the 
adsorbed cys-L Ts from the resin. The methanol is again 'blown ofT under nitrogen and the 
L Ts resuspended in 500J.ll EIA buffer. 
7.1.3 Molecules measured in the EIAs: 
All three EIAs employ the same standard protocol with the exception that an initial step of 
derivitisation is required for the preparation ofbicyclo-PGE2. 
LTE4 is the final cysteinyl-L Tin that pathway, is stable in the urine and is measured as 
representative ofthe bodies production ofcysteinyl-LTs. 
In order to measure production of PGD2 9-alpha, ll-dehydro-PGF2 (PGF2a) was 
measured, as discussed this is the primary breakdown product of PGD2 in the urine and has 
been shown to be a measure of both PGD2 and of mast cell activation. 
Bicyclo-PGE2 is not a naturally occurring PG, however it is a stable product of the 
conversion of all PGE2metabolites. PGE2 is rapidly converted in vivo to it's 13,14-
dihydro-15-keto metabolite of which 90% is cleared by the lungs in its first pass; this 
product is not stable. It and its product 13, 14-dihydro-15-keto PGA2 (both excreted in the 
urine) are both converted to the stable bicyclo-PGE2 by reaction with Na2C03. Thus an 
initial step in the preparation for this EIA is the 'derivatisation'. Both the bicyclo-PGE2 
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standard and samples are incubated with carbonate buffer over night, then phosphate buffer 
and bicyclo-EIA buffer (for dilution). 
7.1.4 Enzyme Immuno-Assay: 
Three Enzyme-Immuno Assays (EIA) were employed, they are commercially available 
kits from Cayman Chemicals (USA). 
Each employs the same basic concept of competition, between the relevant eicosanoid and 
an acetylcholinesterase (AChE) conjugate of that eicosanoid, for a limited number of rabbit 
antiserum binding sites, specific for the molecule being measured. Because the 
concentration of conjugate is held constant while the concentration tested varies, the 
amount of conjugate that is able to bind to the rabbit antiserum will be inversely 
proportional to the concentration of eicosanoid in the well, for a portion of its reaction 
curve. This rabbit antiserum-eicosanoid (either free or conjugate) complex binds to the 
rabbit IgG mouse monoclonal antibody that has been previously attached to the well. The 
plate is washed to remove any unbound reagents and then Ellman's Reagent (which 
contains the substrate to AChE) is added to the well. The product of this enzymatic 
reaction has a distinct yellow colour and absorbs strongly at 412 nanometres (nrn). The 
intensity of this colour, determined spectrophotometrically, is proportional to the amount 
of conjugate bound to the well, which is (as stated) inversely proportional to the amount of 
free eicosanoid present in the sample well during the incubation. 
7. 1.5 Biochemistry of AChE EIAs: 
The electric organ of the electric eel, Eleclrophoru\· electricus, contains an avid AChE 
capable of massive catalytic turnover during the generation of its electrochemical 
discharges. The electric eel AChE has a clover leaf-shaped tertiary structure consisting of a 
triad oftetramers attached to a collagen-like structural fibril. This stable enzyme is capable 
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of high turnover (64,000 per second) for the hydrolysis of acetylthiocholine. A molecule of 
the analyte (eicosanoid) covalently attached to a molecule of AChE serves as the tracer in 
these AChE based enzyme immunoassays. 
Ellman's reagent consists of acetylthiocholine and 5,5' -dithio-his-(2-nitrobenzoic acid). 
Hydrolysis of acetylthiocholine by AChE produces thiocholine. The non-enzymatic 
reaction ofthiocholine with 5,5' -dithio-his-(2-nitrobenzoic acid) produces 5-thio-2-
nitrobenzoic acid, which has a strong absorbance at 412 nm. AChE has several advantages 
over other enzymes commonly used for enzyme immunoassays: Unlike horseradish 
peroxidase, AChE does not self-inactivate during turnover. This property of AChE also 
allows multiple development of the assay if it is accidentally splashed or spilled. In 
addition, the enzyme is highly stable under the assay conditions, has a wide pH range (pH 
5-1 0), and is not inhibited by common buffer salts and preservatives. Since AChE is stable 
during the development step, it is unnecessary to use a "stop" reagent, and the plate may be 
read whenever it is convenient. Plates are pre-coated with mouse monoclonal antibody 
and blocked with a proprietary formulation of proteins. 
50 J.tl samples are added to the test well (each in duplicate) with a I in I 0 dilution 
performed in addition to the main (purified) sample. This enables identification of 
contamination and allows a result, which falls in the linear and reliable portion of the 
concentration absorbance curve, to be more easily obtained at 'first run'. 
EIA Buffer was added to Non-Specific Binding wells (lOOJ.tl) and to Maximum Binding 
wells (50J.tl). Two fold serial dilutions of the PG standard, were added to duplicate 
standard wells (50J.tl). 50 J.tl of AChE labelled eicosanoid, was then added to all wells 
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except the Total Activity and the Blank wells and 50 f.ll of eicosanoid anti-serum to each 
well except the Total Activity, the Non-Specific Binding and the Blank wells. 
The plate is then covered with a plastic film and incubated at room temperature in the dark 
for 18 hours prior to developing. The wells are emptied and washed five times with wash 
buffer, then 200fll ofEIIman's reagent is added to each well and, in addition, 5 J.d of AChE 
labelled eicosanoid. 
This is then allowed to develop for 60 minutes (with a maximum binding reading of 
approximately 0.2 A.U. with blank subtracted). The plate was read at a single wavelength 
between 405 and 420 nm. 
Thus the blank wells have and measure only the Ellman's reagent absorbance. The non 
specific binding wells have AChE labelled eicosanoid, no sample activity to compete but 
also no anti-sera to bind the eicosanoid and thus represent only non-specific binding of 
AChE labelled eicosanoid to the well. The maximum binding wells have AChE labelled 
eicosanoid, no sample to compete with that and anti-sera such that all anti-sera sites should 
bind AChE labelled eicosanoid. The total activity wells have AChE labelled eicosanoid 
that has not been washed and therefore represent the total activity of that enzyme in the 
development. 
7.1.6 Analysis of Results: 
All results are analysed as PGIL T per unit creatinine to normalise for urine dilution. The 
urine creatinines were evaluated by the Derriford Hospital Combined Laboratory. 
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7 .1. 7 Statistics: 
Unpaired t-tests were used to analyse the data if the data did not significantly differ from a 
normal distribution (Shapiro-Wilk test). If the data was not normally distributed a non-
parametric test (Mann-Whitney U) was used. The results were also assessed for equality of 
vanance. 
7.2 Genetic Studies: 
Two studies were performed looking at the A(- 444 )C L TC4 synthase polymorphism. One 
in AP and one in CP. The difference in urinary L TE4 levels discussed in Results Chapter 
I 0, suggested a possible genetic component to levels in AP and thus we studied this known 
functional polymorphism in the first dedicated enzyme in the cysteinyl LT pathway. In CP 
a pilot study showed a significant difference in ICP and a, non-significant, difference in 
AICP; thus the analysis was also performed in CP. 
7.2.1 Subjects: 
Acute pancreatitis samples were taken from patients with a clinical diagnosis of AP and an 
amylase level greater than 3x the upper limit of the normal level. Aetiology was based on 
history, examination and investigations. For the purposes of this studied aetiologies were 
gall stones, alcohol (a history of ethanol consumption of greater than 80g per day for 6 
months or more) or idiopathic (which also includes other minor causes such as 
hyperlipidaemia). ERCP induced AP was excluded. AP patients were further subdivided 
by severity; based on organ failure or local complications (Bradley, E. L., lll, 1993). One 
hundred and sixty nine patients had mild disease (MAP, 71%) and sixty nine had severe 
disease {SAP, 29%). One hundred and forty were females (59%). Aetiologically 141 had 
gallstones (60%); 50 (21%) alcohol and 48 (20%) idiopathic. Age range was 19 to 91 
years; with a median of 60 years. 
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Tn CP, samples on 57 Caucasoid patients, with late- or end-staged CP based on the Zurich 
Criteria for Alcohol Induced Chronic Pancreatitis (Ammann, R. W., 1997b) were 
collected. Aetiologically sub-divided as alcohol induced ( 41 patients) or idiopathic ( 16 
patients). Females were 19 in number (33%). Age range 27 to 87 years, median 53 years. 
Controls were cord blood samples and totalled 103, 60 (58%) of whom were females. 
7.2.2 Polymerase Chain Reaction: 
DNA amplification was performed for the promoter region ofL TC4 synthase, employing 
amplimers 5'-TCC ATT CTG AAG CCA AAG GC- and 5'-GTG ACA GCA GCC AGT 
AGA GC- (after Sanak et al.(1997)). The standard reaction settings were again used with 
the optimised annealing tempemture found to be 59°C, with a magnesium concentmtion of 
2mM. 
7.2.3 Restriction Endonuclease digestion: 
The PCR products were subjected to digestion by the restriction endonuclease Msp I 
(Roche Diagnostics, Lewes, UK) in a total volume of25J..Ll. The polymorphism removes a 
cutting site for the enzyme Mspl and thus the PCR product can be subjected to digestion 
and the frequency of the polymorphism analysed (Figure 7.1 ). 
The digestion mixture mix included: 18J..LI PCR product, 3.5J..LI water, 2.5J..LI endonuclease 
buffer and 1111 (5 units) of enzyme Msp I at 5000unitsmr1• The digest was performed over 
4 hours at 3~c. To confirm complete digestion analysed on a 1.5% agarose gel stained 
with 0.01%v/v ethidium bromide, viewed under Ultraviolet light and compared to 50 and 
100 bp molecular weight ladders (Roche Diagnostics, Lewes, UK). Digestion was 
optimised to take 4 hours with samples run on gels after I and 16 hours also, complete 
digestion was present in the majority of samples tested at I hour and all samples at 4 and 
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16 hours. A consistent cutting site for Msp I in the PCR product is also present, this acted 
as an internal control showing complete digestion as no 'full length' 563 bp product should 
remain. 
7.2.4 Statistics 
Two sided Fishers' Exact tests were used throughout (SPSS 9.0, SPSS Inc., Chicago, Ill., 
USA). A p value of <0.05 was taken as significant. Where appropriate multisided 
contingency tables were employed initially for comparisons with sub-group analysis only 
when a statistically significant result was seen in the initial comparison. 
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563bp 
PCR product 
446bp 
Wild Type 
85bp 
Polymorphic 
PCR product ofLTC4 synthase promoter region with separation of 
fragments at Msp I cutting sites in the Wild Type and Polymorphic forms. 
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.RESULTS: 
CYTOCHROME P450 2El 
Results are displayed in Tables 8.1 to 8.3. Of208 normal controls 12 (5.8%) had the 
insertion polymorphism (Figure 8.1 ), and all were heterozygotes. In contrast, 5 of 239 
ALC subjects (2.1 %) had the insertion. Of these, in the AICP group two subjects had the 
insertion and one of these was homozygous for the insertion. In the AC group three 
subjects had the insertion. In addition, one AICP and one AC had a band which would 
correspond to the 48 base pair deletion found in GenBank (Figure 8.2), as did two normal 
controls. 
Results from the British and German groups, all European Caucasoids, were similar: Three 
of the 138 German subjects (2.2%) and 2 of the 102 British (2%); two of the 32 German 
AC, I ofthe 35 British AC, I of the 106 German AICP and I ofthe 39 British AICP had 
the insertion. 
Analysis in the first instance is with regard to presence or absence of the 96bp insertion. 
This is used as the primary outcome as the paper demonstmting a functional effect of the 
polymorphism was that the effect was associated with presence of the polymorphism 
(McCarver, D. G. et al., 1998). Further analysis is of the genotypes for the insertion. 
Analysis for the deletion, not known to be associated with a functional effect, is not 
performed. 
Comparing ALC to normal controls for presence of the insertion polymorphism, showed 
that it was less abundant in the former than the latter (p=0.049), table 8.2. The same 
comparison for genotype of the insertion was comparable (p=0.030), table 8.3. 
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Employing Fisher's exact test for presence of the insertion a three by two contingency 
table of normal controls, AC and AEOD again revealed a statistically significant difference 
(p=0.045), table 8.2. Again, analysis for insertion genotypes was comparable (p=O.Oll ), 
table 8.3. 
To delineate whether the difference was for alcoholism per se or end organ disease we 
further analysed sub-groups. Comparing AC with NC and comparisons within ALC 
subgroups analysis did not reveal any significant differences, as might be expected with 
such a low frequency in the patient groups. Although genotype analysis for those with end-
organ disease compared with alcoholic controls approached significance with p=0.068. 
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Figure 8. L: Agarose gel showing wild type homozygotes (633 b.p., lanes 2-7) and a 
heterozygote for the insertion polymorphism (729 b.p., lane 1 ). 
Run alongside a molecular weight marker (M). 
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Figure 8.2: Agarose gel showing wild type homozygotes (633 b.p., lanes 1-3 and 5) and 
a heterozygote for the deletion polymorphjsm (585 b.p., lane 4). 
Run alongside a molecular weight marker (M). 
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Patient Total Homozygote Heterozygote Homozygote Heterozygote 
Group wild type for insertion for insertion for deletion 
{wt/wt} (wt/Ins} (Ins/Ins} (wt/Del) 
Normal 
Controls 208 194 (69%) 12 (5.8%) 0 (0.0%) 2 (1.0%) 
ALC 239 232 (97%} 4(1.7%) I (0.4%) 2 (0.8%) 
OfALC: 
AC 67 63 (94%) 3 (4.5%) 0 (0.0%) I (1.5%) 
AEOD 172 169 (98%) 1 (0.6%) I (0.6%} 1 (0.6%) 
OfAEOD: 
AICP 144 141 (98%) 1 (0.7%) I (0.7%) I (0.7%) 
ALD 28 28 (100%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Table 8.1. Full genotype data on all subjects. 
ALC = ICD 10.1110.2 
AC = alcoholic controls 
AEOD =alcoholic end organ disease 
AICP =alcohol induced chronic pancreatitis 
ALD = alcoholic liver disease 
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Patient Group Total Presence of insertion 
polymorphism 
(wt/Jns and Ins/Ins) 
Normal Controls"·b 208 12 (5.8%) 
ALe" 239 5 (2.1%) 
Of ALD: 
ACb 67 3 (4.5%) 
AEODb 172 2 (1.2%) 
OfAEOD: 
AICP 144 2 (1.4%) 
ALD 28 0 (0.0%) 
Table 8.2. Subjects with the (high activity) insertion polymorphism. 
Fisher's Exact Test: p = 0.049" 
p= 0.045b 
ALC = ICDIO.I/10.2 
AC =alcoholic controls 
AEOD =alcoholic end organ disease 
AICP =alcohol induced chronic pancreatitis 
ALD =alcoholic liver disease 
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Patient Group Total Genotype of Insertion Polymorphism 
Normal Controls"·b 
ALe" 
Of ALC: 
ACb,c 
AEODb,c 
OfAEOD: 
AICP 
ALD 
208 
239 
67 
172 
144 
28 
Table 8.3. Insertion Polymorphism Genotypes. 
Fisher's Exact Test: p = 0.030" 
p=0.011b 
p = 0.068c 
ALC =reo IO.I/10.2 
AC = alcoholic controls 
AEOD =alcoholic end organ disease 
Heterozygote 
(wt/Ins) 
12 (5.8%) 
4(1.7%) 
3 (4.5%) 
I (0.6%) 
1 (0.7%) 
0 (0.0%) 
AICP = alcohol induced chronic pancreatitis 
ALD = alcoholic liver disease 
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Homozygote 
(Ins/Ins) 
0(0.0%) 
1(0.4%) 
0(0.0%) 
1(0.6%) 
1(0.7%) 
0(0.0%) 
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RESULTS: 
INTERLEUKIN 1 ALPHA 
The full results, in terms of both alleles and genotypes, are displayed in Tables 9.1 and 9.2, 
respectively. Whilst a PAGE picture representing genotypes is seen in Figure 9.1. 
9.1 Direct Comparisons based on Acute Pancreatitis Results: 
The specific comparison ofNC versus all CP for the 1,2 genotype (Figure 9.2), which 
Smithies study (Smithies, A. M., 200 I) implicated in worse organ severity score in AP, 
did not show a significant difference (Fisher's exact test). The 1,2 genotype occurring in 
23% and 17%, respectively. While the comparison of AICP, ICP and NC (18%, 13%,23% 
respectively) was again not significant. Thus the weak suggestion in the AP study of an 
association with severity does not translate to a predisposition to CP. 
The other specific question addressed was whether the significant association between the 
2,4 genotype and alcohol induced AP was also seen in AICP, Figure 9.3. This genotype 
was found in 12% of controls and 18% of subjects with AlCP which is not a statistically 
significant difference (Fisher's exact test). 
9.2 Alleles: 
The common alleles 1,2 and 4 occurred in control (NC) and patient (AIPC, ICP) groups in 
37%,36% and 38% for allele I (respectively); 33%,29% and 34% for allele 2 and 17%, 
24% and 16% for allele 4. There are no sibrnificant differences for the multi-sided table of 
NC versus CP. Comparison with aetiological subdivisions and all alleles was again non-
significant (x2 test). Thus simple direct comparisons were not performed further. 
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9;3 Genotypes: 
the gellorypes also sliowed!fio overall statistically·significaflt (fitference, .x/ test p=•O~J,72. 
With aetiological subdlvlsion•ofthe patient groups .x/ test1p= 0!038. 0n,tliis basis it .Is 
statistically valid' to look atthe subdivision. AICP ,vNG. for genotypes x2 tesf(Y"" 0.434 .. 
ICP vNC Fishef'siexactiiF0!084;,there was!nosignificant difference: 
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01 02 03 04 05 06 07 08 09 10 11 12 13 14 
Figure 9.1. PAG autoradiograph showing a number of IL-Ia polymorphism genotypes. 
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Allele Nonnal CP Of which: 
Controls [N=J08] 
ICP [N=300] ACIP [N=76] [N=32] 
-1 0 (0.0%) 1 (0.9%) 1 (1.3%) 0 (0.0%) 
0 7 (2.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
1 111 (37%) 39 (36%) 27 (36%) 12 (38%) 
2 100 (33%) 33(31%) 22 (29%) 11 (34%) 
3 13 (4.3%) 3 (2.8%) 3 (3.9%) 0 (0.0%) 
4 51 (17%) 23 (21%) 18 (24%) 5 (16%) 
5 11 (3.7%) 7 (6.5%) 3 (3.9%) 4 (13%) 
6 I (0.3%) I (0.9%) I (1.3%) 0 (0.0%) 
7 2 (0.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
8 4 (1.3%) 1 (0.9%) 1 (1.3%) 0 (0.0%) 
Table 9.1. Interleukin la alleles in control and patients groups. 
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Genotype Normal CP Of which: 
Controls [N=54] 
ACIP ICP [N=l50] [N=38] fN=16] 
1,1 18 (12%) 6(11%) 2 (5.2%) 4 (25%) 
1,2 35 (23%) 9 (17%) 7 (18%) 2 (13%) 
1,4 22 (15%) 10 (19%) 9 (24%) 1 (6.3%) 
2,2 ° 19 (13%) 6 (11 %) 3 (7.9%) 3 (19%) 
2,4 18 (12%) 7 (13%) 7 (18%) 0 (0.0%) 
4,4 2 {_1.3%) 3 (5.6%) I (2.6%) 2 (13%) 
Less common 
genotypes: 36 (24%%) 13 (24%) 9 (24%) 4 (25%) 
-1,1 0 (0.0%) 1 (1.9%) 1 (2.6%) 0 (0.0%) 
0,1 l (0.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
0,2 6 (4.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
1,3 3 (2.0%) 2 (3.7%) 2 (5.2%) 0 (0.0%) 
1,5 4 (2.7%) 4 (7.4%) 3 (7.9%) 1 (6.3%) 
1,6 1 (0.7%)_ 1 (1.9%) 1 (2.6%) 0 (0.0%) 
1,7 l (0.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
1,8 3 (2.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
2,3 4 (2.7%) 1(1.9%) I (2.6%} 0 (0.0%) 
2,5 2(1.3%) 3 (5.6%) 0 (0.0%) 3 (19%) 
2,7 1_(0.7%} 0(0.0%) 0(0.0%) 0 (0.0%) 
2,8 l (0.7%)_ 1 (1.9%} 1 (2.6%) 0 (0.0%) 
3,4 4 (2.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
3,5 2 (1.3%) 0 (0.0%) 0 (0:0%) 0 (0.0%) 
4,5 3 (2.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%1 
Table 9.2. lnterleukin la genotypes in control and patients groups. 
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RESULTS: 
CYSTEINYL LEUKOTRIENE RECEPTOR ANTAGONIST 
TRIAL IN CHRONIC PANCREATITIS 
Twenty three patients were recruited. Of these five dropped out of the within the first 1 to 
2 months, failing to attend after repeated call for follow up without completion of a month 
oftherapy. Of the remaining 18 three withdrew; one due to a new abdominal pain on 
placebo, one due to rash on active treatment and a further participant for personal reasons 
whilst on placebo. 
Of these 15, seven had definite alcohol induced chronic pancreatitis (on the Zurich 
Criteria), 6 idiopathic chronic pancreatitis (although one of these had had moderate alcohol 
consumption) and 2 hereditary pancreatitis. 
10. I Visual Analogue Score Results: 
In V AS crossover analysis, the primary outcome measure, a non-significant difference was 
seen between the groups with the marginally better outcome in the placebo arm (Figure 
10.1 ); t=l.51, p=O.l56. 
In addition, when compared to baseline month neither first arm was significantly different, 
although these were not stated outcome measures. A non-significant decrease is seen in the 
mean V AS during Singulair treatment in comparison to baseline and washout for both the 
AB and BA groups respectively (Figure 10.2, Tables I 0.1 ). In the crossover analysis there 
is a non-significant benefit for placebo. Taken with the findings of improvement in the AB 
and BA arms for active drug this crossover difference appears to be due to the fact that the 
randomisation allotted a disproportionate number of patients with the higher mean V AS to 
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the AB ann and the Period 2 placebo effect was thus, possibly, more exaggerated in this 
group. This is also seen as a decrease in the active second ann but less dramatically from a 
lower baseline. This is a possible explanation for the non-significantly lower scores on 
placebo. 
Thus in the primary outcome measure there is no significant effect for active drug (or 
placebo). 
I 0.1.1 Analgesic Consumption: 
Analgesic use, as one might expect, was seen to mirror V AS. This is demonstrated when 
comparing graphs of analgesic consumption and VAS as in figure I 0.3. With the scoring 
system employed those patients using opiates as first line for pain, as in patient 12, are seen 
to have zero or scores of 5 plus when their pain scores are anything above zero. 
10.2 Inflammatory markers: 
All baseline CRP results were ::;;13. 
Soluble TNF-Receptor results are laid out in table 10.2. Levels are those in the diluted 
plasma and thus levels are approximately half those in plasma. Analysis employing paired 
t-tests revealed no significant effect for treatment for sTNF-R I, sTNF-R2 and total sTNF-
Rs, figure I 0.4. 
I 0.3 Quality of Life Questionnaires: 
In view of the smaller numbers and risk of introducing type I error in this secondary 
outcome measure a simple crossover comparison was made, without sub-division to 
analyse the more discrete areas. Only six patients in each ann sufficient data for full 
analysis. The data was non-nonnally distributed (Shapiro-Wilks test 0.625 (p<O.Ol) and 
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10.5,1il.(p<O!Ol), respectively) ;for!both,arms, Mann Whitriey U;test failed to sltow a 
significant: d.i ffererice in difference;ofplly.sical 1 scqr(!s. 
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Crossover Analysis : 
Mean Differences of VAS 
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Figure I 0.1. Crossover Analysis. 
Error bar shows 95% confidence intervals. The error bar showing no effect. 
The error bar is narrow as the difference in means is around means of I. 7 
and 4.3 in the two treatment arms. 
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GROUP 
"ll 
0 AB 
J BA 
Period 2 
Figure I 0.2. Graph of mean daily Visual Analogue Scores (y-axis) for the four periods 
studied. Period A is active, B placebo. 
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Group Statistics 
Std. Std. Error 
Treatment group N Mean Deviation Mean 
BASE AB 9 3.8023 2.6822 .8941 
BA 10 2.2365 2.0710 .6549 
Base-Period 1 AB 8 -.2732 1.6444 .5814 
BA 8 .1829 .7737 .2735 
Washout-period 2 AB 8 -1 .4152 2.3045 .8148 
BA 7 -.2028 .6368 .2407 
DIFF AB 8 .9947 1.6598 .5868 
BA 7 -.1293 1.1338 .4286 
Table 10.1a 
lnd~pendent Samples Test 
Lewne's Test for 
Equalily of Variances Hest lot Equalily of Means 
95% Confidence 
lntetVal of the 
Sig. Mean Std. Enor Difference 
F Sig. I df (2-talled) Di!lerence Dilference LCMier Upper 
BASE Equal variances 
.341 .567 1.433 17 .170 1.5658 1.0927 -.7397 assumed 
Equal variances 
1.413 15.039 .178 1.5658 1.1083 -.7959 not assumed 
Base-Period 1 Equal variances 3.887 .069 -710 14 489 -.4561 .6425 -1.8342 assumed 
Equal variances 
- 710 9.955 .494 -.4561 .6425 -1.8886 not assumed 
Washout-period 2 Equal variances 8.401 .012 -1.342 13 .203 -1.2124 .9034 -3.1640 assumed 
Equal variances 
-1 427 8.202 190 -1.2124 8496 -3.1631 not assumed 
DIFF Equal variances 1.304 1.507 13 .156 1.1240 7458 assumed .274 -.4873 
Equal varianc:es 
1.547 12.357 .147 1.1240 .nfJ1 -.4542 not assumed 
Table 10.1 b 
Tables I 0. I: Showing mean V AS data for each period and the t-test results of the 
analysis. 
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Patient 12 
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Figure 10.3. Correlation of analgesic consumption and pain typified by Patient 12, who 
was in arm AB (active drug in Period I). 
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sTNF-R1 sTNF-R2 Total sTNF-Rs 
Patient Pre Post Pre Post Pre Post 
Number 
1 18.5 19.8 49.9 38.4 68.3 58.2 
2 29.2 29.9 66.0 78.5 95.2 108.4 
3 32.2 36.9 63 .1 73.1 95.3 110.1 
4 25.8 13.6 59.4 37.7 85.2 51.2 
5 50.0 28.9 108.6 57.8 158.6 86.7 
6 31.3 55.5 71.0 109.9 102.2 165.4 
7 63.7 71.4 173.9 221.3 237.6 292.7 
8 20.0 23.0 57.7 61.2 77.8 84.2 
9 43.6 41.2 81.1 82.1 124.7 123.3 
10 23.4 33.3 65.9 67.1 89.3 100.4 
11 32.2 56.5 65.4 111.7 97.6 168.1 
12 32.5 34.9 107.3 66.9 139.8 101.8 
13 54.6 39.0 106.0 97.5 160.7 136.5 
14 49.0 63.3 127.5 214.6 176.5 277.9 
Table 10.2 Patients mean soluble TNF-R levels, in pg/ml. 
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E 0 
-C) a. 
Total sTNF-R sTNF-R1 sTNF-R2 
Figure I 0.4. Mean paired differences in soluble TNF receptors, separately and in total. 
Error bars show 95% confidence intervals. 
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RESULTS: 
ARACHIDONIC ACID METABOLITES 
A pre-study power calculation revealed a power of98% to identify a doubling of urinary 
metabolite level (given a normal distribution); if 12 patients and 12 controls were recruited. 
This based on the mean levels and standard deviation found previously in healthy 
volunteers (O'Sullivan, S. et al., 1996). The level of2 fold increase was chosen as, in 
response to allergen, in the study cited asthmatics had a 3.5 fold increase whilst another 
study showed healthy volunteers have a 3 fold increase to methacholine (O'Sullivan, S. et 
al., 1998). 
11.1 Urinary LTE4 levels: 
11.1.1 Acute Pancreatitis: 
Analyses were performed based on the prospectively designed pairings this study included 
15 patients and controls. The Mann-Whitney U test was employed as the data was non-
normally distributed. This did not reveal any significant difference. The distribution can be 
seen in Box-Whisker plot in Figure 11.1. In addition, normal distribution (of the larger 
groups, mild and their controls) was obtained on log transformation, independent samples 
t-tests on this transformed data again did not attain significance. 
However, Levene's test for equality of variance did show a significant difference 
(p=0.003). In figure 11.2 this can be seen graphically with higher levels seen especially a 
higher and longer 'tail' to the patient graph. The explanation for this could have been a 
variation in data as the study was not specifically designed or powered to assess such 
variation. However, as one explanation could have been a genetic predisposition to 
increased levels in the setting of an appropriate stressor this issue was addressed; on the 
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basis of a known genetic variation responsible for elevated L TE4 responses in asthma, as 
discussed. 
1 felt it appropriate to confirm the result excluding smokers, as smoking has been 
associated with raised urinary levels (Fauler, J. & Frolich, J. C., 1997}, although Cys L Ts 
have also been shown to be lower in smokers in saliva (Wu-Wang, C. Y. et al., 1992) and 
no different in broncho-alveolar lavage fluid (Zijlstra, F.J. et al., 1992). In the AP group 
smokers constituted two of the three high 'tail' values (figure 11.2) though this was not the 
case for the two smoking controls. This would thus if anything weaken the possibility of a 
minor importance of cysteinyl L Ts in AP in humans. The result in CP was again no 
different on excluding smokers, see below. 
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Figure 11.1: Urinary LTE4 levels (ng/mmol creatinine) in AP. Box-Whisker plot showing 
median (bold line), interquarti le range (box), range (whiskers) and outliers. 
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Figure I 1.2: Urinary L TE4 levels (ng/mmol creatinine) for AP. 
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11.1.2 Chronic Pancreatitis: 
There was no significant difference between the 19 CP patients studied and their age and 
sex matched controls. This despite a pilot study of ours of 19 CP patients with unmatched 
healthy, young controls (numbering 16) which suggested a possible difference in ICP (5 
patients) (p= 0.04; unpaired t-test) and non-significantly higher levels in AICP. 
Interestingly, one control patient had levels considembly higher than all other subjects; on 
review of the control questionnaire this person had a degree of what was believed to be 
stress incontinence and may possibly have been interstitial cystitis which has been 
associated with raised L TE4 (Bouchelouche, K. et al., 200 I). 
In light of this gross outlier we analysed the data both including and excluding this result 
(and the relevant matched CP patient). Employing the Mann-Whitney U test neither 
analysis showed a significant difference. In this group Levene's test did not show a 
significant difference of variance. Figure 11.3. 
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Box whisker plot of urinary LTE4 levels (ng/mrnol creatinine) in 
CP. 
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AA AC cc AC AA 
Genotypes 
Figure 11 .4: An agarose gel showing the Msp I restriction endonuclease digestion 
products of the L TC4 synthase promoter region. The relevant products for 
each genotype are seen (see also figure 7.1 ). 
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11.2.1 Acute Pancreatitis: 
The variation in skew in urinary L TE4 levels implied a possible genetic component and we 
have studied the - 444 functional polymorphism in L TC4 synthase, which is associated 
with increased cysteinyl LT production and asthma. The results are laid out in Table 11.1, 
showing genotypes and Table 11.2, showing alleles. As can be seen in the same proportion 
bars in the bar charts for the severe and mild groups there were no significant differences 
in distribution of either genotypes or alleles. In comparing this group to controls again no 
difference was seen, for genotype or allele. 
This implies that the observed variation in variance and the group with high L TE4 levels in 
AP is not due to genetic predisposition. This despite the known association of increased 
production of the cysteinyl LT with the 'C' allele in the promoter region of the enzyme 
L TC4 synthase. 
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Genotype 
AA AC cc Total 
Mild 75(44%) 76(45%) 18 (11%) 169 
Severe 32 (46%) 30 (44%) 7 (10%) 69 
Total AP 107 (45%) 106 (45%) 25 (11%) 238 
Controls 47 (46%) 47 (46%) 9 (9%) 103 
Table I I. I AP patients with Leukotriene C4 Synthase Genotype by Severity. 
Allele 
A c Total 
Mild 226 (67%) 11 2(33%) 338 
Severe 94 (68%) 44 (32o/o)_ 138 
Total AP 320 (67%) 156 (33%J 476 
Controls 141 (69%) 65 (3 1%) 206 
Table 11 .2 The Distribution ofLeukotriene C4 Synthase Allele in AP by Severity. 
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11.2.2 Chronic Pancreatitis: 
We similarly assessed the frequency of the above genotypes and alleles in 57 patients with 
CP ( 41 AICP and 16 ICP) and assessed it in relation I 03 samples from a geographically 
similar normal control group. This based on the pilot study data referred to above for 
urinary L TE4 levels. 
Again there were no significant differences, in the genotype study (Table 11.3) and in the 
allele study (Table 11.4 ). 
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Genotype 
AA AC cc 
CP 32 (56%) 19 (33%) 6 (1 1 %) 
Controls 47 (46%) 47 (46%) 9 (9%) 
Table 11 .3 CP patients and controls with Leukotriene C4 Synthase Genotype 
Alleles 
A c 
CP 83 (73%) 31 (27%) 
Controls 14 1 (69%} 65 (3 1%) 
Table 11.4 The Distribution ofLeukotriene C4 Synthase Al leles in patients with 
Chronic Pancreatitis (CP) and Controls. 
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103 
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206 
11.3 Urinary PGE2 Levels: 
11.3.1 Acute Pancreatitis: 
CHAPTER 11 : RESULTS- AA METABOLrms 
The study looked at PGE2 levels in 18 patients with AP and their matched controls 
revealed a statistically significant difference. The AP patients had a higher level in 
comparison to controls; t = 3.078, p=0.006; employing an unpaired t-test. The data was 
broken down to analyse whether this difference was maintained for just the mild or severe 
patients. Comparing the mild AP patients to their matched controls using an unpaired t-test 
gave a p value ofO.O 11; t = 2.902. In addition, this significance was maintained when 
comparing mild AP (n= 14) to the grouped controls; p = 0.012. One way analysis on 
variance for the groups mild AP, severe AP (n=4) and controls gave an F value 3.613; p = 
0.024. For the severe group it can be seen (Figure 11.5) that the PGE2 levels and means are 
higher than the control groups, however this did not reach statistical significance in light of 
the small numbers, and the study was not powered to detect such a difference. Comparing 
the mild to severe groups, though with small numbers, did not attain statistical significance 
(p=0.188; t=l.390). 
These results show that PGE2 is elevated in AP and that in light of the ANOVA and 
subgroup analysis that this is most marked in mild disease. 
Evidence on smoking or nicotine and PGE2 is variable with a number of studies showing 
decreases especially in gastric mucosa (Quimby, G.F. et al., 1986) but also saliva (Wu-
Wang, C. Y. et al., 1992); a few increases (Badawi, A. F. et al, 2002) and some no change 
(Zijlstra, F.J. et al., 1992; Hawkey, C.J. 1986). For completeness sakes the analysis was 
performed excluding smokers and this confirmed the significant difference in AP and also 
the CP result below. 
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Mean urinary PGE2 (ng/mmol creatinine) for all AP patients and also the 
mild and severe groups separately. 
Analysed by unpaired t-tests: p = 0.0068 
p = O.Oll b 
p = 0.29lc 
Comparing the higher levels in mild disease with severe AP did not attain 
significance with these numbers, p = 0.188. 
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I ;J.3.2 .€hronic:Pancreatitis: 
Tlhe sl_ll!fy of.PGE2 llrin~lleveiJi in CSP!~n= ·I'8);gi(l not Sll9Wil111Y signiftc!lnt diff~rence 
(Mann; Whifuey-U ·test). 1Jn: fact1the controls gave slightly: higher values·than tlieipatients, 
!figure l);§.Thenon-!liWlificant result was confirmecJI,When:e~cludingsmokers, . t. 
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Figure 11 .6: Box whisker plot of urinary PGE2 levels ( ng/mmol creatinine) in CP 
patients (n= 18) and matched controls. 
155 
CHAPTER 11: REsULTs-AAMETAilOLI'ffiS 
11.4 llp-PGFza Urinary Levels: 
The PGD2 stable metabolite which is also a marker of mast cell activation. 
11.4.1 Acute Pancreatitis: 
The analysis in AP of 14 patients revealed no significant difference (means 29 and 26.1 
ng/mmol creatinine) on independent samples t-testing for this normal data (t = 0.416; p = 
0.681). The data is shown in figures 11.7 and 11.8. The inclusion of a 'mean' for severe 
and matched controls is somewhat dubious as there were only two in each group. The 
actual values were 72.2 ng/mmol creatinine and 5.2 (severe AP) and 39.9 and 2.7 
(controls). 
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11.4.2 Chronic Pancreatitis: 
In chronic pancreatitis for 11 ~-PGF 20 we studied 17 patients and their matched controls, 
Figure 11.9. In the comparison ofCP with controls a highly significant difference was seen 
(Mann Whitney U test, 45.0), p = 0.00 I. 
Analysed with sub-groups employing Kruskal Wall is was again highly significant (p < 
0.0009). Thus individual subgroup analyses were performed to assess if the difference was 
consistent or reserved to particular groups (Mann Whitney U). The difference was found to 
hold for both AICP (n=IO), p = 0.001 and ICP (n=7), p = 0.038 (each group compared to 
their matched controls). 
Evidence on smoking and PGD2 and metabolites is minimal, the one study show no 
difference (Zijlstra, F.J. et al., 1992). However, again for completeness sake the study was 
confirmed excluding smokers and again the negative result in AP and the sibrnificant 
difference seen in CP was confirmed. 
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DISCUSSION 
This thesis has addressed a number of genetic and molecular factors in the initiation and 
progression of both acute and chronic pancreatitis. 
The first study looked at a functional polymorphism in the gene encoding a major enzyme 
(cytochrome P450 2EI) in the metabolism of ethanol, the most well recognised 
aetiological factor in chronic pancreatitis. There was then a small study looking at 
polymorphic variation of the gene of a cytokine (IL-l a) which itself is implicated in, at 
least the progression of, chronic pancreatitis. The studies then moved to the major body of 
work looking at arachidonic acid metabolites: A trial of a receptor antagonist of the 
cysteinylleukotrienes (Montelukast Sodium) was performed. Leukotriene E4, 
Prostaglandin E2, Prostaglandin D2 levels (directly or via stable metabolites) were then 
assessed in both acute and chronic pancreatitis and as was a functional polymorphism in 
the gene encoding the first committed enzyme (L TC4S) in the pathway of one of these 
Ethanol is a major cause of both acute and chronic pancreatitis. However, the mechanism 
is poorly understood. Whether it is via direct toxic effects, effects of its metabolites, effects 
of other metabolites of enzymes induced by ethanol, oxidative stress induced by these 
factors or a combination is far from fully delineated (Braganza, J. M., 1996). Which ever 
one (or more) of these prove to be the case in the fullness of time a possible role for 
genetic factors in ethanol metabolising enzymes may well be relevant. As discussed, 
studies looking at genetic predisposition to alcoholism and alcohol induced liver and 
cerebral disease initially showed a genetic factor to both with a separate (additional) 
genetic component to end-organ disease. However, the continuation of that study with 
further numbers concluded that the majority if not all of genetic predisposition to these 
end-organ diseases was conferred within the predisposition to alcoholism itself (Reed, T. et 
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al., 1996). However, this study only addressed alcohol induced liver and cerebral disease, 
not pancreatic disease. 
The study perfonned here looking at CYP 2E 1 indicates a decreased frequency of the high 
production (in the induced state) fonn in those ICD 10.1110.2 alcohol consumers. This is 
the first study to look at this polymorphism in patient groups. In previous studies of healthy 
b'TOups of American Caucasoids frequencies of6.9% (McCarver, D. G. et al., 1998) and 
4.2% (Fritsche, E. et al., 2000) are seen. Another previous study found the insertion in 
2.1% of healthy Swedish subjects (Hu, Y. et al., 1999). 
At low frequencies these results on Caucasoid subjects could all be consistent with the 
frequencies found in my patient, as well as my control, groups; 2.1% of total ALC; 2.2% of 
Gennan ALC and 2% of British ALC; 5.8% of controls (British). However, in the large 
numbers in this study the results do indicate a statistically significant difference, which 
remains when isolating the smaller numbers of only local, British subjects for insertion 
genotype between NC and ALC (p = 0.03). Population stratification is a confounding 
factor in all genetic association studies and the possibility of this is recognised. 
The original study describing the polymorphism studied showed greater CYP2EI 
metabolic activity associated with the insertion. In that study chlorazoxone hydroxylation 
was higher in the patients with presence of the polymorphism and who were obese or 
recent consumers of alcohol (McCarver, D. G. et al., 1998); both circumstances when 
CYP2E I would be induced. The two later descriptions delineate the pattern of 8 repeats of 
42-60 bp, as opposed to 6 in the wild type ( Hu, Y. et al., 1999; Fritsche, E. et al., 2000). 
Hu et al ( 1999) did not find an increased constitutive expression in luciferase transfection 
experiments, which would agree with McCarver et als' ( 1998) findings of increased 
enzymatic activity only in the induced state (obese subjects and recent alcohol consumers). 
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The finding oflower frequency in ICD 10.1 and 10.2 implies that if you more rapidly 
metabolise ethanol the increased levels of toxic/ unpleasant metabolites would decrease the 
chances of your consuming larger quantities of ethanol. This is synonymous with the 
findings that high activity forms of ADH and low activity forms of ALDH are associated 
with protection against alcoholism in a number of studies, as previously reviewed (Bosron, 
W. F. et al., 1993). This is due, it is believed, to the increased production/ decreased 
metabolism of the ethanol metabolite acetaldehyde, to which associated unpleasant side 
effects such as flushing are ascribed (Bosron, W. F. et al., 1993). The slight caveat to this 
is that CYP2E1 can also metabolise acetaldehyde (Terelius, Y. et al., 1991), however 
analogous effects and conversion of substrates to alternative (toxic) metabolites may still 
be increased. 
Due to the low frequency in my patient populations it was not possible to delineate 
whether there was only a relationship to alcohol misuse per se, or a relationship to end-
organ disease. Especially, as my subject group has a disproportionately large number of 
individuals with end-organ disease when compared to the proportions in alcoholics in the 
wider community, as described earlier. If a lower frequency existed in alcoholics it could 
then be expected to be increased in those with end-organ disease compared to alcoholic 
controls, if a toxic metabolite were involved. The sole homozygote was a patient with 
AICP and genotype analysis of AEOD versus AC approached significance, with p=0.068. 
However, to infer a finding from such a result would not be justified. Although, it was only 
in isolating the homozygotes of another functional polymorphism in CYP2E1 that an 
association with ALD was found in a previous study (Maezawa, Y. et al., 1994). 
This study thus indicates a possible novel genetic factor in predisposition to alcoholism 
though no definitive claims could be made. A further line of investigation is would be to 
confirm or refute the association found in alcoholism and also assess any contribution of 
this genetic factor to alcohol induced end-organ disease. Thus, further analysis in ethnic 
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populations with a higher frequency (e.g. Chinese (Hu, Y. et al., 1999), Taiwanese or 
African American (Fritsche, E. et al., 2000) populations) of this polymorphism would be 
useful. 
Another interesting finding was the smaller band identified (figure 8.2). The very first 
sequencing of this region showed a run of 5 repeats (Umeno, M. et al., 1988)(Assession 
No. J02843), which had not been seen in the two further studies (Fritsche, E. et al., 2000; 
Hu, Y. et al., 1999), this form would correspond to the smaller band seen in four of my 
447 samples, corresponding to 585 bp. Initial attempts were made to sequence this (and the 
other) bands by PCR, running of products on TAE agarose gel, band excision and repeated 
PCR. However, commercial sequencing failed to succeed probably due to the repeats 
present in the sequence. Further PCR of a smaller area (nested PCR) would have been the 
next line but time constraints did not allow this. 
With regard to IL-1 a the results did not show a significant result in the pre-planned 
(primary outcomes). These being comparing the genotypes previously associated with 
severity in AP (I ,2) for predisposition to CP and that associated with alcohol induced AP 
(2,4) for association with AICP. There were no significant differences in allele or genotype 
distribution. These negative data are only strengthened in light of this as a continuation of 
that study employing the same control group. 
With regard to the results of the Singulair trial it was adequately powered and although 
some drop out occurred the results hold suggesting it is not of value in the treatment, 
especially with regard to pain, of Chronic Pancreatitis. This is perhaps less surprising when 
taken in light of the urinary L TE4 results in CP patients which showed no increase in 
levels; despite the fact that this was in contrast to the unmatched control pilot study 
performed by our group. Other therapies do hold out hope e.g. reduction of oxidant stress, 
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where small studies showing benefit (las Heras, Castano G. et al., 2000; Baneljee, B. & 
Bagchi, D., 2001; Uomo, G. et al., 2001); though of only two controlled trials one showed 
benefit (with anti-oxidant therapy) (Uden, S. et al., 1990) and one, employing indirect 
suppression of oxidation with allopurinol, no benefit (Banks, P.A. et al., 1997b ). This 
situation is well reviewed (Warshaw, A.L. et al., 1998). Potentially, larger studies of these 
and pilot studies of further novel therapies could improve our ability to manage chronic 
pancreatitis. 
The bulk of evidence on cysteinyl L Ts is in acute pancreatitis. They are elevated in 
pancreatic lymph and ascites in pigs with experimental AP (Vollmar, B. et al., 1989) and 
in the pancreas in a sodium taurcholate (necro-haemorrhagic) rat model (Folch, E. et al., 
1998). Hirano et al. showed that in a rat model pretreatment with a cysL T receptor 
antagonist decreased pancreatic oedema and microvascular leakage (Hirano, T., 1997). 
Though my data on urinary L TE4 levels showed no significant difference overall the 
difference in variance led me to address this further. The genetic studies in both AP and CP 
do not show a genetic component, at least in relation to LTC4 synthase. The conclusions 
must be from these studies that there is no relevance for cysteinyl L Ts (either functionally 
or genetically) in pancreatitis in humans. 
With regards to the results in the PGE2 study. These show that PGE2 is elevated in AP and, 
although it cannot be categorically stated, that in light of the ANOVA and subgroup 
analysis this is most marked in mild disease. This is the first study ofPGE2 in humans in 
AP and would be in agreement with the bulk, though by no means all, of the animal data. 
As addressed in the introduction PGE2 has been seen to be elevated in a number of animal 
models of AP (Glazer, G. & Bennett, A., 1976; Closa, D. et al., 1993; Jaworek et al., 
2001) and in a necrotising, 'though not oedematous model, in rats (Gioor, B. et al., 2001). 
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In contrast one study examining arachidonic acid metabolites in AP and CP in rat models 
found that although PGE2 increased in a duct ligation model ofCP it decreased in their AP 
model (Zhou, W. et al., 1994 ). Of course my CP study would again be contradictory to 
this single study. Of note Victorov & Hoek ( 1995) found that PGE2 was produced by 
cultured mt Kupffer cells this occurred in response to lipo-polysaccharide (after a lag) and 
ethanol (gradually). 
The suggestion of higher levels in mild disease would again concur with the majority, 
though not all, animal data. Administration ofPGE2 has decreased mortality and markers 
of the pancreatic damage mortality and inflammation (Manabe, T. & Steer, M.L., 1980; 
Coelle, E. F. et al., 1983; Standfield, N. J. & Kakkar, V. V., 1983; Ramirez, R. et al., 
1984; Robert, A et al., 1989). Possibly via membmne and lysosomal stabilisation 
(Standfield, N. J. & Kakkar, V. V., 1983; Manabe, T. et al., 1993). 
Some of this effect is dependent on model and time scale (Taylor, I. L. et al., 1985). Some 
studies have shown no significant benefit (Lankisch, P. G. et al., 1983) or questioned the 
longer term relevance of the previously seen short term effect (Martin, D. M. et al., 1981). 
Of concern with regard to potential therapy, and showing the need for confirmatory 
studies, is that Reber required PGE2 to cause pancreatitis with enterokinse and 
glycodeoxycholate (Reber, H. A, 1985). Whilst a negative effect ofPGE2 treatment has 
also been seen (Oiazabal, A, 1986). 
Despite these few negative studies with regard to a potential benefit associated with PGE2, 
the majority of positive studies and the data presented here, the only study in humans, 
suggest that, as thought previously, this avenue warrants pursuing and perhaps indicates a 
potential therapeutic option. Though confirmation in appropriately powered studies, 
assessing the difference between mild and severe disease, is required. 
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The results on ll P-PG F 2a as a product ofPGD2 and a marker of mast cell activation 
(Schleimer, R. P. et al., 1985) are interesting. In AP there was no association, but it was 
marked in CP. As discussed earlier PGD2 has been shown to be elevated in pancreatitis in a 
small number of studies in AP (Closa, D. et al., 1994a) and CP (Zhou, W. et al., 1994), 
this second study finding no significant increase in AP, agreeing with the results of this 
thesis with regard to PGD2. 
Three studies have shown mast cells in increased numbers in CP, two as abstracts, (Okolo 
CN et al., 2000; Emmrich, J. et al., 2000) and one paper which showed numbers 
correlating with fibrosis and inflammation (Esposito, I. et al., 2001). 
The mast cell is well positioned to be a major player in chronic pancreatitis since it is 
increasingly being found to have a crucial role in fibrosis and tissue remodelling. 
Firstly, mediators involved in CP (as outlined in the introduction) are integral in the 
function of mast cells and mast cells in their formation: 
•TNF-alpha. Mast cells produce TNF-alpha (Gordon, J.R. & Galli, S.J., 1990; Bischoff, 
S.C. et al., 1999; Gibbs, B.F. et al., 2001; Coward, W.R. et al., 2002). 
•Chemokines. The CXC chemokine IL-8, involved in CP, is also produced by mast cells 
(Moll er, A et al., 1998; Gibbs, B.F. et al., 2001 ), as is MCP-1 (also a player in CP), the CC 
chemokine (Baghestanian, M. et al., 1997). Also deletion of the receptor for this in mice 
(CCR2) shows protection from pulmonary fibrosis (Moore, B. B. et al., 2001 ). 
In addition, in one study mast cell tryptase leads to IL-8 production by human umbilical 
vein endothelial cells (Compton, S.J. et al., 1998). 
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•IL-6 is also produced by mast cells ( Moller, A. et al., 1998; Lorentz, A. et al., 2000). 
•TGFbeta. Mast cells are integrally involved with TGFbeta which as discussed is believed 
to have a major role in CP. 
TGFbeta 1 causes mast cell adhesion (in mice) (Rosbottom, A. et al., 2002). It also 
promotes their migration while inhibiting growth (Oisson, N. et al., 2001), this is true for 
isoforms TGFbeta1, 2 and 3 (Oisson, N. et al., 2000). 
In addition to being chemotactic for mast cells, mast cells have been shown to secrete 
TGFbetal (Kanbe, N. et al., 1999; Lindstedt, K.A. et al., 2001) which is also activated by 
the mast cell product chymase (Lindstedt, K.A. et al., 2001 ). 
Both TNFalpha and TGFbeta from mast cells are the cause of type 1 collagen production 
by fibroblasts in mice (Gordon, J.R. & Galli, S.J., 1994). 
This discussion brings us on to the evidence of mast cells directly in fibrosis and tissue 
remodelling. 
Mast cell products have been shown to cause fibroblast proliferation and collagen synthesis 
(Garbuzenko, E. et al., 2002) via not only the cytokines mentioned but tryptase (Gruber, 
B.L. et al., 1997). TGFbeta and tryptase cause fibroblast collagen IV and VIIl production 
(Xu, X. et al., 2002) though in this study (with human mast cells) TNFalpha and chymase 
decreased collagen production. Such actions are not only via mediators but direct contact 
with fibroblasts leading to contraction collagen lattice (Yamamoto, T. et al., 2000). Mast 
cells can produce, indeed, type VIII collagen (Ruger, B. et al., 1994). 'In return' fibroblasts 
produce factors chemotactic for mast cells (Kiener, H.P. et al., 2000) 
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Mast cell products chymase and tryptase are also involved in these actions. Chyrnase 
releases TGFbeta 1 from extracellular matrix (Taipale, J. et al., 1995) and causes a 
mitogenic response in fibroblasts, also true of tryptase. Tryptase causes fibroblast 
chemotaxis and collagen type I mRNA (Gruber, B.L. et al., 1997). Tryptase has again been 
shown to cause proliferation of, and also collagen type production by, fibroblasts (Abe, M. 
et al., 1998). 
The complexity of this remodelling role and the fact that it is not simply fibrotic can be 
seen. In a study by Cho et al. (2000) there was production by stimulated mast cells of 
plasminogen activator inhibitor I but, not only its absence, indeed the production of tissue 
type plasminogen activator and heparin in others (Valent, P. et al., 1998; Sillaber, C. et al., 
1999). In these later studies production was constitutive rather than from stimulated mast 
cells, this could imply 'abnormal' continued stimulation of mast cells in fibrotic 
conditions, such as CP, may disturb the vital balance of mast cell control of remodelling, as 
discussed in vascular disease by Wojta et al. (2002). 
Mast cells are not simply a single homogenous lineage but have varied role and 
characteristics based on site and products. The primary division employed is tryptase 
positive (all mast cells) and chyrnase positive or negative. Also delineation on cytokine 
profile has been proposed, different cytokine roles for different mast cells (Bradding, P. et 
al., 1995). These divisions are early in their delineation, however, not all characteristics 
identified may be attributable to all subdivisions. That said the known actions of mast cells 
fit with the cytokines found in CP, the cell types found and histological findings. Thus a 
conclusion can be made of an active, indeed central, role for mast cells in CP. Playing a 
part in healing, fibrosis and remodelling, as in other conditions (Miyachi, Y. & Kurosawa, 
M., 1998; Chiappara, G. et al., 200 I; Li, C. Y. & Baek, J.Y., 2002). This central 
remodelling, but especially fibrotic, role would fit with Espisito et al.'s study (200 1) and as 
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such they present a potential therapeutic target. As all proposed ideas of pathogenesis 
involve inflammatory cascades, and as discussed they are not mutually exclusive, these 
findings would not exclude any one theory of aetiopathogenesis of chronic pancreatitis in 
humans. However, they could fit most closely with the 'fibrosis' aspect of the 'necrosis 
fibrosis' theory. 
In summary, these studies have addressed various issues of interest in Acute and Chronic 
Pancreatitis assessing areas not previously addressed in Humans. 
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SYMPOSIUM ON THE PANCREAS 
Acute pancreatitis~ 
MT Cartmell, AN Kingsnorth 
Acute pancreatitis is a common disease. As knowledge of its 
pathophysiology improves, evidence is found to confirm and refute present 
management and also to suggest new approaches. This article addresses 
some of these areas in the context of the management of acute pancreatitis. 
A cute pancreatitis (AP) is a common disease, seen in both surgical and non-surgical practice, accounting for around 3% of admissions with acute 
abdominal pain. It carries a relatively high mortal-
ity of 5-10% and, at present, there is no specific 
non-operative therapy. Mortality seems to have 
plateaued in the last decade. In the previous two 
decades a decrease in mortality has resulted from 
a number of factors: increased diagnosis of mild 
cases, improved diagnosis, understanding of nat-
ural history, imaging and selective operative inter-
vention. Unsurprisingly, mortality varies with the 
severity of cases: the mortality for severe cases is 
=20%, for cases of infected necrosis is =25%, and 
for cases of sterile necrosis is "'I 0%. 
Death tends to occur in the first week from 
multiple organ failure or thereafter from sepsis, 
either local to the pancreas or systemic. Patients 
who survive, even severe episodes, generally have 
low long-term morbidity and good quality of life. 
DEFINITIONS 
Attempts to categorize AP have been made in 
recent years in light of improved knowledge of the 
pathology and natural history of the disease. From 
Marseilles and Cambridge to Atlanta (Bradley, 
1993) these have given a basis from which to com-
pare the outcomes of different management tech-
niques and enabled discussions to be carried out 
using agreed and standardized terminology. 
Many aspects of management have developed 
and are developing. Although many of these are 
still contentious a number of consensus documents 
have been produced giving guidelines on the man-
agement of AP (Banks, 1997; Glazer and Mann, 
1998; Dervenis et al, 1999). This article discusses 
some recent developments and contentious areas, 
within a framework of the management of AP. 
ASSESSMENT 
Aetiology 
The two common causes of AP remain gall-
stones, accounting for around 40-50% of cases 
in Britain, and ethanol, accounting for around 
20-30% of cases. The mechanisms by which the 
various causes lead to AP are not fully under-
stood. If these causes are not identified other 
potential causes should be sought which include: 
• Hyperlipidaemia 
• Tumours (especially periampullary tumours) 
• Infective causes, including viral, e.g. mumps 
and coxsackie, and parasitic, e.g. ascaria and 
clonorchis. 
'Idiopathic' (or unidentified aetiology) 
remains a common diagnosis in reported series 
and appears to diminish with repeated investiga-
tion. The UK guidelines (Glazer and Mann, 
1998) suggest that this group should constitute 
no more than 20-25% of diagnoses of AP. 
Diagnosis 
Common presenting features are abdominal pain, 
especially epigastric, with or ·without radiation to 
the back, associated with vomiting. There may be 
signs of abdominal tenderness (ranging from mild 
through rebound to rigidity) and, less commonly, 
Cullen 's and Grey-Turner's signs, which contribute 
to a more specific diagnosis. However, presenta-
tion can be varied and missed diagnosis remains a 
factor in the high monality (Kingsnonh, 1998). 
From 12-42% of cases of fatal AP go undiag-
nosed before death. In one analysis of patients 
diagnosed post-mortem, Wilson and lmrie 
(1988) suggest that a timely diagnosis may have 
altered management, potentially allowing sur-
vival, in 45% of cases. In addition to a variable 
clinical presentation, the lack of a highly $pe-
ci fie diagnostic test leads to difficulties. 
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Diagnostic tests 
At present the mainstay of diagnosis, beyond clin-
ical assessment, is the biochemical tests of amy-
lase (blood or urine) and lipase. These pancreatic 
enzymes are typically elevated (amylase >3-5x 
normal, lipase >2x normal) during an attack of 
AP. However, they must be sought to give a result. 
Levels may not be elevated even in a severe attack 
(lack of sensitivity) and can be non-specifically 
elevated in clinically similar conditions (lack of 
specificity). In addition, amylase is short lived in 
the blood (leading some commentators to recom-
mend urine levels to be tested). Amylase has other 
isoenzymes which may, rarely, be the source of an 
abnormally high result. Lipase is marginally supe-
rior to amylase (Table 1). Combination of the two 
investigations improves sensitivity and specificity. 
Assays which show promise include: 
• Trypsin 2-alpha I antitrypsin complex, which 
also correlates with severity 
• Alpha 2 macroglobulin-trypsin complex 
• Trypsinogen 2. This is probably closest to a 
practical, accurate form and a simple urine test 
is available (Kylanpaa-Back et al, 2000) (Table 
/). Serum levels also correlate with severity. 
Prognostic tests, indicators, systems and 
imaging 
As AP has such a range of clinical courses it is 
useful to be able to predict which patients are 
likely to have a severe (complicated) course. This 
allows intensive observation of those at greatest 
risk, implementation of investigation and appro-
priate and opportune management. It also pro-
vides for standardized comparisons in studies. 
Attempts at predicting severity in AP have 
been made for over two decades, initially con-
sisting of multi-factor scoring systems, such as 
Ranson's (Ranson et al, 1974) and Glasgow cri-
teria (Blarney et al, 1984). Other simple indica-
tors are now also known and a large number of 
potential serum markers are being evaluated. 
The details of all the potential predictors are 
extensive and a number of reviews exist. A com-
bination of recognized predictors of severe out-
come is, at present, the best approach: 
• Simple tests: 
a. Clinical assessment - not regularly reli-
able, still a vital component 
b. Obesity - body mass index 2:30 kglm2 
c. Chest X-ray - pleural effusions (espe-
cially left sided and bilateral) 
d. C-reactive protein level > 150 mg/litre. 
• Multi-factor scoring systems: e.g. APACHE-
11 score 2:8 (values between 2:6 and 2:9 recom-
mended by various authors), which is equal or 
superior to other systems 
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• Computed tomography (CT) imaging: 
(dynamic) contrast-enhance<FCT of the pan-
creas. Necrosis and fluid collections correlate 
with outcome. Systems such as that of 
Balthazar et al ( 1990) are useful measures. 
TREATMENT 
The mainstay for the patient with a predicted 
severe or severe episode of AP is supportive care 
and appropriate fluid resuscitation in a high 
dependency or intensive care setting. There are 
also medical and interventional options available. 
Antibiotic prophylaxis 
As discussed above, mortality in AP is primarily 
the result of septic complications beyond the 
first week, this accounting for the majority of 
deaths. In addition infected pancreatic necrosis 
is associated with a much higher mortality than 
sterile necrosis. A debate regarding antibiotic 
prophylaxis has been ongoing for many years, 
with the weight of evidence most often said, in 
the past, to fall against prophylaxis. However, 
much of the data covered ampicillin which we 
now know has limited pancreatic penetration, 
and studies included mild cases which may have 
masked a significant effect in severe cases. 
With more recent trials and increasing evi-
dence on which antibiotics attain appropriate tis-
sue levels this debate continues (Barie, 1996), but 
on balance probably favours antibiotic prophy-
laxis in patients with predicted severe disease 
(Golub et al, 1998; Powell et al, 1998). This cor-
responds to current practice in the UK (Powell et 
al, 1999). Comparisons of penetration in different 
degrees of inflammation, into pancreatic juice 
and even into peripancreatic fat (Baric, 1996) 
may be of significance in the clinical setting. 
However, even recent studies have not consis-
tently shown a survival benefit or reduced pan-
creatic infections with antibiotic prophylaxis. 
The question of 'which antibiotic?' leads to even 
less widespread evidence; with clinical trials, 
animal studies and penetration studies not con-
sistently testing the same antibiotics and varia-
tion also seen within antibiotic 'families'. 
Although further studies are required, it would 
be reasonable to recommend one of: 
TABLE 1. ' -
Sensitivity and speclflcity of sol'lle tests for acute pancreatiti~ 
Amylose 
lipase 
Trypsinogen·2 (serum or urine) 
Dolo from KempfXlinen et ol ( 1998) 
Sensi~vity 1%1 
52-95 
74-100 
91-8 
Specificity l%1 
86-98 
34-100 
89-95 
383 
384 
Cefuroxime, which has been shown to 
= decrease total infectious complications, need 
for operative intervention and death, but not 
pancreatic infection, in a trial of 60 patients 
(Sainio et al, 1998) 
Ceftazidime, which (with amikacin, which is 
poorly penetrant, and metronidazole) reduced 
all infections but not mortality in a small trial 
(Delcenserie et al, 1996) 
Ofloxacin, which (with metronidazole) in a 
small trial was shown to decrease physiologi-
cal disturbance (Schwarz et al, 1997) and has 
good penetration and spectrum characteristics 
lmipenem, which has been shown to decrease 
pancreatic and extrapancreatic infection 
(Pederzoli et al, 1993) and be superior to per-
floxacin without metronidazole (Bassi et al, 
1998), but not to show survival benefit. It has 
good pancreatic penetration and is the most 
consistently tested; however, its cost may 
exclude it as first-line prophylaxis, especially 
in light of its lack of comparison with some 
of the viable altematives. 
Any of the above (except imipenem) should 
probably be combined with metronidazole. 
Other issues in antibiotic prophylaxis awaiting 
resolution include the role of gut decontamination 
in an attempt to prevent bacterial translocation, 
either alone or with systemic prophylaxis, the 
duration of administration, and whether to com-
mence antibiotics on purely prognostic grounds or 
only after necrosis is seen (as in most of the trials}. 
Pancreatic rest and suppression 
A mainstay of AP management has been to 
maintain the patient nil by mouth. This can avoid 
worsening pain and nausea and rests the pan-
creas from stimulation by food, with the aim of 
decreasing pancreatic secretion and thus autodi-
gestion, although basal secretion may already be 
suppressed in AP Other avenues to rest the pan-
creas seem to lack any significant benefit: 
Nasogastric aspiration has not been shown to 
benefit outcome; however, it has a role in 
selected cases to rest an ileus and prevent 
vomiting and aspiration 
Cimetidinc has not consistently been shown 
to benefit patients 
Evidence for ranitidine in patients is limited 
although it probably plays a worthwhile role 
in gastritis and ulcer prophylaxis 
Somatostatin and its analogue octreotide arc 
known to decrease pancreatic secretion but 
have failed to consistently show benefits in 
patients with AP (Uhl et al, 1999a). Although a 
meta-analysis suggested a benefit (Andriulli et 
al, 1998) this was before the largest study (Uhl 
et al, 1999b), a randomized, double-blind trial 
which failea to show any significant benefit. 
Suppression of the inflammatory response 
Blockade or suppression of the inflammatory 
pathways involved in AP is an appealing therapeu-
tic avenue. As our rapidly developing understand-
ing of this area is in its early days, there are many 
potential but not yet fully evaluated therapies. 
The most studied to date is the platelet-activat-
ing factor antagonist lexipafant. After two phase 
11 trials and a multicentre UK phase Ill trial there 
appeared to be a significant improvement in 
organ failure incidence and severity, and reduc-
tion in pseudocyst formation and mortality in 
selected patients (Kingsnorth, 1997). However, a 
second larger, international phase III trial failed 
to show any benefit for lexipafant (unpublished 
data, British Biotech, Oxford, 1999). 
Nutrition 
Patients unable to eat for a prolonged period, in the 
catabolic state of AP, require nutritional supple-
mentation. This is most commonly achieved with 
total parenteral nutrition (TPN). With the apparent 
paradox of feeding enterally a patient whose gut 
and pancreas is being rested, recent evidence (in 
the form of three small, randomized trials) would 
suggest that enteral nutrition Gejunal feeding, dis-
tal to the cholecystokinin cells) is safe and possi-
bly superior to TPN (Dervenis et al, 1999). 
The potential benefits are improved nutritional 
status, protection of the gut's mucosal barrier 
against bacterial translocation and fewer septic 
complications of the means of administration. 
Analgesia 
Many AP patients suffer from severe abdominal 
pain. Prescription of pethidine, rather than mor-
phine, in acute biliary pain (including pancreatitis) 
is often advised because of the potential for mor-
phine to cause the sphincter of Oddi to spasm, thus 
increasing intraductal pressure. However, concem 
over the addictive potential of pethidine and possi-
ble inferiority to morphine confounds the issue. 
Anecdotal evidence abounds on both sides of this 
debate, but objective clinical data are lacking. 
Morphine causes increased rate and amplitude 
of sphincter of Oddi contractions and increased 
basal pressure (Helm et al, 1988) while pethidine 
can decrease the frequency of contractions 
(Thune et al, 1990). However, findings are incon-
sistent and the clinical significance is untested. 
Patient-controlled analgesia with pethidine can be 
useful for systemic analgesia in AI'. Altematives 
include epidural analgesia, transcutaneous electri-
cal nerve stimulation and coeliac plexus block. 
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Interventions 
CT-guided aspiration of pancreatic necrosis is a 
useful technique for distinguishing between 
infected and sterile pancreatic necrosis (Banks, 
1997; Dervenis et al, 1999), which are often 
clinically indistinguishable. 
Endoscopic retrograde cholangiopancreatogra-
phy (ERCP) definitely has a role to play in man-
agement of AP. However, the exact circumstances 
in which it should be used have not been fully 
evaluated. A number of trials have shown a bene-
fit of early ERCP in biliary pancreatitis, although 
those showing survival benefit did not exclude 
patients with cholangitis or biliary obstruction 
(Banks, 1997; Dervenis et al, 1999). A study 
which did so failed to show survival benefit 
(Folsch et al, 1997). It can be said that ERCP 
should be used in biliary pancreatitis with evi-
dence of cholangitis or biliary obstruction and 
may benefit patients with severe AP caused by 
gallstones. These groups of patients may be indis-
tinguishable, so ERCP is reasonable in all patients 
with prognostically severe AP and gallstones. 
Surgical intervention is indicated in patients 
with infected pancreatic necrosis, but its role in 
sterile necrosis is uncertain and should probably 
only be employed in patients who are deteriorating 
or failing to settle after attempts at conservative 
management have been exhausted (Banks, 1997; 
Dervenis et al, 1999). A further indication, which 
is not uncommon, is the patient in whom imaging 
is unavailable or unable to exclude an intra-
abdominal catastrophe for which an operation 
would be necessary, e.g. mesenteric infarction. 
CONC&.USIONS 
Many aspects of our knowledge of AP and its 
management have been and are being advanced. 
In many areas further evaluation is required. The 
end-point of such work will hopefully be 
improved outcome for our patients. Debate and 
study to this end can be facilitated by use of 
standardized terminology and assessment 
against accepted guidelines and practices. 1111 
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Letter In Press: Clinical Chemistry and Laboratory Medicine. 
Faecal Elastase 1 Measurement in Chronic Pancreatitis. 
Further to the review article by Messr's Dominici and Franzini we concur with the 
importance of considering faecal pancreatic elastase 1 as a good test of pancreatic 
function, the role of which is yet to be fully defined in Chronic Pancreatitis. Comparing 
it with other tests for chronic pancreatitis is more about defining this role for pancreatic 
function testing. A small study we conducted would indicate faecal pancreatic elastase 1 
testing is not only reliable over a few days but over several months (mean co-efficient of 
variation 16%, median 6%) whilst decreasing levels pre-date clinically evident 
insufficiency, potentially allowing earlier treatment in this nutritionally vulnerable 
group. 
Keywords: Elastase I; Pancreatic function tests; Chronic pancreatitis. 
Abbreviations: CP, chronic pancreatitis; El, faecal pancreatic elastase I; 
We are writing further to the review article on faecal elastase by Mssr's Dominici and 
Franzini(l ). We concur with the authors that the commercially available faecal pancreatic 
elastase I test (E I) is a simple and valid test of pancreatic exocrine function. We also agree 
with the important distinction discussed between studies showing good correlation with 'gold 
standard' tests of pancreatic function, such as Loser et al., 1996 (2) and those studies showing 
reasonable, although poorer, correlation in comparison with a combination of structural and 
functional tests(3). It is unsurprising that El lacks some correlation in 'mild' cases in 
comparison with the very complex secretin (caerulein)-cholecystokinin test given this 
measures a number of digestive enzymes (as well as volume and bicarbonate) and the 
definition of mild includes a decrease in 1 to 3 of the enzymes tested. Thus although elastase 
correlates with the duodenal enzymes measured and faecal elastase with its duodenallevels(4) 
it will not always decrease when the secretin-cholecystokinin test reveals mild insufficiency. 
The lack of correlation in some cases ofCP is also unsurprising as pancreatic insufficiency is 
not required for a definitive diagnosis of CP. Thus a patient suffering from CP, which is 
diagnosed on a combination of findings (5), may demonstrate no insufficiency. This raises the 
issue of the role of pancreatic function tests, including the uncomplicated El, in CP. 
To address our concern with regard to the tests reproducibility in an individual over time and 
to look at possible roles for El we looked at 13 patients with CP (5) with 3 to 4 tests over 7 
months. Only three patients varied between diagnostic categories: One had a single reading in 
the mild to moderate category then 3 normal readings, this patient was on oral enzyme 
supplements and although, as discussed in the review article, these do not interact 
immunologically with this test there is some evidence that they may affect secretion via a 
negative feedback loop (6,7), which might explain this variation. 
The other two patients both showed !,rradual decreases in function, figure I. One of these has 
(within a year) developed steatorrhoea and commenced on enzyme supplements. The other 
has been unavailable for follow up. On this basis, excluding these two patients, intra-
individual variation revealed a mean (median) co-efficient of variation of 16% (6%). 
This would indicate that the test is reproducible overtime and that decreasing levels may 
predate clinical deterioration (as also seen by one study, available in abstract form, in cystic 
fibrosis over 5 years (8)). This would indicate one role for El in CP where earlier detection of 
pancreatic exocrine insufficiency would enable supplementation in a nutritionally vulnerable 
group; especially given that 90% of pancreatic exocrine function can be lost prior to its being 
clinically evident (9). 
Yours sincerely, 
Mark T. Cartmell 
Professor Andrew N. Kingsnorth 
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Christine Porter 
Rohit Makhija 
Department of Surgery 
Peninsula Medical School 
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